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Abstract 
Chagas disease is a neglected disease endemic in Central and South America but is 
becoming more widespread. The current treatments for Chagas disease, nifurtimox 
and benznidazole, were developed over 40 years ago and have detrimental side 
effects which inhibit the treatment process. In search for a new treatment for Chagas 
disease, an in vitro screening of commercially available fungicides and pesticides 
against T. cruzi was conducted and identified pyrifenox as having good inhibition 
against the parasites. This research focussed on the synthesis of pyrifenox analogues 
to improve the inhibition against the parasite. 
  
 
 
As there were limited routes to synthesise pyrifenox, a new modular synthetic 
method was developed. A variety of methods were used to obtain the ketone 
intermediate 65. The hydration of an alkyne proved to be the most effective method 
using an acid and a gold catalyst. The alkene 101 was inactive towards hydration and 
alkylation reactions. The carboxylic acid 108 could be converted to the ketone 65 via 
a Curtius rearrangement in 47% yield but was rapidly oxidised to a diketone. A 
condensation reaction of a carboxylic acid 114 and methyl ester 115 produced the 
ketone 65 in low yield. The final method was a palladium catalysed cross-coupling 
reaction which produced the unsubstituted ketone in high yields but no reaction 
occurred when using halogenated acetophenones. 
  
A variety of oximes were synthesised from the ketone 65 to produce 24 different 
analogues that were tested against T. cruzi. The substituents on the phenyl ring 
appeared to be important with the most active analogue containing chlorine 
substituents on the phenyl ring. The E oxime was also shown to be more potent than 
the Z oxime. Extension of the methyl oxime of pyrifenox to larger alkyl chains gave 
more potent analogues, with the benzyl oxime being the most potent.  
 
 
 
 
The backbone of pyrifenox was modified to examine the contribution of structural 
rigidity to the biological activity of the compound. The stereochemistry of the oxime 
was removed by incorporating a nitrogen atom between the two rings creating a more 
flexible compound. The amide 168 showed decreased anti-trypanosomal activity. 
The structural rigidity of pyrifenox was increased. This compound was based on a 
naphthol system to produce a compound that mimicked the preferred E isomer. 
Unfortunately the increased rigidity in this compound decreased the anti-
trypanosomal activity. 
 
 
 
The linker between the pyridyl ring and the benzyl ring was also investigated. The 
longer linker was based on a hydrogenated chalcone. The longer linker series showed 
a diminished activity compared to the pyrifenox derivatives, however the substituents 
on the phenyl ring and the length of the oxime showed a similar trend to the first 
series of pyrifenox analogues. The chloro substituents on the phenyl ring appeared to 
be the most potent and a bulkier oxime was shown to improve the biological activity 
to 0.24 µM. 
  
A side product of the chalcone synthesis was shown to have excellent inhibition 
against T. cruzi. The additional substituents on the phenyl ring were shown to be the 
most effective with the difluoro compound exhibiting the most promising results. 
This series of compounds provide a new lead as a drug target for the treatment of 
Chagas disease. 
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 Abbreviation
 
AUD  Australian dollars 
Bn  benzyl 
CPI  cysteine protease 
inhibitors 
CSA  camphorsulfonic acid 
CYP3A4 cytochrome P450 3A4 
CYP51 sterol 14α-demethylase 
DCE  1,2-dichloroethane 
DCM  dichloromethane 
DIPEA diisopropylethylamine 
DMAP  dimethylaminopyridine 
DMF  dimethylformamide 
DMSO  dimethyl sulfoxide 
DNDi Drugs for Neglected 
Diseases initiative 
e
−
  electron 
EC50 half maximal effective 
concentration 
ED50  median effective dose 
Et  ethyl 
ether  diethyl ether 
eq  equivalence 
FDA food and drug 
administration 
h  hour(s) 
Hz  hertz 
IC50  half maximal inhibitory 
concentration 
IR  infra-red 
 
J  coupling constant 
mCPBA m-chloroperbenzoic 
acid 
Me  methyl 
mp  melting point 
NaHMDS sodium 
bis(trimethylsilyl) 
amide 
nM  nano molar 
NOE nuclear Overhauser 
effect 
NTR  nitroreductases 
o/n  overnight 
PFT protein 
farnesyltransferase 
ppm  parts per million 
PTC  phase transfer catalyst 
qd quaque die (one per 
day) 
rt  room temperature 
sec  second 
SI  selectivity index 
SM   starting material 
T. cruzi Trypanosoma cruzi 
TES  triethylsilane 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran  
TLC thin layer 
chromatography 
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1 Introduction 
 
 
 
 
 
 
Diseases that affect poverty-stricken communities are often neglected by industrial 
and academic research as they are not considered of commercial importance.
1
 Most 
of these neglected diseases are found in areas with unsafe drinking water, poor 
sanitation, substandard housing, and little or no access to healthcare. As these 
diseases mainly occur in poor or rural areas, there is a lack of government 
commitment for drug development even though there are high rates of mortality and 
morbidity caused by these diseases.
2–5
 Recently, research has been sponsored by not-
for-profit organisations (eg. World Health Organisation and Drugs for the Neglected 
Diseases initiative) to develop new drugs and vaccines, diagnostics, prevention and 
provide access to affordable medications. One major neglected disease is American 
trypanosomiasis, more commonly known as Chagas disease.
6,7
 
 
1.1 Chagas Disease 
Chagas disease is caused by a parasite, Trypanosoma cruzi, which affects 
approximately 16 to 18 million people
8
 and kills greater than 15,000 people each 
year.
2,9
 T. cruzi is endemic in Central and South America
10
 affecting 21 countries
1
 
2 
 
but is becoming more widespread due to international travel.
11
 Chagas disease is 
most commonly transmitted through the faeces of triatomine insects, also known as 
kissing bugs (Figure 1), which carry the parasite.
12
 The parasite enters the body of 
the mammalian host through broken skin from the insect bite or other cuts and 
abrasions, and soft skin around the eyes and mouth from the faeces of infected 
insects.
8,9
 Other modes of infection include blood transfusions, organ transplantation, 
perinatal infection and importation of infected livestock.
8
 Accurate assays have been 
developed to help screen donated blood for the T. cruzi infection but organ 
transplantation still remains an issue. 
 
 
Figure 1. Swelling at the site of infection (left) and the triatomine insect that carries the parasite (right).13 
 
The life cycle of T. cruzi is complex and involves two intermediate hosts and three 
morphological forms (Figure 2).
14
 The triatomine bug is infected with the parasite 
when it takes a blood meal from mammals that are infected with the non-dividing 
bloodstream trypomastigotes. The insect appears to be unaffected by the parasite.
15
 
The trypomastigotes then transform into epimastigotes in the gut of the insect.
16
 The 
epimastigotes form replicates in the midgut of the bug and develop into 
nonreplicative metacyclic trypomastigotes.
8,17
 T. cruzi is then transmitted to 
mammals when the faeces of the infected insect come into contact with broken 
skin.
16
 Once the trypomastigotes enter the host cells, they transform into amastigotes 
and multiply.
16
 The cell then bursts, releasing the trypomastigotes to infect other 
cells and enter the blood stream.
8
 The life cycle is complete when a triatomine insect 
takes another blood meal of the infected blood.
16
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Figure 2. Representation of the lifecycle of T. cruzi. a) Triatomine bug takes a blood meal. b) Metacyclic 
trypomastigotes penetrate cells and transform into amastigotes. c) Amastigotes mutiply in cells. d) Intracellular 
amastigotes transform into trypomastigotes and enter bloodstream. e) Triatomine bug takes a blood meal. f) 
Epimastigotes in midgut. g) Multiply in midgut. h) Metacyclic trypomastigotes in hindgut. Adapted from 
Clayton.9 
 
There are three phases of infection: acute, indeterminate and chronic phases.
2,10
 The 
acute phase normally occurs in children with 75% of cases in patients less than 15 
years old.
18
 The acute phase begins one to two weeks after infection and usually lasts 
six to eight weeks.
19
 Many people experience no symptoms in the acute phase or the 
symptoms are very mild and non-specific.
17,20
 Therefore they may not realise they 
have been infected and they go untreated.
9
 Acute symptoms include local swelling of 
the site of infection (Figure 1), fever, anorexia and myocarditis with diagnosis being 
made by detecting parasites in the blood by microscopy (Figure 3).
9
 The mortality 
rate in the acute phase is approximately 10%, with the majority being children.
2,8
 
After the acute phase, if untreated, patients appear to be immune with no symptoms 
observed but they will still remain infected. This is known as the indeterminate stage 
and can last 10 to 30 years before chronic symptoms appear. Chronic symptoms 
include cardiac abnormalities, digestive tract problems and neurological problems 
which tend to be fatal.
9
 Mortality in the chronic stage is mainly due to 
cardiomyopathy.
2
 One in three carriers develop chronic symptoms
21
 and it is often at 
4 
 
this stage that they are first diagnosed with the infection.
9
 Although these are typical 
symptoms of Chagas disease, the pathology is still not fully understood and can vary 
between regions.
22
 
 
 
Figure 3. T. cruzi trypomastigote in a thin blood smear stained with Giemsa (left). T. cruzi amastigotes in heart 
tissue stained with hematoxylin and eosin (right).23 
 
1.2 Current therapies 
There are currently two drugs available to treat Chagas disease: nifurtimox 1 and 
benznidazole 2 (Figure 4).
20
 In the acute phase both drugs reduce severity of the 
symptoms and are thought to cure 60 to 80% of patients treated.
19
 Both compounds 
function as prodrugs and undergo enzyme-mediated activation within the cell.
1,2,24
 
These reactions are catalysed by nitroreductases (NTRs) and are divided into two 
groups based on oxygen sensitivity (Figure 5).
1,2,8
 Type 1 NTRs are oxygen 
insensitive and function through a two electron reduction of the nitro group to 
generate the nitroso intermediate.
25
 The nitroso intermediate rapidly undergoes 
reduction to a hydroxylamine derivative. This leads to compounds that promote 
DNA damage. Type 2 NTRs are oxygen-sensitive and mediate one electron 
reduction of the nitro group generating an unstable nitro radical. In the presence of 
oxygen, the nitro radical undergoes futile cycling to produce superoxides and 
regeneration of the parent nitro compound. 
5 
 
 
Figure 4. Chemical structures for Nifurtimox and Benznidazole. 
 
 
Figure 5. Activation of antichagasic nitroheterocyclic drugs. Adapted from Salas et al.2 
 
Nifurtimox 1 was the first drug commercialised to treat Chagas disease and was 
released under the name Lampit® in 1972.
1
 The production of nifurtimox was 
discontinued in 1997
1
 and the treatment is no longer used due to serious 
gastrointestinal tract and central nervous system side effects, and its limited efficacy 
and genotoxicity.
24
 Other side effects include seizures and other nervous system 
disorders, anorexia, weight loss, digestive problems and skin rashes.
2,3,8,25
 The more 
serious effects are usually resolved when the treatment is stopped. Children appear to 
tolerate the treatment better than adults, however there is no known correct dosage 
for children.
19
 Nifurtimox contains a nitrofuran ring that inhibits the pyruvic acid 
synthesis in T. cruzi during glycolysis. It appears to be catalysed by both types of the 
NTRs (Figure 6).
25
 In type 1, the nitrofuran undergoes a two electron reduction to the 
nitroso 4 intermediate which readily undergoes another two electron reduction to a 
hydroxylamine derivative 5. The hydroxylamine 5 can then be processed further to 
6 
 
generate the amine 7 which is inert or the nitronium ions 6 that promote DNA 
breakage.
25
 Fragmentation of the furan ring may also occur giving open chain nitriles 
9 that are toxic.
25
 The nitrofuran can also react with oxygen via type 2 NTRs to form 
the superoxide anion and the nitro anion radical 10.
8
 
 
Figure 6. Reactions of the nifurtimox nitrofuran ring are catalysed by type 1 and type 2 NTRs. 
  
Benznidazole 2, also known commercially as Rochagan®, was discovered in 1974 
but was not introduced for clinical use until 1978.
1
 It is a nitroimidazole derivative 
considered more trypanocidal than nifurtimox.
19
 Benznidazole inhibits RNA 
synthesis and generates the accumulation of superoxides.
26,27
 The reduced 
metabolites of benznidazole interact with the DNA of the parasite and inhibit the 
respiratory chain.
8
 It appears to be catalysed only by type 1 NTRs (Figure 7). The 
nitroimidazole 11 undergoes a two electron reduction to the nitroso intermediate 12 
which readily undergoes another two electron reduction to a hydroxylamine 
derivative 13. The hydroxylamine metabolite can undergo rearrangement and 
7 
 
hydration to produce a dihydro-dihydroxyimidazole 15 that can decompose to release 
glyoxal 17. Both products can interact with the biomolecules forming adducts with 
DNA and thiols.
24
 
 
 
Figure 7. Reactions of the benznidazole nitrofuran ring are catalysed by type 1 NTRs. 
 
Benznidazole is still used to treat the early acute stage, curing 16−76% of patients 
compared to only 8−9% of chronic patients.28 It is thought the effectiveness of 
benznidazole occurs in the infected extracellular forms of T. cruzi in the acute phase 
rather than the intracellular forms in the chronic phase.
8
 The side effects are severe 
and can lead to resistance.
19
 Side effects include skin rashes, nausea and kidney and 
liver failure.
3,5,8
 The effectiveness of the drug also varies according to geographical 
area.
29
 Children are known to tolerate the treatment better than adults but there is no 
known correct dosages or formulation for children with benznidazole tablets being 
split by hand into half and quarters.
20
 This is not ideal as there is a high risk of 
delivering incorrect dosage and raises concerns about safety, efficacy and decreased 
stability.
30
 This is seen as a major issue as most patients in the acute stage are 
children.
20
 
 
8 
 
Both nifurtimox and benznidazole have shown positive results in treating the early 
acute stage but they have low effectiveness in the chronic phase of the disease
10
 and 
resistance of different strains against the drugs has been documented.
29
 They also 
required prolonged treatments (greater than 60 days) and the detrimental side effects 
often lead to abandonment of treatment. As there is limited efficacy of nifurtimox 
and benznidazole, undesirable side effects and drug resistances, there is a need to 
develop new drugs for the treatment of Chagas disease.  
 
1.3 Advances in Chagas disease drug development 
The current treatments for Chagas disease have problems with toxicity, efficacy, 
length of treatment and the administration of drugs to children. Therefore new drugs 
need to be developed that are less toxic but provide the same or better inhibition than 
benznidazole and nifurtimox. As the disease targets poorer communities, the new 
drug also needs to be relatively cheap to produce. The development of new drugs to 
treat Chagas disease has been a challenge because T. cruzi is an intracellular parasite. 
This means that the drugs are required to cross the cell membrane in order to kill the 
parasite.
9
 Early stage research into other compound classes to treat Chagas disease 
might show promising activity but there is no standardised assays for the parasites 
used.
1
 Therefore the results are not reproducible between the testing laboratories and 
few compounds have advanced to clinical trials. The most promising compounds 
have been shown to inhibit cysteine proteases and sterol biosynthesis. 
 
1.3.1 Cysteine protease inhibitors (CPI) 
The toxicity and lack of efficacy of nifurtimox and benznidazole has prompted 
interest into the development of a vaccine based on the cruzipain antigen (also 
known as cruzain). Cruzain is a cathespin of ʟ-cysteine protease that is responsible 
for the proteolytic activity in all life stages of T. cruzi.
27,31,32
 The genes that code for 
this protein have been cloned and expressed, and drugs have been studied to 
specifically target the inhibition of the CPI protease in vitro by blocking the growth 
of the cells.
27
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It has been demonstrated that drugs can block the development of cruzain and its 
transport of lysomes.
31,33
 The lack of cruzain weakens the parasite and it is therefore 
unable to survive.
32
 The cysteine protease is expressed on the surface of the parasite 
and has shown some promising results. One cruzain inhibitor that has shown the 
most promising results is K777 18 (Figure 8).
33,34
  
 
 
Figure 8. Structure of K777 and nonpeptidic cruzain inhibitor 
 
K777 18 is a peptidic vinyl sulfone protease inhibitor of cruzain that is irreversible 
(Figure 9).
34,35
 The vinyl sulfone serves as a Michael acceptor for the nucleophilic 
cysteine residue within the active site of the protease. The peptidic backbone 
contains several hydrogen bond acceptors that interact with complimentary residues 
in the active site. Studies have shown that K777 18 is effective in selectively 
targeting T. cruzi in acute and non-acute models of the infection in mice and treating 
cardiac damage in dogs.
31
 The development of K777 18 was halted in 2005 due to 
hepatotoxicity and manufacturing problems.
31
 Further investigations into these 
problems are currently being assessed.
31
  
10 
 
 
Figure 9. Mechanism of irreversible inhibition of cysteine peptidase by vinyl sulfones.36 
 
Nonpeptidic analogues of K777 18 have been investigated and a 1,2,3-triazole based 
tetrafluorophenoxymethyl ketone 19 (Figure 8) has shown suppressive activity in the 
mouse T. cruzi model and did not show any toxicity.
33
 This analogue does not 
contain the vinyl sulfone and therefore the mechanism for inhibition differs from 
K777 18. The mode of action is still under investigation. 
 
Although cruzain is an ideal target, the short half-life of the drug requires high and 
increasing doses which inhibits its use in clinical practice.
27
 Nonpeptidic compounds 
may help improve pharmacological properties of cruzain inhibitors and are still under 
investigation.
33
 
 
1.3.2 Sterol biosynthesis inhibitors 
Sterol biosynthesis inhibitors have been shown to be some of the most promising 
anti-T. cruzi agents.
37,38
 Sterols, such as cholesterol 24 in animals and ergosterol 26 
in fungi, are essential structural components of cell membranes and serve as 
precursors for biologically active molecules.
39
 In the T. cruzi biosynthetic pathway 
lanosterol 22 is converted to eburicol 25 which is the preferred substrate of sterol 
14α-demethylase (CYP51) and eventually will give ergosterol 26 in fungi (Figure 
10) and cholesterol 24 in humans.
39–41
 The parasite has an essential requirement for 
ergosterol for survival and multiplying, and cannot survive solely on cholesterol 
from the host.
42
 Ergosterol 26 differs from cholesterol 24 by the presence of a C-24 
11 
 
methyl group and a double bond at C-7 and C-22.
27
 The enzymes in CYP51 which 
produce the demethylation and double bonds to form ergosterol 26 in fungi differ 
from those found in humans.
27
 This makes the sterol biosynthesis pathway in the 
parasite an attractive target for drug development.
39
 Several steps in the sterol 
biosynthesis pathway have been investigated as potential targets, with CYP51 being 
the most favourable.
39
  
 
 
Figure 10. Biosynthetic pathway of cholesterol in humans and ergosterol in T. cruzi. 
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The CYP51 is the cytochrome P450 monooxygenase that catalyses the removal of 
the 14α-methyl group from eburicol.39 When the CYP51 is disrupted there is an 
alteration in the ultrastructure of several organelles, decline of endogenous sterols in 
the parasites and accumulation of various 14α-methyl sterols with cytostatic and 
cytotoxic consequences. Although humans have CYP51, it is much less sensitive to 
the drugs than T. cruzi.
27
 The azole compounds appear to be the most potent 
inhibitors in the in vitro studies against T. cruzi cultures.
37
 It has been thought that 
the potency could be due to the CYP51 structure, which has been elucidated by x-ray 
crystallography (Figure 11). The substrate binding cavity is quite rigid creating an 
actual binding cavity rather than a flexible pocket. It also contains a heme where 
azole heterocycles can coordinate to whilst the rest of the molecule occupies the 
active site cavity.
21
 The coordination to the iron in the heme alone is insufficient for 
a strong inhibitor as small molecules, like imidazole, have a low binding affinity. 
There is also a long hydrophobic tunnel connecting the chamber adjacent to the heme 
with the protein surface.
42
 The hydrophobic part of the inhibitor may enhance the 
molecules interaction with the cavity and increase the strength of the binding. 
 
 
Figure 11. Representation of the binding cavity of CYP51.42 
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Commercially available ergosterol biosynthesis inhibitors such as ketoconazole 27, 
fluconazole 29 and itraconazole are highly successful at treating fungal diseases but 
fail to inhibit T. cruzi in animal models and human patients.
6,31
 They exhibit 
suppressive effects but are unable to stop the progression of the disease.
6
 When the 
dosing of the drug stops, the parasite will start to replicate again. Other azole 
antifungal agents posaconazole 28, ravuconazole 30 and TAK-187 32 have 
demonstrated potent in vivo activity with IC50 values in the picomolar range.
31
 These 
are thought to inhibit the CYP51 of lanosterol biosynthesis pathway.
37
 
 
Posaconazole 28 is a structural analogue of itraconazole that was developed from 
ketoconazole 29. It is a broad spectrum antifungal drug that has been FDA approved 
for systemic fungal infection and targets CYP51.
6,42
 Posaconazole 28 contains a 
similar backbone to ketoconazole 29 (Figure 12). The triazole binds to the heme iron 
in the cavity (Figure 13) similar to fluconazole.
42
 The binding is strengthened by van 
der Waals contacts with amino acid residues in the binding cavity and in the 
substrate access channel surrounding the long arm.
43
 This is important in the potency 
of the drug inhibition. It has been reported to have 100% suppression of T. cruzi in 
mice treated with 20 mg/kg/day of posaconazole 28 at 54 days post infection, 
compared to only 50% suppression of mice treated with benznidazole.
44
 Evidence 
also suggests that there is less cardiac damage obtained than when treated with 
benznidazole 2.
6
 Although posaconazole 28 is potent, it has a complex structure that 
makes it expensive and difficult to synthesise.
39,42
 There is also limited selectivity 
over other CYP enzymes, rapid appearance of laboratory induced resistance to azoles 
and has significant toxicity.
45,46
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Figure 12. Structures of ketoconazole 27 and its analogue, posaconazole 28. 
 
 
Figure 13. X-ray structure of posaconazole 28 binding in CYP51 active site.42 
 
Another triazole that is in development is ravuconazole 30. Ravuconazole 30 is an 
investigational triazole that is based on fluconazole 29 and has shown potent and 
broad spectrum antifungal activity (Figure 14).
38
 It is currently in phase II trials as an 
anti-fungal agent and is an option for clinical development for Chagas disease. 
Ravuconazole 30 has been shown to be very active against T. cruzi in vitro, but only 
has limited activity in vivo in mice.
38
 It has a short half-life in mice (4.5 hours) which 
limited its activity in the experimental model but appears to have a long terminal 
15 
 
half-life (120 hours) in humans.
37,38
 The drug also appears more tolerable by humans 
than other drugs investigated.  
 
 
Figure 14. Strutures of fluconazole 29  and its derivatives ravuconazole 30  and E1224 31. 
 
A Japanese company, Eisai, has developed a new antifungal prodrug E1224 31 
which is water soluble and converts to the active drug ravuconazole in the body.
33,47
 
This improved the absorption and bioavailability of the drug. In 2009, the phase II 
trial was started in conjunction with DNDi to evaluate its potential as an oral, easy-
to-use, safe and affordable treatment for chronic human Chagas disease.
37
 Initial 
results showed good clearing of the parasite and a long terminal half-life but little 
sustained efficacy after one year.
22
 Less than one third of the patients remained 
parasite free after one year compared with 80% of patients treated with benznidazole. 
The study showed promise for combined treatment using E1224 with benznidazole.  
 
Another Japanese company, Takeda Chemical Company, has discovered a long 
lasting triazole derivative with a broad-spectrum anti-fungal activity known as TAK-
187 32 (Figure 15).
6
 It has been shown to have in vitro and in vivo activity against T. 
cruzi, is capable of curing both acute and chronic infections in animals, and has no 
detectable toxicity.
6,38
 TAK-187 32 also has a long half-life (35.6 h in mice) leading 
to longer drug exposure time for the same number of doses. 
 
16 
 
 
Figure 15. Structure of TAK-187 32. 
 
An imidazole derivative, VNI 33, was recently shown to inhibit CYP51 with high 
selectivity to fungal CYP51 and not the human CYP51 (Figure 16).
48,49
 It was the 
first compound not to come from an antifungal agent but from studying the inhibition 
of T. cruzi CYP51 activity.
48
 It appears to bind to CYP51 in a similar manner to 
posaconazole 28.
21,49
 Research has suggested that the potency for the inhibition of 
CYP51 by VNI 33 is enhanced by the hydrogen bond interactions found in the active 
site.
48
 As well as showing good inhibition against T. cruzi, VNI 33 has a low toxicity 
and is cheap to synthesise (<USD $0.10/mg).
21,49
 This makes it a good candidate for 
clinical trials and it is currently undergoing further investigation.
48–50
 
 
 
Figure 16. Structure of VNI 33. 
 
It has been reported that a preclinical anticancer drug, tipifarnib 34, has shown potent 
activity against T. cruzi (EC50 4 nM). Tipifarnib is an inhibitor of human protein 
farnesyltransferase (PFT) but has recently been shown to inhibit CYP51 in T.cruzi.
51
 
As tipifarnib would target human PFT and lead to undesirable side effects there have 
been investigations into analogues that avoid the inhibition of human PFT whilst 
retaining good inhibition of CYP51. Analogues have been designed to minimise the 
anti-PFT activity whilst improving CYP51 inhibitory activity (Figure 17).
6,7
 The 
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racemic mixture of the tipifarnib analogue 35 has an EC50 0.5 nM which is similar to 
tipifarnib (4 nM) but does not bind to the human CYP51.
51
 It only has a short half-
life in mice of 2 hours. Therefore there is no drug accumulation making it a good 
candidate for further investigation.
51
  
 
 
Figure 17. Structure of tipifarnib 34 and its analogue 35. 
 
Although azole derivatives remain the most potent inhibitors, other non-azole 
compounds have also been considered. A high-throughput screening identified a 
pyridine derivative LP-10 36 as a potential lead for development with an EC50 7 
µM.
52,53
 LP-10 inhibits the synthesis of endogenous sterol and is curative in 60% of 
cases of acute Chagas disease in murine models.
47
 It has been found to selectively 
bind to the T. cruzi CYP51 and is not cytotoxic in the cell.
47
 
 
 
Figure 18. Structure of LP-10 36. 
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Amiodarone 37 is currently used for its anti-arrhythmic effect in cardiomyopathy for 
chronic Chagas disease patients.
3,6,21
 Some observations have shown that it kills T. 
cruzi in cell cultures and animals cells. Reports suggest that it may reduce the levels 
of parasitemia in infected humans as well. It is active against T. cruzi by interfering 
with parasite calcium homeostasis by inducing the release of calcium from 
intracellular stores and by blocking ergosterol biosynthesis by inhibiting 
oxidosqualene cyclase.
3,6,21,47
 A study on mice has shown that using amiodarone 37 
alone resulted in a 0% cure rate, but when combined with posaconazole 28 it resulted 
in an 80% cure rate. Further clinical studies are being conducted on the anti-parasitic 
activity of this drug. 
 
 
Figure 19. Structure of amiodarone 37. 
 
The high selectivity of azole inhibitors for the pathogenic sterol 14α-demethylase of 
T. cruzi are desirable to prevent harmful methylated sterols in the human body and 
avoid negative side effects.
39
 This area is a prime target for further investigations. 
 
1.4 Initial investigation of the lead target compound 
DNDi has a goal of developing a superior drug candidate and has provided funding 
to a team of experts from Epichem Pty Ltd (medicinal chemistry), Murdoch 
University (parasitology) and the Centre for Drug Candidate Optimisation at Monash 
University (DMPK evaluation) for this to occur. The Murdoch University 
Parasitology group conducted in vitro screening of various commercially available 
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pesticides and herbicides against the T. cruzi strain Tulahuèn.
54
 The plant fungicides 
fenarimol 38 and pyrifenox 42 showed good inhibition against T. cruzi parasites with 
an IC50 of 350 nM and 290 nM respectively. These fungicides are used to treat 
powdery mildew and fungus on fruits and vegetables. Fenarimol has recently been 
reported to show inhibition against a related protozoan parasite Leishmania 
donovani
55
 and has demonstrated activity against T. cruzi in vitro and orally in an 
acute mouse model.
54
  
 
 
Figure 20. Fenarimol 38 and its analogues UDO 40 and UDD 41. 
 
Under the DNDi, fenarimol 38 was used as a lead compound and developed further 
(Figure 20). Initial results showed the replacement of the 5-pyrimidine with a 
pyridine ring led to significant improvements in potency when the nitrogen is in the 
3-position (compound 39).
22,54
 This compound suppressed the parasitemia to 
negligible levels in an in vivo mouse model of T. cruzi infection. However, the 
parasites re-emerged in the blood after three cycles of immunosuppression after 
dosing had ceased, which indicated that it was not curative.
54,56
 Further 
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functionalization of the two aromatic rings produced two candidates UDO 40 and 
UDD 41, which have been identified for possible preclinical development.
22,54,56
 
They can be prepared by a short synthetic route, have potent in vitro activity and are 
noncytotoxic. UDO 40 has an EC50 of 7.5 nM against T. cruzi and in the acute 
Chagas mouse model an ED50 of 20 mg/kg/qd for 20 days. UDD 41 has an EC50 of 
15 nM and ED50 of 20 mg/kg/qd for 20 days. The effectiveness is comparable to 
posaconazole 28 and better than benznidazole 2.
56
 Both UDO 40 and UDD 41 have 
been shown to inhibit the CYP51 in T. cruzi by the nitrogen in the pyridine ring 
binding to the heme (Figure 21) but do not inhibit the CYP3A4 in microsomes.
41
 
This furthers the investigation of non-azole compounds to be highly potent CYP51 
inhibitors of T. cruzi.  
 
 
 
The other fungicide, pyrifenox 42 (Figure 22), was also identified as a good CYP51 
inhibitor of T. cruzi by Witschel et al. with an IC50 of 491 nM.
57
  Although pyrifenox 
42 has been identified in two different high-throughput screenings of commercially 
available agrochemicals there has been no further investigations published in the 
literature into analogues of this compound as a new drug candidate for Chagas 
disease. Pyrifenox 42 has been reported to block the enzyme required for the 
biosynthesis of ergosterol and is thought to act on the enzyme CYP51.
42,58
 It has low 
toxicity and has no allergenic or mutagenic effects as an antifungal making it a 
suitable target for further research.
59
  
Figure 21. X-ray structure of UDO 40 and UDD 41 bound to the heme in the binding site of CYP51. 
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Figure 22. Analogues of pyrifenox have not been investigated. 
 
The structure of pyrifenox 42 has three distinct components− the pyridine ring, the 
oxime and the substituted phenyl ring (Figure 23). Initial investigations conducted at 
Epichem Pty Ltd have shown the aromatic nitrogen in the pyridine ring is essential 
for activity.
*
 The compounds synthesised without the pyridine ring (43) showed a 
decrease in biological activity with an IC50 greater than 10 µM. Therefore it appears 
the nitrogen in the pyridine ring is essential for binding to the heme in the active site. 
Having at least two carbons in the linker between the pyridyl ring and the phenyl ring 
also appears crucial. Where there is only one carbon between the two aromatic rings 
the biological activity is greater than 1 µM (44). The oxime group was also briefly 
investigated. The longer oxime 45 improved the activity slightly with one isomer 
showing an IC50 of 0.023 µM whilst the other isomer was only 0.26 µM. The 
stereochemistry of the two isomers was not identified. This indicates that the 
stereochemistry could also be important and requires investigation. Further research 
is still required into the structure activity relationship of pyrifenox to effectively 
inhibit CYP51 of T. cruzi. 
                                               
*
 Alexander, P; Keenan, M and Best, W. Epichem Ltd Pty. Personal communication, 2011 
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Figure 23. Pyrifenox made of 3 components- pyridine ring (red), oxime (green) and substituted phenyl ring 
(blue) and the initial analogues. 
 
1.5 Synthesis of pyrifenox 
The synthesis of pyrifenox 42 and related fungicides have been reported in a patent.
60
 
Dorn identified ketone 48 as the key intermediate to synthesise pyrifenox (Scheme 
1).
60,61
  The ketone intermediate 48 was synthesised from the reaction between ethyl 
3-pyridylacetate 46 and ethyl 2,4-dichlorobenzoate 47 with sodium methoxide. The 
ketone 48 was then reacted with methylhydroxylamine hydrochloride to give 
pyrifenox 42 as two isomers. The yield for the ketone formation was low (30%) and 
the starting materials are expensive. This procedure was also not repeatable in the 
initial investigations at Epichem Ltd Pty.
*
  
                                               
*
 Alexander, P; Keenan, M and Best, W. Epichem Ltd Pty. Personal communication, 2011 
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Scheme 1. Reported patent for the synthesis of pyrifenox 42. 
 
As the ketone 48 has been identified as the key intermediate this will be synthesised. 
An extensive literature search showed limited routes to the ketone 48. The other 
methods to synthesise this compound were also developed by Dorn et al.
61
 The first 
technique condensed 3-chloromethylpyridine 49 with 50 under phase transfer 
conditions to eliminate hydrogen cyanide to give compound 51 (Scheme 2). Acid 
hydrolysis of 51 gives the desired ketone 48. This method was also low yielding 
(30−50%)61 and therefore not economical on a large scale. 
 
 
Scheme 2 
 
Another technique for the synthesis of the ketone intermediate 48 is shown in 
Scheme 3.
61
 3-Pyridineacetophenone 52 and 2-chloro-1-(2,4-dichlorophenyl)- 
ethanone 53 were reacted with sodium methoxide to give the epoxyketone 54. The 
carbon chain was then shortened by a benzylic acid type rearrangement before an 
oxidative decarboxylation with ceric ammonium nitrate to give the desired ketone 
48. Although this method was higher yielding, the ceric ammonium nitrate is 
24 
 
expensive and the authors found that it could not be replaced with a cheaper 
reagent.
61
 
 
 
Scheme 3 
 
Due to the limited routes to synthesise the ketone intermediate 48, the literature 
search was broadened to produce a ketone (Table 1). This search also produced 
limited results.
61–66
 In recent publications, the use of palladium catalysts have be 
shown to be effective in cross coupling reactions. Biscoe and Buchwald developed a 
palladium precatalyst 59 that was used to synthesise similar ketones in one step from 
an aryl halide 56 and an acetophenone 57 (entry 1).
67
 Cao et al. then developed 
another palladium catalyst, (SIPr)Pd(Py)Cl2 60 (entry 2) that could be used under 
similar conditions.
66
 Both catalysts were reported to work in high yields (90% and 
70% respectively) but the use of the catalysts appeared temperamental. Crawford et 
al. developed a method using a DalPhos-based (61) catalyst system with 
[Pd(cinnamyl)Cl]2 in dioxane (entry 3).
62
 Although this system showed high yields 
with some ketones, the use of a 3-pyridyl ring was low yielding (21%). 
 
25 
 
 
Table 1 
Entry Conditions Yield 
1 KOBu
t
, toluene, 59 90% 
2 KOBu
t
, toluene, (SIPr)Pd(Py)Cl2 60 70% 
3 NaOBu
t
, 1,4-dioxane, [Pd(cinnamyl)Cl]2, 61 21% 
 
 
 
Other methods published in the literature appear quite dated. Miller et al. reported a 
procedure in 1956 where the ketone was prepared from 3-picoline 62, methyl 
benzoate 63 and potassium in liquid ammonia (Scheme 4).
68
 The reaction was low 
yielding (38%) and the strong base used restricts a variety of functional groups.  
 
 
Scheme 4 
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Due to the published procedures for the synthesis of a ketone requiring expensive 
catalysts and low yielding reactions, a new synthetic route to synthesise pyrifenox is 
required. 
 
1.6 Aim of project 
The commercially available antifungal pyrifenox 42 has been reported to have good 
inhibition against T. cruzi in vitro but has not been investigated further.
54,57
 This 
could be due to limited routes available to synthesise pyrifenox
60,61
 or the simplified 
ketone intermediate.
62–66
 This research will focus on a new and economical synthesis 
of the desired ketone intermediate and therefore a new synthesis for pyrifenox 42. 
 
Once an efficient method has been developed to synthesise pyrifenox 42, other 
analogues will be synthesised. The possible areas for investigation to increase the 
trypanosomal activity are shown in Figure 24. The areas for investigation will follow 
on from the initial investigations conducted by Epichem Pty Ltd mentioned in 
Section 1.4. The oxime chain appears to be an ideal target for investigation. The 
length and bulk of the oxime chain will be explored to determine the steric bulk 
required to bind effectively in the enzyme. The substituents on the phenyl ring can 
also be modified to explore the steric bulk required to fit into the hydrophobic pocket 
of the enzyme. The linker between the phenyl ring and the pyridine ring can also be 
investigated. Initial results have shown that having only one carbon linker between 
the pyridyl ring and the phenyl ring decreases biological activity (>1 µM). Other 
modifications of the linker include increasing the length of the carbon chain between 
the pyridyl ring and the phenyl ring, changing the position of the oxime and 
alkylation of the CH2 linker. 
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Figure 24. Proposed changes to pyrifenox. 
 
Initially the synthesis of pyrifenox will be examined. There have been reports in the 
literature that show the hydration of an alkyne can achieve the desired ketone 65 
(Scheme 5).
69–72
 Once the ketone has been synthesised a simple condensation of the 
ketone with a variety of alkoxyamine derivatives 66 will give a variety of pyrifenox 
analogues 67. The substituents X on the phenyl ring will also be varied. The main 
substituents that will be focussed on are hydrogen, fluorine and chlorine. 
 
 
Scheme 5. Proposed method to synthesise pyrifenox analogues from an alkyne.  
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2 Synthesis of 3-(pyridyl)acetophenones 
 
 
 
 
 
 
In order to access derivatives of pyrifenox, the synthesis of the ketone 65 was the 
initial focus of attention. Surprisingly, the published synthesis of the ketone 65 was 
sparse (Section 1.5) and a new more modular synthesis was mapped out. The plan 
was to make the key intermediate 65, containing an internal ketone, as shown in 
Scheme 6. 3-Bromopyridine 68 and an aryl bromide 70 would be connected to an 
acetylene equivalent 69 using two sequential Sonogashira coupling reactions.
73,74
 
The alkyne 64 could then be hydrated to form the key ketone intermediate 65. There 
were two key variations that were investigated: the substituents X and R on the 
pyrifenox analogue 67. The substituents X that were focussed on were hydrogen, 
fluorine and chlorine. The variation of the substituents on the phenyl would explore 
the steric bulk to see how large the pocket is where the aryl group binds inside the 
enzyme. 
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Scheme 6. General synthetic plan for the synthesis of pyrifenox derivatives.  
 
2.1 Synthesis of alkyne 64 
The alkyne 64, identified as the precursor to the ketone intermediate 65, could be 
made by two Sonogashira coupling reactions (Scheme 7). One side of the alkyne 
would need to be protected for the first Sonogashira reaction to stop other reactions 
from occurring. There are two common compounds that could be used. The most 
common protected alkyne used in literature was trimethylsilylacetylene.
75–77
 The 
trimethylsilyl protecting group could easily be removed under mild conditions in the 
presence of a base or fluoride ion.
75
 The main drawback with using 
trimethylsilylacetylene was the cost. A cheaper alternative would be to use 2-methyl-
3-butyn-2-ol 71, as the protecting group can readily be removed with the addition of 
a strong base to give the unprotected alkyne 73.
75,78
 Reaction of a phenyl substituted 
ring 70 and an unprotected alkyne 73 would give the desired alkyne 65. An unwanted 
by-product in Sonogashira reactions is the formation of a diyne 74 formed by a 
Glaser coupling between two terminal alkynes.
73,79
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Scheme 7. Proposed synthesis of the alkyne 64. 
 
The first target that was investigated was the difluoronated alkyne 76. The 
preparation of the alkyne 76 was more challenging than expected. Using the 
conditions outlined by Cosford et al,
74
 3-bromopyridine 68 and 2-methyl-3-butyne-2-
ol 71 were heated with PdCl2(PPh3)2 and copper(I) iodide in 1,2-dimethoxyethane 
under reflux (Scheme 8), no reaction was observed. On changing the solvents to neat 
diethylamine, the reaction gave the expected coupled product 72 in 37% yield.
80
 The 
spectral data matched that in the literature.
81
 The low reactivity of 3-bromopyridine 
could be attributed to the aromatic ring being electron-deficient. A study by Shoji et 
al. showed that in electron rich systems the Sonogashira reaction occurs in excellent 
yields but in electron-deficient systems the cross coupling product occurs in lower 
yields.
82
  
 
The alkyne 72 was then deprotected with toluene and sodium hydride to form the 
terminal alkyne 73. The spectral data was consistent with that in the literature.
74
 The 
1
H NMR spectrum showed the terminal alkyne signal at 3.20 ppm which was similar 
to phenylacetylene (3.06 ppm).
83
 The product did not require any further purification 
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and was used in the subsequent Sonogashira reaction. When the terminal alkyne 73 
and 1-bromo-2,4-difluorobenzene 75 were heated under reflux in the presence of 
PdCl2(PPh3)2 and copper(I) iodide in diethylamine, a complex mixture was produced. 
 
 
Scheme 8 
 
The nitrogen on the pyridine ring was suspected to interfere with the reactions. A 
solution to this problem was to rearrange the order of the two Sonogashira reactions 
(Scheme 9). The aryl bromide 70 could be reacted with 2-methyl-3-butyne-2-ol 71 to 
give the protected alkyne 77. The alkyne 77 could then be deprotected and reacted 
with 3-bromopyridine 68 to give the desired product 64. This approach would 
introduce the problematic pyridyl group at a later stage in the synthesis. 
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Scheme 9. Alternate proposed synthesis of the alkyne 64. 
 
1-Bromo-2,4-difluorobenzene 75 was heated with 2-methyl-3-butyne-2-ol 71, 
PdCl2(PPh3)2 and copper(I) iodide in diethylamine under reflux to give 79 (Scheme 
10). The 
1
H NMR spectrum showed two multiplets at 6.77−6.85 ppm and 7.33−7.41 
ppm with the integration of three hydrogens which corresponded to the aromatic 
hydrogens. There was also a singlet at 1.62 ppm with the integration of six 
hydrogens which corresponded to the two methyl groups. The signal at 3371 cm
−1
 in 
the IR spectrum corresponds to an OH stretch. This reaction was high yielding (83%) 
and was performed on a large scale (17 g). Surprisingly the solvent did not need to be 
dried and only stirred under nitrogen for one hour without purging the system. The 
Glaser by-product 80 was not observed with this reaction. 
 
 
Scheme 10 
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The removal of the alkyne protecting group proved to be difficult (Scheme 11). The 
use of sodium hydride and toluene produced a complex mixture. There was no signal 
at approximately 3 ppm in the 
1
H NMR spectrum corresponding to the terminal 
alkyne. Isolation by flash chromatography separated starting material and a 
compound that was not observed in the 
1
H NMR spectrum of the crude material. This 
suggested that the crude reaction mixture was decomposing during isolation and 
purification. The base was changed from sodium hydride to potassium hydroxide. 
The deprotection of the alkyne 79 with powdered potassium hydroxide in toluene
84
 
also did not produce the desired terminal alkyne 81. The 
1
H NMR spectrum of the 
crude material showed a complex mixture that was different from the previous 
attempt. Wang et al. reported that a mixture of terminal alkyne 81, dimer 82 and 
arylethynyl isopropyl ether 83 were obtained upon the deprotection using sodium 
hydroxide or potassium hydroxide in toluene on a large scale.
80
 Examination of the 
1
H NMR spectrum of the complex mixture showed there was a small singlet at 3.28 
ppm which was consistent with the terminal alkyne signal. This suggested that the 
terminal alkyne 81 was produced but was only a minor product. There were signals 
in the aromatic region which could be associated with the dimer 82 and two singlets 
between 1 and 2 ppm which could be compound 83 and starting material 79. Wang et 
al. also reported that upon changing the solvent from toluene to benzene and having 
a dilute solution improved the yield without any of the by-products occurring.
80
 The 
protected alkyne 79 was heated with potassium hydroxide in benzene under reflux. A 
Dean-Stark apparatus was used to remove the acetone generated. This gave the 
desired terminal alkyne 81 but the compound decomposed upon workup. The 
1
H 
NMR spectrum of the reaction mixture in benzene suggested that the reaction did 
occur by the terminal alkyne signal at 2.40 ppm which was consistent with literature 
spectral data.
85
 As the terminal alkyne 81 was decomposing upon workup it was not 
isolated and used directly in the next reaction. 
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Scheme 11 
Entry Conditions Product 
1 NaH, toluene, reflux, 3 h Decomposition 
2 KOH, toluene, 80 °C, 2 h Complex mixture 
3 KOH, benzene, reflux, o/n  Decomposed on workup 
 
The crude reaction mixture in benzene was used in the second Sonogashira reaction 
with 3-bromopyridine 68, PdCl2(PPh3)2 and copper(I) iodide in diethylamine under 
reflux to give the alkyne 76 (Scheme 12) in moderate yield (37%). The 
1
H NMR 
spectrum showed two broad singlets at 8.59 ppm and 8.79 ppm corresponding to the 
hydrogens next to the nitrogen in the pyridine ring. The 
13
C NMR spectrum showed 
two signals at 85.0 ppm and 90.7 ppm corresponding to the alkyne carbons. The 
lower yield (37%) was due to the low reactivity of 3-bromopyridine as it is electron 
deficient. The slower reaction allows the Glaser coupling to occur forming 82. 
Elangovan et al. found when oxygen is present in the reaction mixture the Pd(0) may 
reoxidise back to Pd(II) which is thought to catalyse the homocoupling of the 
terminal alkyne.
86
 To prevent the formation of the Glaser by-product from occurring, 
the reaction mixture was completely degassed using the freeze-pump-thaw method to 
remove oxygen from the system. 
35 
 
 
Scheme 12  
 
The other factor that could be affecting the yield of the second Sonogashira reaction 
was the solvent.
80
 The benzene was dried before use to see if that would affect the 
reaction and was found not to have any effect on the yield. If there was any water 
present in the solvent the Dean-Stark apparatus would help dry the reaction. It could 
be assumed that not removing the benzene from the deprotection step could be 
affecting the second Sonogashira reaction. By having a minimal amount of benzene 
in the reaction the yield improved slightly but there needed to be enough benzene for 
the deprotection to occur. Thus by diluting the reaction further with diethylamine, it 
was possible to obtain a maximum yield of 41%. This reaction was done on a 2 gram 
scale. 
 
A sequential Sonogashira-deprotection-Sonogashira one-pot synthesis was also 
investigated (Scheme 13).
75
 3-Bromopyridine 68 and 2-methyl-3-butyne-2-ol 71 in 
neat diisopropylamine were heated in an 50 °C oil bath with PdCl2(PPh3)2 and 
copper(I) iodide. Once TLC analysis showed no remaining starting material, 1-
bromo-2,4-difluorobenzene 75 and potassium hydroxide were added into the reaction 
mixture with additional PdCl2(PPh3)2 and copper(I) iodide and increased the 
temperature of the oil bath to 110 °C. This method produced the desired alkyne 76 in 
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low yield (28%) which could be due to more by-products being produced than in the 
previous two step sequence. Thus, the best procedure for preparing the alkyne 76 was 
by isolating the first Sonogashira product 79 (Scheme 10) before the deprotection 
and second Sonogashira reaction (Scheme 12). This method produced a compound 
that was easier to purify and gave a slightly better overall yield. The optimised 
conditions were used to synthesise a library of alkynes. 
 
 
Scheme 13. Conditions: i) PdCl2(PPh3)2, CuI, diisopropylamine, 50 °C, 2 days; ii) KOH, PdCl2(PPh3)2, CuI,    
110 °C, 3 days. 
 
Using the optimised method developed for compound 76 the chloro-substituted 
alkyne 87 was synthesised (Scheme 14). 1-Bromo-2,4-dichlorobenzene 84 and the 
protected alkyne 71 were reacted with PdCl2(PPh3)2 and copper(I) iodide in 
diethylamine to give 85. The 
1
H NMR spectrum showed a doublet of doublets at 7.16 
ppm, a doublet at 7.34 ppm and a doublet at 7.38 ppm corresponding to the aromatic 
hydrogens and a singlet at 1.62 ppm with the integration of six hydrogens 
corresponding to the two methyl groups. The IR spectrum showed a signal at 3362 
cm
−1
 corresponding to an OH stretch. This reaction was high yielding (94%) and was 
done on a large scale (15 g). The alkyne 85 was then sequentially deprotected with 
potassium hydroxide in benzene followed by a Sonogashira reaction with 3-
bromopyridine 68, PdCl2(PPh3)2 and copper(I) iodide in diethylamine to give the 
desired alkyne 87. The 
1
H NMR spectrum showed a doublet of doublets at 8.50 ppm 
and a broad singlet at 8.71 ppm corresponding to the hydrogens next to the nitrogen 
on the pyridine ring. The 
13
C NMR spectrum showed two signals at 88.6 ppm and 
91.9 ppm that corresponded to the alkyne carbons. The reaction yield was modest (32 
%), but acceptable. 
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Scheme 14 
  
Since the halogenated alkynes produced low yields, a model unhalogenated system 
was synthesised using the optimised Sonogashira reaction conditions (Scheme 15). 3-
Bromopyridine 68 was heated under reflux with phenylacetylene 88, PdCl2(PPh3)2 
and copper(I) iodide in diethylamine to give the alkyne 89. The spectral data 
matched that in the literature.
87
 The 
13
C NMR spectrum showed two peaks at 86.0 
ppm and 92.7 ppm corresponding to the alkyne carbons. This reaction was done on a 
large scale (3.5 g) and in high yield (88%).  
 
 
Scheme 15 
 
Three different alkyne systems have been successfully synthesised from the 
optimised reaction conditions. Having effectively produced three different alkyne 
systems the next key step was to form the ketone. 
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2.2 Hydration of the alkyne 
The next key reaction was to convert the alkyne 89 to the ketone 93. As this system 
has an internal alkyne there are two possible positions where the ketone can be 
formed: 92 and 93 (Scheme 16). Under acidic conditions, the nitrogen in the pyridine 
ring would be protonated generating a positive charge. For the ketone to form next to 
the pyridyl ring, compound 92, the carbocation would need to form on the carbon 
next to the pyridyl ring. This intermediate would be unstable due to the close 
proximity of two positive charges. The favoured position under acidic conditions 
would be compound 93. Under specific conditions the reaction can be regiospecific 
to form only compound 93.
71
 There has been limited work done on the hydration of 
disubstituted alkynes, particularly in biaryl systems. This could be due to the biaryl 
systems being electron deficient making it less reactive.
71
 Another drawback is the 
nitrogen in the pyridine ring can co-ordinate to metals involved in the hydrolysis 
reaction. Mercury(II) salts are effective for the hydration of alkynes but usually 
require strongly acidic conditions. Recent interest for the hydration of alkynes lies in 
using transition-metal-complex catalysts.
88
 These include ruthenium, rhodium, 
platinum and gold. The most common of these methods uses gold as the catalyst.
71,89–
91
 Brønsted acids and microwave irradiation are also common methods for hydration. 
 
 
Scheme 16 
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2.2.1 Brønsted acid promoted hydrations 
A recent review by Hintermann and Labonne
71
 discussed various methods where 
Brønsted acids are used to hydrate alkynes to form ketones. However, it was 
previously reported that the use of Brønsted acids required a large excess of the 
acidic reagent and would generally react in low yields with only electron-rich 
acetylene systems reacting in high yields.
92
 The unsubstituted alkyne 89 was used as 
a model compound to test the most efficient hydration reactions (Table 2).  
 
 
Table 2 
Entry Conditions Product 
1 Formic acid 98%, reflux, o/n No reaction 
2 CF3COOH, H2O, reflux, o/n 34% 
3 0.5 M HCl, microwave, 180 °C, 60 min 20% 
 
Formic acid has been shown to hydrate terminal and internal alkynes in moderate to 
high yields.
71,72,93
 On heating the alkyne 89 in a large excess of formic acid under 
reflux
72
 no reaction occurred. It has been noted in the literature that less activated 
alkynes require a ruthenium catalyst to facilitate the reaction in formic acid.
71,93
 The 
formic acid might not be strong enough to hydrate this internal triple bond. Therefore 
the acid was changed from formic acid to trifluoroacetic acid.
94
 Trifluoroacetic acid 
is a much stronger acid (pKa −0.5) compared with formic acid (pKa 3.75). When the 
alkyne 89 was stirred at room temperature in trifluoroacetic acid and water, no 
reaction occurred, but heating the reaction under reflux gratifyingly gave the ketone 
93 in 34% yield. The spectral data matched that in the literature.
66
 The 
1
H NMR 
spectrum showed a singlet at 4.27 ppm integrating for two hydrogens. The key 
diagnostic signal at 4.27 ppm corresponded to the CH2 between the pyridyl ring and 
the ketone. The 
13
C NMR spectrum showed a peak at 42.3 ppm corresponding to the 
40 
 
CH2 and a peak at 196.4 ppm corresponding to a carbonyl carbon. The IR spectrum 
showed a signal at 1679 cm
−1
 which suggested that a carbonyl group was present. 
Although the reaction with trifluoroacetic acid afforded the ketone 93, the reaction 
did not go to completion and was therefore low yielding (34%). On a larger scale (4 
mmol) the yield decreased further to only 4%. Due to the low yield it was not a 
reasonable method to use to hydrate the alkyne. 
 
The use of microwave irradiation in water
69,95
 or in conjunction with a Brønsted acid 
has shown good results in the literature for the hydration of alkynes.
69,71,95,96
 It has 
been thought that in pure water the H3O
+
 catalyses the reaction and the addition of 
protic acids increases the reaction rate.
71
 The alkyne 89 was reacted with a solution 
of hydrochloric acid (0.5 M) by microwave irradiation at 180 °C for 60 minutes. The 
1
H NMR spectrum of the crude material showed the key diagnostic signal at 4.27 
ppm. The desired ketone was isolated by column chromatography in 20% yield. 
Initial studies have shown the alkyne 89 was only slightly soluble under these 
conditions and the reaction does not go to completion. Therefore this reaction 
required further investigation. 
 
2.2.2 N-Oxides 
As the previous reactions were low yielding, the formation of the N-oxide was 
investigated to prevent the protonation of the nitrogen in the pyridine ring (Table 3). 
The use of hydrogen peroxide and acetic acid at 70 °C to oxidise the 3-
bromopyridine 68 gave no reaction. Using m-chloroperbenzoic acid in 
dichloromethane at room temperature produced the N-oxide 94 in high yield (82%). 
The 
1
H NMR spectrum showed a multiplet at 8.09−8.14 ppm and a triplet at 8.32 
ppm corresponding to the hydrogens next to the nitrogen in the pyridine ring. There 
was also a doublet of doublets at 7.13 ppm and a multiplet at 7.35−7.39 ppm 
corresponding to the other two aromatic hydrogens. The reaction product was pure 
and did not require further purification. 
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Table 3 
Entry Conditions Product 
1 H2O2, CH3COOH, 70 °C, 1 day No reaction 
2 mCPBA, DCM, rt, o/n 82% 
 
The N-oxide 94 and 2-methyl-3-butyn-2-ol 71 were heated under reflux with 
PdCl2(PPh3)2 and copper iodide in diethylamine to give the protected alkyne 95 in 
high yield (98%) (Scheme 17). The 
1
H NMR spectrum showed broad peaks at 7.21, 
8.12, and 8.22 ppm corresponding to the aromatic hydrogens. The singlet at 1.59 
ppm with the integration of six hydrogens corresponded to the two methyl groups 
and the singlet at 3.47 ppm corresponded to the OH group. The protected alkyne 95 
was difficult to purify and was used without further purification in the next step 
using the previously established deprotection conditions. The alkyne 95 was heated 
with sodium hydride in toluene under reflux, but under these conditions gave a 
complex mixture of products. 
 
 
Scheme 17 
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An alternate approach was to form the N-oxide of the alkyne 89 in the step before the 
hydration reaction. The alkyne 89 was heated with m-chloroperbenzoic acid in 
dichloromethane under reflux to give the N-oxide 97 (Scheme 18). The 
1
H NMR 
spectrum showed multiplets at 7.21−7.28 ppm, 7.33−7.41 ppm and 7.49−7.56 ppm 
corresponding to the aromatic hydrogens. The doublet at 8.18 ppm and singlet at 
8.34 ppm corresponded to the hydrogens next to the nitrogen on the pyridine ring. 
The yield (43%) was much lower than with 3-bromopyridine (Table 3, 82%). This 
could be due to the formation of the N-oxide being a more complicated system and 
the alkyne being oxidised to form unwanted by-products. The next step was the 
formation of the ketone. Using the previously established hydration condition of 
trifluoroacetic acid in water gave no reaction. As the N-oxides 94−97 were difficult 
to purify, this route was abandoned. 
 
 
Scheme 18 
 
2.2.3 Optimisation study on the hydration of alkynes using microwave 
irradiation 
The hydration of the alkyne 89 showed promising results by microwave irradiation 
(Section 2.2.1). The hydration reaction using microwave irradiation was investigated 
by heating 0.5 mmol of the alkyne and changing the solvent system (Table 4). The 
use of only water at the maximum temperature (195 °C) for 20 minutes produced a 
mixture of degradation products (entry 2). The addition of ethanol was used to 
increase the solubility. The alkyne 89 was reacted with a solution of hydrochloric 
acid (0.5 M) and ethanol by microwave irradiation at 180 °C for 90 minutes (entry 
3), but only trace amounts of the desired ketone was observed in the 
1
H NMR 
spectrum of the crude material. Another similar method used on internal aryl alkynes 
involved the use of  camphorsulfonic acid and ethanol.
96
 The reaction of the alkyne 
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89 with camphorsulfonic acid and ethanol in a microwave at 150 °C for 30 minutes 
was ineffective with no reaction occurring (entry 4). The use of 2 M hydrochloric 
acid was also ineffective with only starting material being recovered (entry 5). The 
concentration of the solution of hydrochloric acid was decreased from 2 M to 0.5 M 
and was heated at 170 °C for 20 minutes under microwave irradiation (entry 6). This 
produced trace amounts of the product as seen in the 
1
H NMR spectrum of the crude 
material. This suggested that a dilute acid needs to be present for the reaction to 
occur. It also appears that the key temperature of 180 °C is required for the reaction 
to occur. The low yielding reaction could be due to the solubility of the alkyne in the 
solution of hydrochloric acid. 
 
 
Table 4. Standard condition: 0.5 mmol alkyne 
Entry Conditions Yield 
1 0.5 M HCl 180 °C 60 min 20% 
2 Water 195 °C 20 min Degradation 
3 0.5 M HCl, EtOH 180 °C 90 min Trace 
4 CSA, EtOH 150 °C 30 min SM 
5 2 M HCl 170 °C 20 min SM 
6 0.5M HCl 170 °C 20 min Trace 
7 TFA, H2O, Sodium dodecyl sulfate 170 °C 20 min Trace 
 
In the previous study on Brønsted acids (Section 2.2.1), it was identified that 
trifluoroacetic acid hydrated the alkyne in low yields. Therefore trifluoroacetic acid 
was substituted for the 0.5 M hydrochloric acid to see if microwave irradiation could 
assist the reaction to go to completion (Table 4, entry 7). Unfortunately only trace 
amounts of the product was observed in the 
1
H NMR spectrum of the crude material. 
 
 
44 
 
As the alkyne 89 is insoluble in water a few surfactants were explored (Table 5). The 
addition of benzyltriethylammonium bromide and tetrabutylammonium bromide to 
the reaction mixture before microwave irradiation produced trace amounts of product 
whilst the use of sodium dodecyl sulfate gave 14% yield. These reactions were done 
at a high temperature (190 °C) and were reacted for a longer period of time (60 min). 
The surfactant sodium dodecyl sulfate was used to investigate the reaction further. 
 
 
Table 5. Standard conditions: 0.5 mmol alkyne, 0.5 M HCl, PTC, microwave irradiation 190 °C, 60 min. 
Entry PTC Yield 
1 Benzyltriethylammonium bromide Trace 
2 Tetrabutylammonium bromide Trace 
3 Sodium dodecyl sulfate 14% 
 
The temperature and time of the microwave reaction were investigated further using 
a solution of hydrochloric acid (0.5 M) and sodium dodecyl sulfate as a surfactant 
(Table 6). At 150 °C for 10 minutes only starting material was observed in the 
1
H 
NMR spectrum (entry 2). By increasing the temperature to 170 °C for 10 minutes 
trace amounts of the ketone 93 was observed in the 
1
H NMR spectrum of the crude 
material but the majority was starting material (entry 3). Upon increasing the time of 
the reaction to 20 minutes the yield increased to 27% (entry 4) but decreased to 3% 
when reacting for 60 minutes (entry 5). This was due to the increase of degradation 
by-products forming. The reaction was heated to the maximum temperature (195 °C) 
to get the reaction to go to completion (entry 6). Signals corresponding to the starting 
material were no longer present in the 
1
H NMR spectrum and the ketone yield 
increased (20%) but there were more degradation and side reactions occurring. The 
best conditions observed were heating 0.5 M hydrochloric acid and sodium dodecyl 
sulfate to 170 °C for 20 minutes by microwave irradiation. The yield (27%) was still 
too low and therefore this method did not seem a viable way of synthesising the 
ketone. 
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Table 6. Standard conditions: 0.5 mmol alkyne, 0.5 M HCl, sodium dodecyl sulfate. 
Entry Temperature/Time Yield 
1 190 °C 60 min 14% 
2 150 °C 10 min SM 
3 170 °C 10 min Trace 
4 170 °C 20 min 27% 
5 170 °C 60 min 3% 
6 195 °C 60 min 20% 
 
2.2.4 Transition metals 
The use of Brønsted acids and microwave irradiation were shown to be ineffective 
for the hydration of the alkyne 89 in high yields. Another method that has shown 
recent interest in the literature for the hydration of alkynes uses transition-metal-
complexes as catalysts. The most common catalyst used in hydration reactions are 
mercury catalysts, especially mercury(II) sulfate under acidic conditions.
71
 This can 
be obtained by using mercury(II) oxide in aqueous sulfuric acid and diluted in an 
organic solvent.
71
 The alkyne 89 was heated under reflux with mercury(II) oxide in 
sulfuric acid, water and methanol (Table 7, entry 1). The 
1
H NMR spectrum of the 
crude material showed a complex mixture. This suggested that under these reaction 
conditions the starting material could be decomposing. This could be due to the 
nitrogen in the pyridine ring affecting the reaction 
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Table 7 
Entry Conditions Product 
1 HgO 0.8 eq., MeOH, H2O, H2SO4, reflux, o/n Degradation 
2 RuCl3·H2O 0.6 eq., H2O, HCl, reflux, o/n Degradation 
3 K[AuBr4] 0.2 eq., MeOH, H2O, reflux, o/n No reaction 
4 Au(PPh3)Me 7.6 eq., MeOH, H2O, H2SO4, reflux, o/n 28% 
 
Ruthenium catalysts have also been investigated for the hydration of alkynes.
71,97
 
The alkyne 89 was heated with ruthenium(III) chloride in hydrochloric acid and 
water under reflux (Table 7, entry 2). The 
1
H NMR spectrum of the crude material 
showed a complex mixture of products. The 
1
H NMR spectrum of the crude reaction 
mixture clearly did not show the key signal for the CH2 peak at 4.27 ppm, suggesting 
the reaction did not occur. 
 
One of the more recent investigations in the literature was the use of a gold catalyst 
which has shown significant results in the hydration of internal alkynes.
71
 Gold(III) 
catalysts have also been shown to be successful in unactivated alkynes.
89
 The alkyne 
89 was heated under reflux with K[AuBr4] in methanol and water,
89
 however no 
reaction occurred. Using an alternate gold(I) catalyst, Au(PPh3)Me,
70
 the alkyne 89 
dissolved in sulfuric acid, water and methanol under reflux produced the desired 
ketone 93. The spectral data matched that in the literature.
66
 The reaction was low 
yielding (28%) and was not reproducible. Nevertheless, this reaction was promising 
and was investigated further. 
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2.2.5 Synthesis of methyl(triphenylphosphine) gold 
The hydration of the alkyne was investigated using Au(PPh3)Me as the catalyst. As 
the gold catalyst can be expensive to purchase (AU$233 for 500 mg),
98
 the synthesis 
was investigated. Although Au(PPh3)Me has been used extensively in the 
literature,
70,90–92,99–102
 a clear synthesis to prepare the catalyst has yet to be reported 
from gold. The preparation of the gold catalyst is reported here from a gold coin 
(Scheme 19). The gold coin (shown in Figure 25a) was dissolved in a mixture of 
nitric acid and hydrochloric acid (1:4) to give tetrachloroauric acid as an orange 
solution (Figure 25b).
100
 The gold had nearly dissolved after two hours but was left 
overnight to ensure complete dissolution. The tetrachloroauric acid was dissolved in 
methanol and was added dropwise to a solution of triphenylphosphine in 
methanol.
101
 A white precipitate formed immediately on the addition of the 
chloroauric acid and the solution slowly turned yellow as the mixture became more 
concentrated. The precipitate was filtered off to give Au(PPh3)Cl as a fluffy white 
solid (Figure 25c). The 
1
H NMR spectrum showed a multiplet at 7.45−7.55 ppm 
corresponding to the triphenylphosphine hydrogens. The 
13
C NMR spectrum showed 
six carbon signals between 129−134 ppm and were in the aromatic region. The 31P 
NMR spectrum showed only one signal at 33.75 ppm that was different from the 
uncoordinated triphenylphosphine unit (−4.78 ppm). This compound was stable at 
room temperature under normal atmospheric conditions after two years. Au(PPh3)Cl 
was converted to Au(PPh3)Me by reacting with methylmagnesium chloride in 
anhydrous tetrahydrofuran.
100
 The spectral data matched that in the literature.
90
 The 
31
P NMR spectrum showed a peak at 47.96 ppm which was different from the 
starting material (33.75 ppm) and the uncoordinated triphenylphosphine unit (−4.78 
ppm). On a small scale fine white crystals were obtained (Figure 25d) but when done 
on a larger scale the crystals were slightly purple. This could be due to the colloidal 
gold not being fully removed in the first filtration step, however this did not appear 
to affect the catalyst. 
 
 
Scheme 19 
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Figure 25. Gold coin (top left); HAuCl4 (top right); Au(PPh3)Cl (bottom left); Au(PPh3)Me (bottom right). 
 
The ethyl analogue was also synthesised by heating Au(PPh3)Cl with 
ethylmagnesium bromide in anhydrous ether to give Au(PPh3)Et as white crystals 
(Scheme 20). The yield (62%) was similar to the methyl analogue (59%). 
 
Scheme 20 
 
2.2.6 Gold catalysed hydration 
As mentioned previously, the alkyne 89 was reacted with Au(PPh3)Me in a mixture 
of sulfuric acid, methanol and water to give the desired ketone 93 in 28% yield but 
the reaction was not reproducible. A variety of different conditions were investigated 
to optimise the reaction using the gold catalyst (Table 8). It has been reported that the 
addition of ethyl diphenylphosphinite or phosphite prevents catalyst deterioration.
70
 
In this case the addition of triethylphosphite did not improve the reaction as only 
trace amounts of the product were observed in the 
1
H NMR spectrum of the crude 
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material (entry 2). The addition of unbound triphenylphosphine also gave no reaction 
(entry 3) which is consistent with that reported in the literature.
70
 Replacing sulfuric 
acid with triflic acid
70
 or  hydrochloric acid also gave no reaction (entry 4 and 5). 
Doubling the volume of sulfuric acid led to degradation (entry 6). The system also 
appeared to require oxygen free conditions. When there was oxygen present in the 
reaction only trace amounts of the product was observed in the 
1
H NMR spectrum of 
the crude material (entry 7) but on sparging the reaction mixture with nitrogen before 
the addition of the catalyst, the yield improved dramatically (entry 8, 90%). It has 
been reported in the literature that silver salts are useful in gold hydration reactions 
as an alternate method of forming the active catalyst.
103
 The alkyne 89 was heated 
with Au(PPh3)Cl and silver triflate in dioxane and water under reflux, however these 
conditions returned unreacted starting material (entry 9). 
 
 
Table 8 
Entry Conditions Product 
1 MeOH, H2O, H2SO4, Au(PPh3)Me, reflux, o/n 28% 
2 Addition of triethylphosphite Trace 
3 Addition of triphenylphosphine No reaction 
4 Change acid to triflic acid No reaction 
5 Change acid to hydrochloric acid No reaction 
6 Double volume of acid Degradation 
7 No degassing Trace 
8 Completely degassed system 90% 
9 Au(PPh3)Cl, AgOTf, dioxane, H2O No reaction 
10 N,N,N-Trimethylethylenediamine polymer bound 97% 
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The ideal conditions for the hydration reaction with the gold catalyst Au(PPh3)Me 
appeared to be the alkyne dissolved in a mixture of methanol, sulfuric acid and water 
and an oxygen free system. However the reaction was still not reliable as it would 
only occasionally work. Sometimes the reaction would be finished in 30 minutes; in 
other cases it would take overnight for the reaction to go to completion. Therefore 
other impurities could be poisoning the catalyst. Kumar et al. have reported that trace 
amounts of halides and basic components present in the solvent or starting material 
could poison the gold catalyst.
104
 Therefore HPLC grade methanol and MilliQ water 
were utilised to improve the purity of the solvent. The 
31
P NMR spectrum of the 
alkyne 89 showed a signal at 29.09 ppm which was not PdCl2(PPh3)2, 
triphenylphosphine or triphenylphosphine oxide. This could indicate that there was 
some of the catalyst by-products present in the starting material from the 
Sonogashira reaction which could be inhibiting the reactivity of the gold catalyst. 
This was consistent with literature which discussed the product from Sonogashira 
reactions might have a high palladium contamination.
81
 A metal scavenger was 
investigated to clean the alkyne before the reaction. N,N,N-
Trimethylethylenediamine polymer bound (Sigma-Aldrich, catalogue #656836) is a 
metal scavenger used to remove trace metals from solution, including Cu(I), Cu(II) 
and Pd(II). The alkyne was dissolved in dichloromethane and stirred overnight with 
the metal scavenger before being filtered off. The metal scavenger started off as a 
pale cream beads but after filtering off they had swollen slightly and were dark 
brown. This indicated that although the alkyne looked pure in the 
1
H NMR spectrum, 
there were possible metal contaminants that could be interfering with the gold 
catalyst. Upon reacting the clean alkyne with Au(PPh3)Me, HPLC grade methanol, 
sulfuric acid and MilliQ water the desired ketone was produced in high yields (97%). 
 
The mechanism for hydration by gold catalysis has been proposed by Mazzone et al. 
(Scheme 21).
105
 The Au(I) complex coordinates to the triple bond to give the Au-π-
alkyne complex (I). The R’OH adds to the alkyne forming the intermediate (III). 
Protodeauration of the intermediate gives the E isomer of the enolic product and 
releases the catalyst. Hydrolysis of the enol ether under the reaction conditions leads 
to the formation of the ketone product.
105
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Scheme 21. Proposed mechanism for the Au(I)-catalysed hydration of an alkyne. Adapted from Mazzone et al.105 
 
The ethyl gold catalyst was also trialled under the optimised conditions. The alkyne 
89 was heated with Au(PPh3)Et in HPLC grade methanol, sulfuric acid and MilliQ 
water under reflux in an oxygen free system (Scheme 22). This produced the desired 
ketone 93 in 91% yield which was similar to the methyl catalyst (Table 8, entry 10, 
97%).  
 
Scheme 22 
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2.2.7 Scope of gold catalysed hydration of internal alkynes 
Using the optimised conditions for the hydration of the alkyne 89, other internal 
alkynes were explored (Table 9). The alkynes were heated under reflux with 
Au(PPh3)Me, HPLC grade methanol, sulfuric acid and MilliQ water to give the 
desired ketones. The fluoro ketone 99 was high yielding (96%) and there were no 
observable impurities in the 
1
H NMR spectrum. The chloro ketone 48 had a slightly 
lower yield (88%). This was due to impurities present in the sample. Column 
chromatography was unable to isolate the impurities and the compound was used in 
the subsequent reaction. 
 
 
Table 9 
Compound X Yield 
93 H 97% 
99 F 96% 
48 Cl 88% 
 
2.3 Alternative reactions 
In view of the challenges in producing desired ketone intermediate, a series of 
alternative synthetic sequences were investigated to generate the key intermediate 65. 
These methods include a Heck reaction, a Curtius rearrangement and cross-coupling 
reactions to form the ketone 65. 
 
2.3.1 Synthesis of an alkene 
One potential route to form the desired ketone was to form the alkene instead of the 
alkyne. The alkene 101 could be formed via a Heck reaction. The alkene could then 
be hydrolysed to 102 and then oxidised to the ketone 89. Following the procedure by 
Cui et al,
106
 3-bromopyridine 68 and styrene 100 were heated at 130 °C with 
53 
 
acetylacetone, palladium(II) acetate and potassium carbonate in dry N,N-
dimethylformamide to give the alkene 101 (Scheme 23). The spectral data matched 
that in the literature.
107
 The 
1
H NMR spectrum showed two doublets at 7.06 ppm and 
7.16 ppm corresponding to the alkene. The doublets had a J coupling of 16.4 Hz 
which suggested the double bond was in the trans configuration which was the 
expected product. This reaction worked well and in high yields (72%).  
 
 
Scheme 23 
 
2.3.2 Hydrolysis of the alkene 
The next step was to hydrolyse the double bond. The alkene 101 was subjected to a 
variety of hydration conditions to form compound 102 (Table 10). Based on the 
previous result of the hydration of the alkyne, the alkene 101 was heated under reflux 
with trifluoroacetic acid and water. This returned unreacted starting material. The 
trifluoroacetic acid might not be a strong enough acid to hydrolyse the alkene. 
Therefore the acid was changed from trifluoroacetic acid to sulfuric acid. Sulfuric 
acid is a stronger acid (pKa −3) compared to trifluoroacetic acid (pKa −0.5). The 
alkene 101 was heated in sulfuric acid and water under reflux also produced no 
reaction. As there had been some results in Section 2.2.3 for the hydration of the 
alkyne with microwave irradiation this technique was also trialled. The alkene 101 
was treated with 0.5 M hydrochloric acid by microwave irradiation at 180 °C for one 
hour. Unfortunately, only starting material was recovered. 
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Table 10 
Entry Conditions Product 
1 CF3COOH, H2O, reflux, 3 days No reaction 
2 H2SO4, H2O, reflux, 4 days No reaction 
3 HCl, H2O, microwave 180 °C, 1 h No reaction 
 
An alternative to hydrolysing the alkene was the addition of a halogen which could 
then be hydrolysed (Table 11). The alkene 101 was heated to 60 °C with 
hydrobromic acid (48%) (entry 1). This gave no reaction. Since the bromide gave no 
reaction, iodide was trialled. Iodides are better nucleophiles than bromides. I
−
 could 
be formed in situ from potassium iodide and phosphoric acid.
108
 When the alkene 
101 was heated with potassium iodide and phosphoric acid, a new compound was 
isolated in 72% yield (entry 2). The 
1
H NMR spectrum showed a broad singlet at 
8.47 ppm corresponding to the hydrogens next to the nitrogen in the pyridine ring 
and signals relating to the other seven aromatic hydrogens between 7.14 ppm and 
7.47 ppm. There was a multiplet at 2.94−2.96 ppm with the integration of four 
hydrogens. The 
13
C NMR spectrum showed seven signals in the aromatic region and 
two CH2 signals at 34.9 ppm and 37.5 ppm. This suggested that the alkane was being 
formed. The spectral data matched that in the literature for the alkane.
109
 This 
suggested the alkene is being hydrogenated under these conditions. This could be due 
to I
−
 being oxidised to I2 thereby reducing the alkene to the alkane. There is a patent 
which describes a reaction of reducing an alkene 103 to an alkane 104 using 
anhydrous hydrogen iodide and heating to 230 °C in a sealed vessel for 15 hours 
(Scheme 24).
110
 This procedure was high yielding but used harsh conditions of 
heating the reaction to high temperatures in a sealed vessel. In comparison, the 
conditions of potassium iodide and phosphoric acid are less harsh than those 
described in the patent. 
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Scheme 24 
 
There have been reports that the surfaces of silica gel and alumina facilitates 
hydrohalogenation of alkenes by promoting ionic addition through hydrogen-
bonding interactions.
111,112
 The alkene 101 was treated with oxalyl chloride in the 
presence of silica gel (Table 11, entry 3). 
112
 This produced no reaction in this 
system. The reaction was also trialled with alumina which also gave no reaction.  
 
 
Table 11 
Entry Conditions Product 
1 HBr 48%, 60 °C, o/n No reaction 
2 KI, H3PO4, 150 °C, 2 days X = H, 72% 
3 (COCl)2, SiO2, DCM, rt, 4 h  No reaction 
 
The alkene 101 appears to be fairly unreactive. Therefore this route was abandoned. 
Nevertheless, an interesting hydrogenation of an alkene was observed with potassium 
iodide and phosphoric acid reducing the alkene to an alkane.  
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2.3.3 Curtius rearrangement 
Another potential procedure to form the desired ketone 42 is shown in Scheme 25. 
An aldol condensation reaction between 3-pyridinecarboxaldehyde 106 and 2,4-
dichlorophenylacetic acid 107 would form the reported the carboxylic acid 
intermediate 108. Conversion of the carboxylic acid 108 to an acid chloride using 
thionyl chloride would form the salt 109. This could be converted to the ketone 48 
via a Curtius rearrangement. 
 
 
Scheme 25. Proposed synthesis of the ketone 48. 
 
Following a patented procedure, 3-pyridinecarboxaldehyde 106 and 2,4-
dichlorophenylacetic acid 107 were heated with triethylamine in acetic anhydride 
under reflux to give a solid product upon workup (Scheme 26).
113
 Recrystallisation 
of the crude material produced the carboxylic acid 108 in 62% yield. The spectral 
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data was consistent with that in the literature.
113
 A singlet in the 
1
H NMR spectrum at 
7.86 ppm corresponded to the vinylic proton. The 
13
C NMR spectrum showed a peak 
at 166.9 ppm corresponding to the carbonyl carbon. 
 
 
Scheme 26 
 
Treating the forgoing acid 108 with an excess of thionyl chloride at reflux produced 
the acid chloride as the hydrochloride salt (Scheme 27).
113
 The excess thionyl 
chloride was removed via distillation. Trituration of the residue with diethyl ether 
removed the remaining traces of thionyl chloride. This reaction was high yielding 
(97%) and was used in the next step without further purification.  
 
 
Scheme 27 
 
To convert the acid chloride 109 to the ketone 48 required a 3-step synthesis 
(Scheme 28). The acid chloride 109 was dissolved in acetone and reacted with a 
solution of sodium azide and water via a substitution reaction to give the azide 111. 
The reaction mixture was made basic with a solution of sodium carbonate and the 
neutral compounds were extracted with toluene. The toluene extract was heated 
under reflux to give compound 110. The solvent was removed under reduced 
pressure and the residue was heated under reflux with acetic acid and water to give 
the ketone 48 in 44% yield. The spectral data matched that previously synthesised. 
The key peak of a singlet at 4.25 ppm in the 
1
H NMR
 
spectrum corresponded to the 
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CH2 between the pyridyl ring and the ketone. There was an impurity observed in the 
1
H NMR spectrum even after purification which was similar to that observed in the 
gold method (Section 2.2.7). Over time this impurity increased until the ketone was 
fully converted to the impurity. Analysis of the spectral data of the isolated impurity 
suggested that the ketone 48 was converting to form the diketone 112. The 
1
H NMR 
spectrum showed a doublet at 9.24 ppm and a doublet of doublets at 8.90 ppm 
corresponding to the pyridyl ring and there was an absence of the key CH2 signal at 
4.25 ppm. In the 
13
C spectrum there were two peaks in the carbonyl region at 191.8 
ppm and 190.2 ppm. The absence of the CH2 peak in the 
1
H NMR spectrum and the 
two signals in the carbonyl region for the 
13
C NMR spectrum suggested the diketone 
112 was being formed. Therefore, ketone 48 could not be purified as it was 
continually being oxidised to the diketone. However, the oxidation was not as rapid 
in the gold method. The rapid oxidation in this system could be due to an acid or an 
oxidant present in the ketone 48 during isolation and purification. The best storage 
conditions to slow down the rapid oxidation were to store the ketone at −20 °C under 
nitrogen in the dark. 
 
Scheme 28 
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2.3.4 Condensation reaction 
Recently, Wu et al. published a direct Claisen-decarboxylation cascade reaction 
between an α-carboxylic acid and an ester to produce an internal ketone similar to 
compound 48.
114
 This method was investigated to synthesise the ketone 48 (Scheme 
29). The ester was made by according to Potter et al.
115
 by heating 2,4-
dichlorobenzoic acid 113, methanol and sulfuric acid under reflux to give the desired 
methyl ester 114 in 94% yield. The spectral data matched that in the literature. The 
product obtained was pure without further purification. The methyl ester 114 and 
2,4-dichlorophenylacetic acid 115 were reacted with sodium bis(trimethylsilyl)amide 
(1.0 M in THF) in N,N-dimethylformamide at −8 °C. The 1H NMR spectrum of the 
crude material showed mainly the methyl ester 114 and trace amounts of the desired 
ketone 48. The 
1
H NMR spectrum of the ketone after column chromatography 
showed additional peaks not observed in the spectrum of the crude material. The 
impurity signals match that of the diketone 112 that was identified in Section 2.3.3. 
This suggested the ketone was being formed and then being oxidised to the diketone 
112. Due to the very low yield of the unstable ketone, this reaction was not 
investigated further.  
 
 
Scheme 29 
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2.3.5 Palladium catalysed cross-coupling 
The final method examined has recently been reported in the literature and involved 
a cross coupling reaction between an aryl halide and an enolate using a precatalyst as 
a palladium source.
65
 The use of the precatalyst, chloro(2-dicyclohexylphosphino-
2ʹ,4ʹ,6ʹ-tri-iso-propyl-1,1ʹ-biphenyl)[2-(2-aminoethyl)phenyl]Pd(II) methyl-tert-butyl 
ether adduct 59 and potassium tert-butoxide in dry toluene would give the desired 
monoarylation.
65
 Potassium tert-butoxide was used as a base to activate the 
catalyst.
67
 3-Chloropyridine 116 and acetophenone 57 were heated under reflux with 
59 and potassium tert-butoxide in dry toluene to give the desired ketone 93. The 
spectral data matched that previously synthesised. The reaction was high yielding 
(87%) on a small scale (1 mmol) but on increasing the scale the yield decreased to 
only 10%. A variety of other acetophenones were also investigated, however no 
reaction occurred. Due to the high cost of the catalyst and the inconsistent results this 
method was not investigated further. 
 
 
Scheme 30 
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2.4 Conclusions 
A variety of different methods were investigated to synthesise the desired ketone 
intermediate. The use of the Sonogashira coupling reaction was optimised to 
synthesise an alkyne which was then hydrated to form the ketone. The alkyne 
appeared relatively unreactive to many hydration methods. The use of the gold 
catalyst, Au(PPh3)Me, showed optimum results with the ketone being synthesised in 
high yields (99%). However, the dichloro ketone 48 could not be purified as it 
continued to be oxidised to the dione 112. This could be why there are limited 
procedures in the literature to synthesise the ketone 48 and pyrifenox 42. 
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3 Preparation and anti-trypanosomal activity of 
pyrifenox analogues  
 
 
 
 
 
In the previous chapter, a simple synthetic route was established to synthesise the 
ketone intermediate 65. The final step to form the pyrifenox analogues was the 
formation of the oxime 67 (Scheme 31). A condensation reaction of the ketone 65 
with a range of alkoxyamines 66 would give the desired oxime 67 as two isomers. 
 
 
Scheme 31 
 
There are three features to the binding of the molecule. These include the binding of 
the molecule to the heme, the hydrophobic pocket and the access tunnel. Hargrove et 
al. obtained a crystal structure of UDO 40 bound to the active site CYP51 (Figure 
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26).
41
 The nitrogen in the pyridine ring was observed binding to the iron in the heme 
and the phenyl ring twisting perpendicular to the pyridine ring in the hydrophobic 
pocket. The longer chain was orientated down the access channel. It was thought that 
pyrifenox and its analogues would bind to CYP51 in a similar way. 
 
 
 
 
 
Initially this research focused on changing the substituents on the phenyl ring and 
having a methyl oxime. The substituents that were investigated were hydrogen, 
fluorine and chlorine to determine the steric bulk required to fit into the hydrophobic 
pocket. The steric bulk and length of the oxime chain were then investigated to 
determine the fit inside the access tunnel. As two isomers should be formed the 
stereochemistry of the oxime would also be considered. 
 
 
Figure 27. Modification of pyrifenox. 
 
Figure 26 
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3.1 Methyloxime analogues 
The final step in the synthesis was the formation of the oxime. To synthesise 
pyrifenox, Dorn
60
 heated a mixture of the dichloro ketone 42, O-
methylhydroxylamine hydrochloride and sodium carbonate in ethanol under reflux to 
give the methyl oxime as two isomers. This appeared to be the most popular method 
in the literature for the formation of oximes.
60,116–118
 The ketone 93 was stirred with 
O-methylhydroxylamine hydrochloride and sodium acetate in ethanol at room 
temperature (Scheme 32).
117
 The 
1
H NMR spectrum of the crude material showed 
four singlets between 3.8 ppm and 4.2 ppm. These peaks corresponded to the CH2 
and the methyl groups of two isomers. The two isomers were isolated by column 
chromatography due to slightly different polarities. The 
1
H NMR spectrum of the 
less polar isomer showed a singlet at 4.02 ppm with the integration for three 
hydrogens and a singlet at 4.12 ppm with the integration of two hydrogens (Figure 
29). These peaks corresponded to the methyl oxime and the CH2. The signals in the 
1
H NMR spectrum of the more polar isomer are more shielded. The methyl signal 
was seen at 3.88 ppm and the CH2 signal at 3.86 ppm. The high resolution mass 
spectrometry showed that both compounds have the same accurate mass, thus 
indicating that both isomers were synthesised. 
 
 
Scheme 32 
 
The two isomers were successfully synthesised and isolated, and the identification of 
the stereochemistry was investigated. NOE experiments were conducted but it was 
not possible to determine the configuration of the two isomers unambiguously as 
there were no enhancements between the methyl group and any other hydrogen. The 
stereochemistry was determined based on the chemical shifts in a similar system in 
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the literature where a biphenyl system was used.
119
 The 
1
H NMR spectra of the 
methyl and CH2 signals were compared (Figure 28). In compound 118 the less polar 
E isomer showed the CH2 singlet at 4.05 ppm and the methyl singlet at 3.92 ppm. 
This was similar to the less polar isomer in the pyrifenox analogue 117. The more 
polar Z isomer in the biphenyl system 118 showed the CH2 singlet at 3.73 ppm and 
the methyl singlet at 3.80 ppm. This was similar to the Z isomer of the pyrifenox 
analogue 117. Therefore it could be proposed that the less polar isomer was the E 
isomer and the more polar isomer was the Z isomer. In the biphenyl system 118 for 
the E isomer the CH2 signal was more downfield than the methyl signal. For the Z 
isomer both signals were more shielded and the methyl signal was shifted slightly 
downfield to the CH2. This was similar to what was seen in the E and Z isomers of 
compound 117 (Figure 29). The overall yield was 67% with a ratio of the isomers 3:1 
as an E/Z mixture as observed in the 
1
H NMR spectrum of the crude material. 
Although the E isomer was the favoured isomer only 34% was isolated compared to 
the Z isomer 35%. This suggested that some of the E isomer was lost during 
purification. 
 
 
Figure 28. Comparison of a biphenyl system 118 1H NMR signals for the CH2 and methyl to compound 117. 
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Figure 29. Chemical shifts of the E and Z isomers of compound 117 for the CH2 and methyl signals. 
 
The same conditions were used to synthesise the methyl oxime for the fluoro and 
chloro substituted compounds. The ketone was stirred with O-methylhydroxylamine 
hydrochloride and sodium acetate in ethanol at room temperature (Scheme 33). The 
fluoro methyl oxime 119 was successfully isolated with a ratio of isomers 2.4:1 with 
the less polar isomer being the major isomer. The 
1
H NMR spectrum of the less polar 
isomer showed a singlet at 4.00 ppm with the integration of three hydrogens and a 
singlet at 4.08 ppm with the integration of two hydrogens, which corresponded to the 
methyl oxime and the CH2 respectively. The 
1
H NMR spectrum of the more polar 
isomer showed a singlet at 3.83 ppm with the integration of two hydrogens and a 
singlet at 3.87 ppm with the integration of three hydrogens, corresponding to the CH2 
and the methyl oxime respectively. Based on the proposed structure outlined for 
compound 117, it can be proposed that the E isomer was the less polar isomer, and 
was favoured synthetically over the more polar Z isomer. 
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Scheme 33 
Compound X 
Yield 
E Z 
119 F 45% 19% 
42 Cl Complex mixture 
 
The synthesis of pyrifenox 42 was problematic. The E and Z isomers were the major 
products, however extra singlets were seen in the 
1
H NMR spectrum associating to 
methyl groups. Spontaneous oxidation of the ketone 42 to the diketone 112 was 
observed in Chapter 2 and the diketone could then react with O-
methylhydroxylamine forming the methyl oximes on both ketones as a mixture of 
isomers (Figure 30). Due to the very similar polarities of the mixture of compounds 
the E and Z isomers were unable to be purified. 
 
 
Figure 30 
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The methyl oximes 117 and 119 were successfully synthesised and were analysed in 
vitro T. cruzi assays. Unfortunately pyrifenox 42 was unable to be purified and was 
not investigated further. 
 
3.1.1 Methyl oxime inhibition of T. cruzi 
The pyrifenox analogues were assayed in an in vitro whole cell parasite assay by the 
School of Veterinary and Biomedical Science at Murdoch University (Table 12). The 
compounds were incubated in L6 cells against T. cruzi Tulahuèn strain that expresses 
the β-galactosidase gene. Benznidazole (Epichem Pty Ltd) was used as a control. The 
cytotoxicity was determined as a counter-screen in L6 cells. The same conditions 
were used in subsequent testing throughout this thesis. 
 
Table 12. Inhibition and toxicity of the methyl oxime analogues against T. cruzi. 
Structure 
IC50 (toxicity) 
E Z 
 
0.29 µM 
 
0.67 µM (>100 µM) 2.31 µM (>100 µM) 
 
>10 µM (>100 µM) >10 µM (>100 µM) 
 
The methyl oximes synthesised were tested for their ability to inhibit T. cruzi (Table 
12). The pyrifenox that was initially analysed was a mixture of E and Z isomers with 
a ratio 2:1 and had an IC50 of 0.29 µM. The fluoro methyl oximes 119 were isolated 
and both E and Z isomers were tested. The E isomer had an IC50 of 0.67 µM and the 
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Z isomer had an IC50 of 2.31 µM. This showed that changing the chlorine 
substituents on the phenyl ring to fluorine substituents increased the IC50, but not 
significantly. The fluoro compound was also non-cytotoxic (>100 µM). The 
stereochemistry also appeared to be important. The E isomer was three times more 
potent than the Z isomer. The unsubstituted phenyl ring methyl oxime 117 had an 
IC50 greater than 10 µM for both isomers. This suggested that the phenyl ring 
requires bulky substituents to bind better into the hydrophobic pocket of CYP51. 
 
Visualisation of the compounds bound to CYP51 provided some insight to the above 
results. As can be seen in Figure 31, the nitrogen in the pyridine ring binds to the 
heme iron in the enzyme. The phenyl ring has twisted slightly to become 
perpendicular to the pyridyl ring. The substituted phenyl ring appears to orientate 
into the hydrophobic pocket in the enzyme. The chloro substituents are larger than 
fluoro and hydrogen atoms. As the pyrifenox showed a better biological activity than 
compounds 117 and 119, the chlorines must be required to fill the hydrophobic 
pocket to interact better within the enzyme. The Z isomer also appears to not fit into 
the active site. The results obtained for the Z isomer could be due to the 
isomerisation of the Z isomer to the E isomer within the parasite by an acid catalysed 
conversion.  
 
 
 
Figure 31. Visualisation of the methyl oxime analogues 70 and 69 binding in CYP51. 
70 
 
3.2 Longer chain oximes 
To take advantage of extra hydrophobic interactions in the access tunnel, larger, 
bulkier oximes could be utilised. The longer oximes could potentially fit into the 
enzyme better than the methyl oxime. The increased interactions with the 
hydrophobic tunnel could be used to increase the selectivity and potency of the 
compound. Having successfully synthesised the methyl oximes 117 and 119 more 
complicated oximes were sought. In Section 3.1.1, it was shown that the chloro 
substituents on the phenyl ring showed the best activity but the ketone intermediate 
was difficult to synthesise due to it being oxidised to the diketone. Therefore the 
simpler unhalogenated ketone 93 was used to synthesise other oximes.  
 
The first oxime that was investigated was increasing the chain from a methyl to an 
ethyl. The ketone 93 was stirred with O-ethoxylamine hydrochloride 122 and sodium 
acetate in ethanol (Scheme 34). The ethyl oxime 123 was seen as two isomers in the 
1
H NMR spectrum of the crude material as a ratio of 2:1 (Figure 32). It was only 
possible to fully purify and characterise the less polar isomer. The 
1
H NMR spectrum 
showed a singlet at 4.22 ppm corresponding to the CH2, a quartet at 4.29 ppm and a 
triplet at 1.32 ppm corresponding to the ethyl oxime. Based on the proposed structure 
for the methyl oxime it can be suggested that the E isomer was isolated. The E 
isomer and a mixture of E/Z isomers were tested against T. cruzi.  
 
 
Scheme 34 
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Figure 32. The 1H NMR spectrum of the purified E isomer 123 (red) and a mixture of the two isomers. 
 
The bulkiness of the oxime was also considered. The ketone 93 was stirred with O-
benzylhydroxylamine hydrochloride 124 and sodium acetate in ethanol (Scheme 35). 
The 
1
H NMR spectrum of the crude material suggested there were two isomers 
synthesised by the presence of two singlets at 5.18 ppm and 5.05 ppm corresponding 
to the CH2 of the oxime and two singlets at 4.06 ppm and 3.74 ppm corresponding to 
the CH2 between the oxime and pyridyl ring. It was only possible to purify one 
isomer by column chromatography, which was identified as the E isomer. 
 
 
Scheme 35 
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To increase the bulk of the oxime further the pentafluorobenzyl oxime was 
synthesised (Scheme 36). The ketone 93 was stirred with O-
pentafluorobenzylhydroxylamine hydrochloride 126 and sodium acetate in ethanol. 
Column chromatography isolated the ketone starting material 93 (34%) and a 
mixture of the two isomers 127 as a 2.9:1 ratio (40%). The two isomers were seen in 
the 
1
H NMR spectrum as two singlets at 3.81 ppm and 4.09 ppm corresponding to 
the CH2 between the pyridyl ring and the oxime, and two singlets at 5.14 ppm and 
5.32 ppm corresponding to the CH2 of the oxime. The two isomers were unable to be 
separated and were tested as a mixture against T. cruzi. 
 
 
Scheme 36  
 
3.3 Synthesis of alkoxyamines 
Only simple alkoxyamines are commercially available and since a variety of 
alkoxyamines were going to be investigated the precursors needed to be synthesised. 
There were two possible methods that could be used (Scheme 37). The ketone 93 
could be reacted with the hydroxylamine hydrochloride 128 forming the 
hydroxyloxime 129. This could then be alkylated with a variety of alkyl chains to 
give the more complicated oximes 130. The downfall with this method was the 
potential for the pyridyl nitrogen to be alkylated. Another method that could be used 
was to first synthesise the alkoxyamines 66 from hydroxylamine 128. This could 
then react with the ketone 93 to form the oxime 130. As the ketone 93 was difficult 
to synthesise and wanting to limit potential alkylation of the pyridyl nitrogen, the 
latter method was used. 
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Scheme 37 
 
Alkoxyamines can be made by alkylating the hydroxylamine. The reaction could 
occur on the nitrogen or the oxygen. The nitrogen would be the favoured position for 
the reaction to occur due to it being a better nucleophile than oxygen. Therefore the 
nitrogen needed to be protected for the reaction to occur on the oxygen. The nitrogen 
could be protected by using N-hydroxyphthalimide 131 as the starting material 
(Scheme 38). The carbonyl groups are electron withdrawing and protect the nitrogen 
so the alkylation could occur on the alcohol forming an ether type compound 132. 
The protecting group could then be cleaved using hydrazine to form the alkoxyamine 
derivatives 66.
120
 
 
 
Scheme 38 
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Following a procedure by Dendane et al,
120
 1-bromobutane 133 was reacted with N-
hydroxyphthalimide 131 and sodium carbonate in N,N-dimethylformamide at room 
temperature (Table 13, entry 1). The product 134 precipitated out of the reaction 
mixture after the addition of water and was dried under vacuum. The spectral data 
matched that in the literature.
121
 The product obtained was pure and could be used 
without further purification but the yield was very low (2.4%). Upon heating to 45 
°C the yield improved dramatically to 41%. Therefore heat must be required for the 
reaction to progress. The reaction was heated to 90 °C and the yield improved to 
79% and could be done on a large scale (13 g).  
 
 
Table 13 
Entry Conditions Product 
1 Na2CO3, DMF, 1.5 days, r.t. 2.4% 
2 Na2CO3, DMF, 2 days, 45 °C 41% 
3 Na2CO3, DMF, 2 days, 90 °C 79% 
 
The optimised conditions were used to synthesise other alkoxyamine precursors 
(Table 14). The alkyl halide was heated to 90 °C with N-hydroxyphthalimide 131 
and sodium carbonate in N,N-dimethylformamide. The reactions occurred in 
moderate to high yield (34−85%). The majority of the products precipitated out of 
the reaction mixture upon the addition of water. The 1-bromo-3-methylbutane 137 
and ethyl 4-bromobutyrate 141 derivatives were more soluble and required extraction 
from the reaction mixture with dichloromethane first before a solid was formed. 
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Table 14 
Compound R Yield 
135 
 
69% 
136 
 
68% 
137 
 
59% 
138 
 
51% 
139 
 
85% 
140 
 
48% 
141 
 
34% 
 
The hydroxylamines were synthesised from the precursors by reacting with 
hydrazine hydrate. N-Butoxyphthalimide 134 was heated with hydrazine hydrate and 
dichloromethane under reflux (Scheme 39).
117,118
 The 
1
H NMR spectrum of the 
isolated compound showed a triplet at 0.87 ppm corresponding to the CH3 and a 
triplet at 3.61 corresponding to the CH2 next to the oxime. The yield obtained was 
low (1.5%) which could be due to the suspected volatility of butoxyamine 142. 
Mesitylene was added to the reaction mixture as an internal standard to determine the 
reaction yield before isolation. The 
1
H NMR spectrum of the crude material showed 
90% yield of product and LC-MS of the reaction mixture showed full conversion 
after 30 minutes.  
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Scheme 39 
 
As the hydroxylamine 142 synthesised was volatile, a one-pot synthesis was used to 
convert the protected alkoxyamine 134 to the alkoxyamine 142, before the addition 
of the ketone 93. As the unhalogenated ketone 93 was the simplest to make, this was 
used to synthesise the other oximes. N-Butoxyphthalimide 134 was heated under 
reflux with hydrazine hydrate in ethanol for 30 minutes. The ketone 93 and acetic 
acid in ethanol was then added to the reaction mixture (Scheme 40). The 
1
H NMR 
spectrum of the crude material showed trace amounts of one isomer and an unknown 
compound. The two compounds were isolated by column chromatography. The 
desired isomer was observed in the 
1
H NMR spectrum as a singlet at 4.13 ppm 
corresponding to the CH2 between the oxime and the pyridyl ring, and a triplet at 
4.23 ppm corresponding to the CH2 next to the oxime. Although the yield was low 
(3.4%) the reaction was not optimised as there was enough material for biological 
testing. The other compound isolated had a similar 
1
H NMR spectrum to the ketone 
93. The key signal at 4.21 ppm corresponded to the CH2 and the signals at 8.45 ppm 
and 8.59 ppm corresponded to the hydrogens next to the nitrogen in the pyridine 
ring. There was also a broad singlet at 9.05 ppm with the integration of one hydrogen 
and a singlet at 2.02 ppm with the integration of two hydrogens. It has been observed 
in the literature that hydrazine could also add to the ketone. Therefore it can be 
suggested that compound 143 is forming. The GC-MS showed a molecular ion of 
m/z 212, which supported the theory that the hydrazine had reacted with the ketone to 
form compound 143. To prevent this from occurring, the hydrazine hydrate was only 
used in a slight excess. 
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Scheme 40. Conditions: a) NH2NH2·H2O, EtOH, reflux, 30 min; b) 93, CH3COOH, EtOH, reflux, 1 day.  
 
These conditions were used to synthesise a variety of oximes (Table 15). The 
hydroxylamine precursors 132 were reacted with hydrazine hydrate in ethanol for 30 
minutes before the ketone 93 in acetic acid and ethanol were added. This produced 
the desired oximes in a variety of yields. In all cases the E isomer was the 
synthetically favoured isomer. 
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Table 15. Conditions: a) NH2NH2·H2O, EtOH, reflux, 30 min; b) 93, CH3COOH, EtOH, reflux, 1 day. 
Compound R 
Yield 
E Z 
145 
 
2% 0% 
146 
 
4% 0% 
147 
 
32% 0% 
148 
 
44% 3% 
149 
 
36% 9% 
150 
 
48% 9% 
151 
 
12% 1.1% 
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3.3.1 Anti-trypanosomal activity 
All the oximes synthesised were tested for their ability to inhibit T. cruzi following 
the conditions outlined in Section 3.1.1. Initially the length of the alkyl chain was 
investigated (Table 16). As seen previously, the methyl oxime 117 had an IC50 
greater than 10 µM for both the E and Z isomers. The ethyl oxime 123 was tested as 
a single E isomer and a mixture of E/Z as a ratio of 1.68:1. The E isomer had an IC50 
of 4.91 µM whilst the mixture of isomers had an IC50 greater than 10 µM. This 
suggested the E isomer was the preferred orientation over the Z isomer. The length of 
the oxime also appeared to play a role in the inhibition of the site. The ethyl oxime 
123 contained an extra carbon in its chain and the anti-trypanosomal activity has 
doubled. This continued to be the trend with the propyl and butyl oximes. The propyl 
oxime 145 had an IC50 of 2.00 µM whilst the butyl oxime 144 had an IC50 of 1.04 
µM for the E isomers. This suggested that a longer chain was required to interact 
better in the access tunnel. Having a branched chain also appeared to improve the 
activity as well. Compound 146 had an IC50 of 1.55 µM compared to the ethyl oxime 
123 which was only 4.91 µM. The longer branched chain oxime 147 was also 
synthesised and is currently awaiting results. A long chain ester group was also 
investigated. Compound 151 had an IC50 of 4.55 µM for the E isomer and greater 
than 10 µM for the Z isomer. This suggested that having the ester group decreases 
the biological activity. This could be due to the carbonyl group reacting unfavourably 
within the enzyme active site. All the compounds also appeared to be non-cytotoxic 
except for compound 151 which had a toxicity of 57.41 µM for the E isomer. 
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Table 16 
Structure 
IC50 (toxicity) 
E Z 
 
4.91 µM (>100 µM) >10 µM (>100 µM)* 
 
2.00 µM (>100 µM) − 
 
1.04 µM (>100 µM) − 
 
1.55 µM (>100 µM) − 
 
In testing − 
 
4.55 µM (57.41 µM) 
SI = 13 
>10 µM (>100 µM) 
* Mixture of isomers 
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As the biological activity improved with a longer alkyl chain, a bulkier oxime was 
considered. On changing the oxime to a bulkier group the biological activity 
drastically improved (Table 17). Compound 125 showed an IC50 of 0.57 µM for the 
E isomer which was ten times more potent than the ethyl oxime (E 4.91 µM). The 
increased anti-trypanosomal activity suggested the chain that orientates into the 
hydrophobic access tunnel could be bulky to bind more effectively. The addition of a 
fluorine substituent on the para position of the phenyl oxime 148 did not appear to 
improve the IC50 (0.66 µM) but increased the cytotoxicity (34.22 µM, SI = 173). The 
pentafluorobenzyl oxime 127 had an IC50 of 0.37 µM for a mixture of isomers and 
was also toxic (64.06 µM). The increased hydrophobicity tends to be more potent but 
also more toxic. Although the addition of the fluorine substituents did not improve 
the potency, they were significantly more toxic.  
 
Another way to increase the bulk of the oxime was to have a cyclohexane ring 
instead of the phenyl ring on the oxime. The phenyl ring is planar whereas the 
cyclohexane would occur in the chair conformation adding to the bulk of the oxime. 
This improved the anti-trypanosomal activity slightly with an IC50 of 0.22 µM for the 
E isomer. Although it was showed some toxicity (61.10 µM), the SI value is very 
high (278) meaning a large dose would be required for the compound to have toxic 
effects. Having a longer alkyl chain before the bulky phenyl ring was also 
considered. Compound 150 had an IC50 of 0.48 µM for the E isomer and greater than 
1 µM for the Z isomer. The longer alkyl chain between the phenyl ring and the oxime 
in compound 150 did not improve the activity compared to compound 125. This 
could be due to the phenyl ring of the oxime fitting into the access tunnel best with 
compound 125. 
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Table 17 
Structure 
IC50 (toxicity) 
E Z 
 
0.57 µM (>100 µM) − 
 
0.66 µM (34.22 µM) 
SI = 52 
0.95 µM (34.21 µM) 
SI = 36 
 
0.37 µM (64.06 µM)* 
SI= 173 
 
0.22 µM (61.10 µM) 
SI = 278 
In testing 
 
0.48 µM (35.08 µM) 
SI = 73 
>1 µM (20.36 µM) 
* Mixture of isomers 
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3.4 Substituted phenyl ring oximes 
Substituents on the phenyl ring had a greater inhibition against T. cruzi than the 
unsubstituted phenyl ring and a bulky oxime had better anti-trypanosomal activity, 
therefore the benzyl oximes for the fluoro and chloro substituted phenyl ring were 
synthesised. The ketone 65 was stirred at room temperature with O-
benzylhydroxylamine hydrochloride 124 and sodium acetate in ethanol (Table 18). 
The 
1
H NMR spectrum of the crude material for the fluoro substituted compound 152 
showed a mixture of the two isomers as 1.7:1 ratio. Unfortunately it was only 
possible to purify the E isomer in 21% yield. The chloro substituted compound 153 
showed a mixture of the two isomers as 1:1 ratio in the 
1
H NMR spectrum of the 
crude material and both isomers were separated. 
 
 
Table 18 
Compound X 
Overall 
Yield 
152 F E 21% 
153 Cl 70% 
 
3.4.1 Anti-trypanosomal activity 
It has been shown that the substituents on the phenyl ring were important in 
improving the potency of the compound against T. cruzi. The fluoro and chloro 
substituted phenyl oximes were tested for their ability to inhibit T. cruzi and 
compared to compound 125 (Table 19). These compounds appear to follow the same 
trend as seen in Section 3.1.1. The fluoro substituted compound 152 showed an IC50 
of 0.021 µM for the E isomer whilst the chloro substituted compound 153 showed an 
IC50 of 0.20 µM for the Z isomer. The fluoro substituted compound 152 was ten 
times more potent than compound 125 and the Z isomer of compound 153. It was 
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shown in Section 3.1 that the chloro substituted compound had a better inhibition 
than the fluoro and the E isomer was the preferred isomer (Table 12). This would 
suggest the E isomer of compound 153 would show a similar or better activity than 
compound 152. The E isomer of the dichloro compound 153 is currently in testing. 
 
Table 19 
Structure 
IC50 (toxicity) 
E Z 
 
0.57 µM (>100 µM) In testing 
 
0.021 µM (45.65 µM) 
SI = 2174 
− 
 
In testing 
0.20 µM (46.89 µM) 
SI = 234 
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3.5 Conclusions 
A library of twenty four pyrifenox analogues were successfully synthesised and 
tested in whole cell assays for their ability to inhibit T. cruzi. The summary of key 
findings is shown in Figure 33. The substituents on the phenyl ring were shown to be 
important. The unsubstituted phenyl ring was easier to synthesise but was the least 
active. The chloro substituents were the most active which could be due to the bulky 
chlorine atoms filling out the hydrophobic pocket more effectively. The oxime was 
also shown to play a role in improving the activity. The E isomer was the preferred 
isomer as it was able to fit better into the access tunnel. A bulky oxime was shown to 
improve the biological activity over a straight alkyl chain. Compound 152 was 
shown to have the best inhibition with the E isomer being fourteen times more potent 
than pyrifenox. It would be expected that the E isomer of compound 153 would have 
similar or better activity. Further investigations into these two compounds are 
required. 
 
 
Figure 33. Diagram of key findings 
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4 3-Anilinemethylpyridine analogues 
 
 
 
 
 
 
The main difficulty in the pyrifenox analogues was the separation of the two oxime 
isomers. The separation of the two isomers was necessary as the E isomer was shown 
to be more potent (Chapter 3). To overcome this, a nitrogen atom could be 
incorporated into the chain between the two rings to remove the stereochemistry 
(Figure 34). Having a nitrogen at this position is not ideal as the nitrogen is electron 
rich and can react within the enzyme. However it would provide information on how 
important it is to have a rigid system, like the E oxime in the pyrifenox analogues. 
The plan was to use an alkyl chain that is of a similar length to the substituted oxime 
in order to allow comparison with pyrifenox. 
 
 
Figure 34 
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The proposed synthesis of these analogues is shown in Scheme 41. The nitrogen 
could be incorporated between the two rings by a reductive amination reaction to 
give 156. This could then be reacted with an alkyl halide to give 154. This has a 
similar backbone to pyrifenox without the stereochemistry of the oxime.  
 
 
Scheme 41. Proposed synthesis of compound 106. 
 
The intermediate 156 was prepared according to Dickson et al. (Scheme 42).
122
 
Aniline 155 was heated under reflux with 3-pyridinecarboxaldehyde 106 in the 
presence of anhydrous magnesium sulfate and dry 1,2-dichloroethane to give the 
imine 158. The 
1
H NMR spectrum of the crude residue matched that in the 
literature.
122
 The spectrum showed the key imine singlet at 8.47 ppm. The crude 
residue was stirred at room temperature with sodium borohydride in methanol to give 
the secondary amine 156. The spectral data matched that in the literature.
122
 The 
1
H 
NMR spectrum showed a singlet at 4.35 ppm corresponding to the CH2 and a broad 
singlet at 4.09 ppm corresponding to the amine. The IR spectrum showed signals at 
3248 cm
−1
 and 1600 cm
−1
 suggesting a secondary amine was present. This reaction 
was high yielding (90%) on a 2 mmol scale. On increasing the scale to 4 mmol the 
yield decreased dramatically (25%). Therefore the reaction was only done on a small 
scale. 
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Scheme 42 
 
The final step was an alkylation reaction. The alkylation could occur on the amine or 
on the nitrogen in the pyridine ring. The amine 156 was heated at 120 °C with 1-
bromohexane 159 in N,N-diisopropylethylamine and acetonitrile (Scheme 43). The 
1
H NMR spectrum showed the compound isolated was not the desired product 160. 
The peaks corresponding to the pyridine were shifted downfield to 9.39, 8.99, 8.45 
and 7.88 ppm. This suggested that the environment around the nitrogen in the 
pyridine ring had changed which is typical of an alkylated pyridine. A known 
compound, 1-butyl-3-methylpyridinium, showed the hydrogens next to the pyridine 
are shifted downfield with values similar to compound 161. The 
1
H NMR spectrum 
also showed signals relating to the hexane chain. This suggested the nitrogen in the 
pyridine ring was alkylated instead of the amine to give 161. This implied that the 
nitrogen in the pyridine ring is more reactive towards alkylation than the amine. 
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Scheme 43 
 
As the nitrogen on the pyridine ring appeared to be the preferred alkylation position 
other methods were investigated to add a group onto the amine. A reductive 
amination on the amine was conducted under the same conditions used to synthesise 
156 (Scheme 42). Compound 156 was heated under reflux with trans-
cinnamaldehyde 161 and anhydrous magnesium sulfate in dry 1,2-dichloroethane 
(Scheme 44). Upon removal of the solvent, the crude residue was stirred at room 
temperature with sodium borohydride in methanol. This did not produce the desired 
compound with mainly starting material 156 (60%) and cinnamyl alcohol 163 being 
isolated. It appeared the aldehyde was not condensing with the amine in the first step 
and was being reduced to the alcohol with sodium borohydride in the second step. 
 
 
Scheme 44. Conditions: a) MgSO4, 1,2-dichloroethane, reflux, 6 h; b) NaBH4, MeOH, rt, 3 h. 
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An alternate approach was to add the pyridine ring on last (Scheme 45). Aniline 155 
and trans-cinnamaldehyde 161 were heated under reflux with anhydrous magnesium 
sulfate in dry 1,2-dichloroethane. The crude residue was stirred at room temperature 
with sodium borohydride in methanol. The 
1
H NMR spectrum showed an AB pattern 
centred around 3.85 ppm corresponding to the CH2 and a singlet at 4.24 ppm 
corresponding to the amine. This reaction was low yielding (27%) due to an 
incomplete reaction and degradation. Separation of the crude material by column 
chromatography resulted in the recovery of 48% of the aniline 155. The cinnamyl 
alcohol 163 was not observed. The amine 164 was then heated under reflux with 3-
pyridinecarboxaldehyde 106 and anhydrous magnesium sulfate in dry 1,2-
dichloroethane. The crude residue was then stirred with sodium borohydride in 
methanol at room temperature. Flash chromatography separated starting material 
(16%) and degradation products. Due to the low yield of the amine 164 this route 
was abandoned. 
 
 
Scheme 45. Conditions: a) MgSO4, 1,2-dichloroethane, reflux, 6 h; b) NaBH4, MeOH, rt, 3 h. 
 
Another approach to add a group onto the amine was to form an amide from the 
amine and an acid chloride (Scheme 46). The amine 156 was stirred with cinnamoyl 
chloride 165 and 4-dimethylaminopyridine in dichloromethane at 0 °C before 
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warming to room temperature
123
 to produce the desired amide 166 in 91% yield. The 
1
H NMR spectrum showed a singlet at 5.03 ppm corresponding to the CH2 and a 
doublet at 6.30 ppm corresponding to the alkene. The doublet had a J coupling of 
15.6 Hz corresponding to the expected trans alkene. The other doublet overlaps with 
some aromatic signals between 7.69−7.73 ppm.  
 
 
Scheme 46 
 
The next step was to reduce the amide to an amine. The amide 166 was heated under 
reflux with 2.65 equivalents of triethylsilane and palladium chloride in ethanol 
(Scheme 47). The 
13
C NMR spectrum showed a signal at 172.3 ppm corresponding 
to a carbonyl carbon, showing the amide has not been reduced. The 
1
H NMR 
spectrum showed two triplets at 2.29 ppm and 2.85 ppm each with the integration of 
two hydrogens. This suggested that compound 168 was produced as there was still an 
amide present and no alkene. The amount of triethylsilane used was increased to 12 
equivalents to try and reduce the amide. The 
1
H NMR spectrum showed only the 
alkene being hydrogenated.  
 
 
Scheme 47 
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As triethylsilane and palladium chloride were unable to reduce the amide other 
methods were explored. The amide 166 was treated with sodium borohydride and 
methanesulfonic acid in dimethylsulfoxide. The 
1
H NMR spectrum of the crude 
material showed only the alkene being hydrogenated and degradation. Another 
method attempted was by stirring the amide 166 with borane dimethyl sulfide 
complex (2 M in THF) under nitrogen at room temperature (Scheme 48). This 
reduced the amide back to the amine 156 in 49% yield and the rest of the compound 
was degraded. 
 
 
Scheme 48 
 
Due to the difficulties in synthesising the tertiary amine analogues of pyrifenox, the 
reduction of the amide and the incorporation of the nitrogen between the two rings 
were abandoned. Although the target compound was not synthesised, compounds 
166 and 168 still had a similar structure to the target compound and were tested for 
their ability to inhibit T. cruzi. 
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4.1 Anti-trypanosomal activity 
Compounds 166 and 168 were assayed in an in vitro whole cell assay. Compound 
166 showed an IC50 of 1.29 µM whilst compound 168 showed an IC50 of 5.75 µM 
against T. cruzi. In comparing the two structures the only difference is the conjugated 
double bond in the amide chain in compound 166. This double bond could be 
increasing the rigidity making the structure fit better into the enzyme. The results of 
these two compounds were compared against compound 125 that was synthesised in 
Section 3.3. This compound has a similar structure to compounds 166 and 168. The 
amide has a similar rigidity to the oxime, however the addition of the amide group 
decreases the anti-trypanosomal activity. This could be due to the oxygen present in 
the amide group not fitting into the binding cavity. 
 
 
Figure 35. Comparison of the biological activity of compound 125 to 166 and 168. 
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5 Investigation of a naphthol system 
 
 
 
 
 
 
The structural rigidity of new biological compounds has been known to reduce side 
effects and to enhance the biological activity in medicinal chemistry.
124,125
 This is 
due to the drug being designed to specifically target the desired active site. In the 
pyrifenox model, the nitrogen in the pyridyl ring binds to the heme iron in the active 
site and the substituted benzyl ring is free to rotate. In Chapter 3, the E isomer was 
the biologically preferred isomer. A more rigid system mimicking the E isomer could 
be created that prevents the phenyl ring from rotating. This could be achieved by 
enclosing the area between the nitrogen of the oxime and the chlorine substituent on 
the phenyl ring (Figure 36). This would mimic the preferred E isomer of the oxime 
and create a more rigid system.  
 
Figure 36 
95 
 
The proposed structure of the more rigid system is based around a naphthol motif. 
The planned synthesis is shown in Scheme 49. By reacting 3-chloromethylpyridine 
49 with 2-napthol 170 a rigid backbone would be created. A simple alkylation of the 
hydroxyl group would then give compound 172. 
 
 
Scheme 49. Proposed synthesis of a more rigid analogue. 
 
There are two possible alkylation sites in 2-naphthol, the C2 position or the hydroxyl 
group (Figure 37).
126,127
 The position of the alkylation can be controlled by changing 
the solvent system of the reaction.
126,127
 Solvents such as N,N-dimethylformamide 
and dimethyl sulfoxide give predominantly the ether product whilst strong hydrogen 
bonding solvents, such as water, give the carbon alkylated product.
127
 It has been 
proposed that this observation could be due to the dielectric constant of the 
solvent.
127
 Aprotic solvents such as N,N-dimethylformamide and dimethyl sulfoxide 
have relatively high dielectric constants and strongly favour oxygen alkylation.
127
 
Solvents with a low dielectric constant favour carbon alkylation by disfavouring the 
oxygen alkylation.
127
 
 
Figure 37. There are two possible alkylation sites on 2-naphthol. 
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Following the procedure from Kornblum et al.
127
 3-chloromethyl pyridine 
hydrochloride 49 was stirred with 2-naphthol 170 in the presence of sodium 
hydroxide and water at room temperature for three days (Table 20, entry 1). 
Separation of the crude material resulted in the recovery of the unreacted 2-naphthol 
170 (50%) and a new compound. The 
1
H NMR spectrum of the new compound 
suggested that it contained two pyridine rings. There were two signals at 4.56 ppm 
and 5.22 ppm integrating for two hydrogens each and there were extra signals in the 
aromatic region. This suggested that the dialkylated compound 176 had formed. 
Since the pyridine 49 had alkylated 2-naphthol at the C2 position and on the 
hydroxyl group, the reaction time was shortened and the 2-naphthol 170 was used in 
a slight excess (2.1 eq.). Under these reaction conditions, 2-naphthol 170 (30%) and 
another compound, that was not the desired product or compound 176, were isolated. 
The 
1
H NMR spectrum showed one singlet at 5.05 ppm, a doublet at 8.89 ppm and a 
singlet at 8.63 ppm indicating only one pyridine ring was present. The absence of an 
OH stretch in the IR spectrum at ~3200 cm
−1
 suggested that the ether compound 175 
had formed. This indicated that under these conditions the hydroxyl group was more 
reactive than the C2 position. The solvent of the reaction was changed from water to 
2,2,2-trifluoroethanol.
127
 2,2,2-Trifluoroethanol is a better hydrogen bond donor than 
water. The major product obtained from this reaction was 2-naphthol 170 (83%) and 
there were trace amounts of compound 176 (13%). This method was not a viable way 
to synthesise compound 171. 
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Table 20 
Entry Conditions 
Product 
170 171 175 176 
1 NaOH 2 eq., H2O, rt, 3 days 50% − − 19% 
2 NaOH 2.7 eq., H2O, rt, o/n 30% − 16% − 
3 NaOH, 2,2,2-trifluoroethanol, rt, o/n 83% − − 13% 
 
An alternate procedure developed by Huang et al. was investigated.
128
 3-Pyridine 
carboxaldehyde 106 and β-tetralone 177 were reacted in the presence of freshly 
prepared dry hydrogen chloride gas and acetic acid (Scheme 50). The hydrogen 
chloride gas was generated by adding sulfuric acid dropwise to ammonium chloride 
salt. The gas was bubbled directly into the reaction mixture. This reaction gave the 
desired compound 171 in 75% yield. The spectral data of compound 171 was similar 
to that in the literature.
128
 The 
1
H NMR spectrum showed a singlet at 4.47 ppm 
corresponding to the CH2 between the pyridyl ring and the naphthol. The IR 
spectrum showed a broad signal at 2868 cm
−1
 indicating an OH group was present. 
The compound degraded upon purification by column chromatography. Therefore it 
was used without further purification. 
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Scheme 50 
 
The last step to form the desired compound was an alkylation reaction. The 
alkylation could occur on the nitrogen of the pyridine ring or the hydroxyl group to 
form an ether. Under basic conditions and using an aprotic solvent with a relatively 
high dielectric constant, the oxygen alkylation should be the favoured product. The 
naphthol 171 was stirred with 12 equivalents of methyl iodide and sodium carbonate 
in dry N,N-dimethylformamide at room temperature (Scheme 51). The recovery of 
starting material suggested no reaction had occurred. The base was changed from 
sodium carbonate to sodium hydride and methyl iodide was used in a large excess 
(29 eq.). The 
1
H NMR of the crude material showed a singlet at 4.57 ppm with the 
integration of two hydrogens and a singlet at 4.52 ppm with the integration of three 
hydrogens. This suggested that a methyl group could have been present but due to 
the low yield it was difficult to determine whether the methylation had occurred on 
the oxygen or the nitrogen. As the peaks in the 
1
H NMR spectrum corresponding to 
the hydrogens next to the nitrogen in the pyridine ring were not shifted downfield it 
could be thought that the oxygen was alkylated to form compound 169.  
 
 
Scheme 51 
Entry Conditions Product 
1 Na2CO3, 2.9 eq., DMF, rt, 3 days No reaction 
2 NaH 2.2 eq., DMF, rt, o/n Trace 
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A longer alkyl chain was considered instead. The naphthol 171 was stirred with 1-
bromobutane and potassium carbonate in N,N-dimethylformamide (Scheme 52). On 
the first attempt a large excess of bromobutane was used (10 eq.). This gave the 
desired ether 178 in low yield (3%) and compound 179 as the major product. The 
1
H 
NMR spectrum of 178 showed a singlet at 4.46 ppm with an integration of two 
hydrogens corresponding to the CH2 between the pyridyl ring and the naphthol. The 
signals at 8.38 ppm and 8.60 ppm corresponded to the pyridyl ring. There was also a 
triplet at 4.12 ppm, multiplets at 1.73−184 ppm and 1.40−1.54 ppm and a triplet at 
0.92 ppm corresponding to the butyl chain. The IR spectrum showed the lack of a 
signal at 2868 cm
−1
 suggesting that the ether had formed. The 
1
H NMR spectrum of 
the major product 179 showed extra signals due to the butyl chain that were shifted 
slightly downfield. This suggested that although the desired ether is forming the large 
excess of 1-bromobutane was reacting with the nitrogen in the pyridine ring. 
Reducing the amount of 1-bromobutane to two equivalents gave the desired product 
178 in 84% yield without the formation of compound 179. 
 
 
Scheme 52 
Entry Conditions 
Product 
178 179 
1 1-Bromobutane 10 eq., K2CO3 3.7 eq., DMF, 80 °C, 3 days 3% 85% 
2 1-Bromobutane 2 eq., K2CO3 2.9 eq., DMF, 80 °C, 3 days 84% 0% 
 
The desired compound 178 was successfully synthesised and was tested for its ability 
to inhibit T. cruzi. 
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5.1 Anti-trypanosomal activity 
Compound 178 was the target compound which was similar to the E isomer of 
compound 144. It had an IC50 of 6.98 µM compared to 144 which had an IC50 of 1.04 
µM. This suggested the more rigid system in this particular compound decreased the 
biological activity. The ether compound 175 was also assayed and showed an IC50 
greater than 10 µM. As the results for these compounds were not biologically active 
they were not investigated further. 
 
 
Figure 38 
 
  
101 
 
 
 
 
6 Further modification of pyrifenox 
 
 
 
 
 
 
Although the majority of pyrifenox derivatives modified the oxime and the halogens 
on the substituted phenyl ring, further modifications were sought. Two potential 
analogues based on the modification of the oxime fragment were considered (Figure 
39). The position of the oxime in the molecule could be modified such that the 
methyl oxime is next to the pyridyl ring (compound 180). The effect of the oxime at 
this position could be further investigated by substituting it for a cyclopropyl group 
(compound 181). Removal of the oxime from the molecule alleviates the problems 
associated with the separation of the oxime stereoisomers.  
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Figure 39. Modification of the oxime fragment. 
 
6.1 Synthesis of the oxime next to the pyridyl ring 
As in the pyrifenox series, ketone 184 was identified as the key intermediate to 
synthesise the oxime next to the pyridyl ring. Initial investigations conducted at 
Epichem Pty Ltd produced the desired ketone in a two-step synthesis from a 
Grignard reaction of benzyl chloride with 3-pyridyl Weinreb amide (N,methoxy-N-
methyl-3-pyridinecarboxamide).
*
 The synthesis of 3-pyridyl Weinreb amide was low 
yielding and expensive to make. An alternate method was explored (Scheme 53). 
The reaction between methyl nicotinoate 182 and 2,4-dichlorophenylacetic acid 183 
would form the ketone in the position next to the pyridyl ring in one step. A simple 
oxime formation used previously (Section 3.1) would then form the desired product 
180 as two isomers.  
                                               
*
 Alexander, P; Keenan, M and Best, W. Epichem Ltd Pty. Personal communication, 2011 
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Scheme 53. Proposed synthesis of compound 129. 
 
Wu et al. optimised a direct Claisen-decarboxylation cascade reaction between an α-
carboxylic acid and an ester of a similar system.
114
 This method was used to 
synthesise ketone 184 (Scheme 54). The ester 182 was made according to Potter et 
al.
115
 by heating nicotinic acid 185, methanol and sulfuric acid under reflux to give 
the desired nicotinic acid methyl ester 182 in 80% yield. The spectral data of 
compound 182 matched those in the literature.
115,129
 The product obtained was pure 
and was used in the subsequent reaction without purification. Nicotinic acid methyl 
ester 182 was stirred with 2,4-dichlorophenylacetic acid 183 and sodium 
bis(trimethylsilyl)amide (1.0 M in THF) in N,N-dimethylformamide at −8 °C to give 
the ketone 184 in 60% yield.  The spectral data of compound 184 matched that in the 
literature.
114
 A singlet at 4.98 ppm in the 
1
H NMR spectrum was assigned to the 
methylene protons and a signal at 194.7 ppm in the 
13
C NMR spectrum was assigned 
to a ketone. This provided a simple method of synthesising the desired ketone 184 in 
moderate yield (60%) and the ketone did not oxidise in air to the diketone like the 
pyrifenox system. 
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Scheme 54 
 
The mechanism for this reaction was thought to proceed according to Scheme 55.
114
 
2,4-Dichlorophenylacetic acid 183 undergoes a Claisen condensation with nicotinic 
acid methyl ester 182 to form the condensation intermediate 186. The condensation 
intermediate 186 was not observed in the reaction as it spontaneously loses carbon 
dioxide to give the desired decarboxylation product 184.   
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Scheme 55. Proposed mechansim for the direct Claisen-decarboxylation cascade reaction.114 
 
The final step was the formation of the oxime 180. The ketone 184 was stirred with 
O-methylhydroxylamine hydrochloride and sodium acetate in ethanol at room 
temperature (Scheme 56). The two isomers were observed in the 
1
H NMR spectrum 
as two separate singlets at 3.82 ppm and 3.99 ppm for the methyl groups whilst the 
CH2 signals appeared as two singlets at 3.92 ppm and 4.12 ppm. The two isomers 
were inseparable by flash chromatography, however the ratio of the E:Z isomers 
were estimated to be 1.5:1 from the 
1
H NMR spectrum of the product. 
 
 
Scheme 56 
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The oxime 180 was successfully synthesised as 1.5:1 mixture of the two isomers and 
is currently being tested against T. cruzi. Initial investigations conducted by Epichem 
Ltd Pty
*
 showed an IC50 greater than 1 µM.  
 
6.2 Synthesis of an isopropyl group 
The effect of the oxime position next to the pyridyl ring was further studied by 
substituting the oxime for a cyclopropyl group. Since the dichloro-substituted ketone 
was difficult to synthesise the unhalogenated ketone 93 was used. The ketone 93 was 
stirred at 0 °C with 1,2-dibromoethane 187 and potassium tert-butoxide in N,N-
dimethylformamide for 2.5 hours and then at room temperature overnight.
130
 The 
1
H 
NMR spectrum showed two apparent doublets of doublets at 1.32 ppm and 1.68 ppm 
corresponding to the cyclopropyl ring. The lack of singlet at 4.27 ppm in the 
1
H 
NMR spectrum suggested the cyclopropyl ring was on the carbon between the ketone 
and the pyridyl ring. The signal at 199.5 ppm in the 
13
C NMR spectrum 
corresponded to the carbonyl carbon. The low yield (20%) was due to the reaction 
not going to completion and other unidentified by-products being formed. Although 
the yield was low, the reaction conditions were not optimised as there was enough 
material for biological testing. 
 
 
Scheme 57 
 
Compound 188 was successfully synthesised and is currently being tested against T. 
cruzi.  
  
                                               
*
 Alexander, P; Keenan, M and Best, W. Epichem Ltd Pty. Personal communication, 2011 
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7 Preparation and anti-trypanosomal activity of 
hydrogenated chalcone analogues 
 
 
 
 
 
An aspect that was considered important in the structure activity relationship series 
was the linker between the pyridyl ring and the phenyl ring. Preliminary studies
*
 
showed the condensed analogue (B) was less active in the Chagas model, suggesting 
that there needed to be at least one CH2 linkage between the oxime and the pyridyl 
ring to achieve good binding (Figure 40). An alternative was to look at the extended 
analogues (C) which have an extra CH2 between the oxime functionality and the 
pyridyl ring compared to pyrifenox. The core of these extended analogues was based 
on a hydrogenated chalcone, making these compounds readily accessible. As well as 
extending the chain between the oxime and the pyridyl ring, the substituents X on the 
phenyl ring and the oxime R group were also varied. Changing the substituents on 
the phenyl ring from hydrogen to fluorine to chlorine would explore the steric bulk 
required to bind effectively inside the hydrophobic pocket of CYP51. The oxime R 
group was also varied to determine how well the oxime chain interacts with the 
access channel. 
                                               
*
 Alexander, P; Keenan, M and Best, W. Epichem Ltd Pty. Personal communication, 2011 
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Figure 40 
 
The extended analogues (C) could be made using a 3 step synthesis (Scheme 58). An 
aldol condensation between 3-pyridinecarboxaldehyde 106 and an appropriate 
acetophenone 189 would give the chalcone 190. The alkene of the chalcone could 
then be hydrogenated to form the intermediate 191. Finally, a condensation reaction 
between the ketone 191 and a variety of alkoxyamines 66 would give the desired 
oxime 192 as two isomers. 
 
 
Scheme 58. Proposed scheme to synthesise the longer linker analogues. 
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7.1 Synthesis of chalcones 
The most closely related extended analogue to pyrifenox would require the 2,4-
dichloro substituted chalcone 194. This compound was previously prepared by 
Shekarchi et al.
131
, however the procedure used in this work was based on that by 
Attar et al.
132
 3-Pyridinecarboxaldehyde 106 and 2ʹ,4ʹ-dichloroacetophenone 193 
were stirred in a solution of sodium hydroxide in ethanol and water (Scheme 59). 
Deionised water was added immediately causing a solid to precipitate. The solid was 
collected to give the pure chalcone 194. The spectral data of compound 194 match 
that in the literature.
131
 The 
1
H NMR spectrum showed a doublet at 7.20 ppm with a 
J coupling of 16.1 Hz which corresponded to a trans alkene. The corresponding 
doublet was in the middle of the aromatic signals between 7.45−7.53 ppm. The 
signal at 1678 cm
−1
 in the IR spectrum was assigned as a C=O stretch in conjugation 
with the phenyl ring. If the chalcone was left in solution for too long (5 min), 2ʹ,4ʹ -
dichloroacetophenone 193 reacted with the double bond of the chalcone 194 via a 
Michael addition to give the disubstituted product 195. This phenomenon has been 
reported in the literature.
133
 To prevent the Michael addition from occurring, 3-
pyridinecarboxaldehyde 106 was used in a slight excess (1.1 eq.) and a large excess 
of water (400 mL) was added to precipitate out the product immediately after the 
addition of the base. This reaction could be performed on large scales (10 g) with 
high yields (99%) and did not require purification. 
 
 
Scheme 59 
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The synthesis of the chalcone 194 produced exclusively the trans isomer. This was 
confirmed by 
1
H NMR spectroscopy by the two vinylic protons coupling constants 
(16.1 Hz) observed in the spectrum. When the chalcone 194 was allowed to stand in 
solution (CDCl3) for two days, the cis isomer 196 was observed in the 
1
H NMR 
spectrum (Scheme 60). In Figure 42, the initial 
1
H NMR spectrum showed the trans 
alkene at 7.20 ppm. After one week two doublets were observed in the 
1
H NMR 
spectrum at 6.68 ppm and 7.00 ppm both with a J value of 12.5 Hz corresponding to 
a cis alkene as a 10:1 ratio. When the solution was left in the dark for the same 
amount of time the cis alkene was not observed. This was consistent with the 
literature which states that irradiation of chalcones in solution by sunlight converts 
the chalcone from the trans to the cis conformation.
134
 The ratio of the two isomers 
was 10:1 after one week and did not change after a further two weeks. This 
suggested the isomerisation of the trans to cis alkene is in equilibrium. As the alkene 
is hydrogenated in the next step both isomers can be used.  
 
 
Scheme 60 
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Figure 41. 
1H NMR spectrum of compound 194 (top) and after 1 week in CDCl3 solution (bottom). 
 
A variety of pyridyl chalcones were also synthesised under the optimised conditions 
(Scheme 61). The acetophenones 189 and 3-pyridinecarboxaldehyde 106 were 
reacted with a solution of sodium hydroxide in ethanol and water. The 4-fluoro and 
4-chloro chalcones (197 and 198) were synthesised on a large scale (10 g) in high 
yields (90% and 92% respectively) and did not require any further purification. 
However, the reaction to form the unsubstituted chalcone was low yielding (26%) 
and the 
1
H NMR spectrum of the crude material showed a complex mixture. The 
mixture was separated by column chromatography to give the unsubstituted chalcone 
and the Michael addition dimer. 
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Scheme 61 
Compound X1 X2 Yield 
197 H F 90% 
198 H Cl 92% 
199 H H 26% 
 
Another side reaction that could occur is the cyclisation of the chalcone in the solid 
state, molten state and solution by UV irradiation (Scheme 62).
135,136
 The chalcone 
can undergo intermolecular [2+2] photocycloaddition to give a cyclobutane.
135
 
Recrystallisation of the unsubstituted chalcone 199 from dichloromethane and 
petroleum spirits gave fine white crystals. The 
1
H NMR spectrum of the crystals 
showed the absence of an alkene signal and therefore was not the desired compound 
199 but could be the cyclised form. Chalcones similar to this compound have been 
known to dimerize by photochemical pathways.
134,136–138
 There are four possible 
configurations that could form (Scheme 62) and the different configurations may be 
dependent on the physical state of the substrate and the conditions under which it 
absorbs light.
135
 The configurations are syn-head-to-tail 200, syn-head-to-head 201, 
anti-head-to-tail 202, and anti-head-to-head 203.
135,136,138
 The 
1
H NMR spectrum 
showed only one compound was present. X-ray crystallography of the white crystals 
confirmed the configuration as compound 200 (Figure 42). The photodimerisation of 
the chalcone only gave the syn-head-to-tail dimer out of the four possible dimers. To 
prevent the cyclisation of the chalcone 199 from occurring it was stored in a brown 
glass vial. 
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Scheme 62 
 
Figure 42. Crystal structure of compound 200. 
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7.2 Hydrogenation of an alkene 
The next reaction was a selective conjugated reduction of the α,β-unsaturated 
carbonyl of the chalcones. The methods investigated are outlined in Table 21. A 
common form of hydrogenation in the literature was using a highly reactive form of 
zinc.
139,140
 Li et al. developed a method using zinc powder and ammonium chloride 
in water and ethanol.
140
 The authors stated that the way the zinc was added to the 
reaction mixture was critical. It had to be added in three equal portions in order to 
obtain the best yield. The chalcone 197 was stirred with zinc powder and ammonium 
chloride in water and ethanol at room temperature (entry 1). This produced the 
desired compound 204 in 30% yield. The 
1
H NMR spectrum showed two multiplets 
at 3.03−3.09 ppm and 3.24−3.31 ppm each with an integration of two hydrogens 
and were assigned to the methylenes. The 
13
C NMR spectrum showed two CH2 
carbons at 27.2 ppm and 39.7 ppm corresponding to the reduced alkene. The ketone 
was still present due to the 
13
C NMR spectrum showing a peak at 196.9 ppm and the 
C=O peak in the IR spectrum (1682 cm
−1
). The low yield was due to the reaction not 
going to completion with 25% starting material being recovered. An alternate 
method to prepare the activated zinc was sought to improve the yield. Activated zinc 
can also be prepared in situ from magnesium and zinc chloride.
139
 The chalcone 197 
was reacted with magnesium turnings and zinc chloride in water at room temperature 
(entry 2). Unfortunately, only starting material was recovered. 
 
 
Table 21 
Entry Conditions Product 
1 Zn, NH4Cl, H2O, EtOH, 3 h, rt.  30% 
2 Mg, ZnCl2, H2O, 3 days, rt.  No reaction 
3 Pd/C, CH3COOH, NaBH4, toluene, o/n, rt.  Complex mixture 
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The other metal that is commonly used for the selective reduction of alkenes is 
palladium.
141
 The chalcone 197 was stirred at room temperature with palladium on 
carbon, sodium borohydride and acetic acid in toluene (Table 21, entry 3). The 
1
H 
NMR spectrum of the crude material showed the desired hydrogenated product and a 
complex mixture of other side products. These could be other common reductive 
products such as the ketone being reduced to the alcohol (Figure 43).
141
 The 
1
H NMR 
spectrum of the crude material showed two broad signals in the 4.5−5.5 ppm region. 
These could be due to the hydrogen on the carbon with the hydroxyl group (205 or 
206). There were also mutliplets in the same region as the desired compound. This 
suggested that compound 204 was produced but as part of a complex mixture.  
 
 
Figure 43 
  
Hydrogenation of α,β-unsaturated carbonyl compounds has been shown to occur 
with triethylsilane and palladium chloride in ethanol. The palladium would catalyse 
the reaction between ethanol and triethylsilane to generate molecular hydrogen, 
which could then reduce the alkene (Scheme 63).
142
 The chalcone 197 was heated 
with triethylsilane and palladium chloride in ethanol under reflux to give the desired 
hydrogenated product 204 and the ethoxysilane by-product. The by-product was seen 
in the 
1
H NMR spectrum of the crude material as a quartet at 3.67 ppm 
corresponding to the CH2 next to the oxygen, a triplet at 1.19 ppm corresponding to 
the CH3 on the ether chain and multiplets at 0.93 ppm and 0.56 ppm corresponding to 
the CH3 and CH2 of the triethylsilane. On a small scale the product could be purified 
by the extraction of the hydrogenated chalcone 204 with a solution of hydrochloric 
acid (1 M), to separate it from the ethoxytriethylsilane by-product, and then 
neutralising the acidic layer with a solution of sodium bicarbonate. On a larger scale 
(2 g) column chromatography was required, as the impurities were not able to be 
removed with the acid/base washings. The use of column chromatography caused the 
yield to decrease.  
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If an excess of triethylsilane was used compound 197 was hydrogenated further to 
form the alcohol 206. This was observed in the 
1
H NMR spectrum as a doublet of 
doublets at 4.54 ppm corresponding to the hydrogen next to the hydroxyl group and 
two multiplets at 2.59 and 1.83 ppm corresponding to the CH2 groups. This is 
consistent with that reported in the literature
143
 where both alkene and carbonyl 
groups were indiscriminately reduced in the presence of excess triethylsilane due to 
the increased hydrogen content in solution. Therefore, only one mole equivalent of 
triethylsilane was required to obtain compound 204 in optimum yield (94%). 
 
 
Scheme 63 
Entry Conditions 
Product 
204 206 
1 PdCl2, TES 2.8 eq., EtOH, reflux, o/n 31% 32% 
2 PdCl2, TES 1 eq., EtOH, reflux, o/n 94% 0% 
 
The optimised conditions for the selective hydrogenation using palladium chloride 
and triethylsilane in ethanol were also used to hydrogenate the chloro- and dichloro-
substituted compounds (Table 22). The chalcones 190 were heated under reflux with 
palladium chloride and one equivalent of triethylsilane in ethanol. The lower yields 
obtained for the chloro- and dichloro-substituted compounds (208 71% and 209 
78%) compared with the fluoro-substituted compound 204 (94%) were due to the 
reaction being done on a larger scale (1.6 g) and thus column chromatography was 
required to purify them. Both compounds showed the key alkane signals in the 
1
H 
NMR (3.0−3.3 ppm) and the 13C NMR (27−43 ppm) spectra. When an excess of 
triethylsilane (3 eq.) was used the chloro-substituted compound was hydrogenated 
further to remove the ketone giving compound 207 (22%) along with 191 (32%). 
This was seen in the 
1
H NMR spectrum as multiplets integrating for four hydrogens 
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at 2.60−2.70 ppm and a multiplet at 1.90−2.05 ppm integrating for two hydrogens. 
The 
13
C NMR spectrum showed three signals at 32.4, 32.6 and 35.2 ppm 
corresponding to the methylenes. This was different to what is seen in Scheme 63 
where the carbonyl group is hydrogenated to the alcohol. The fluoro substituted 
compound is more electron withdrawing pulling electrons out of the system. 
Therefore it cannot support the carbocation and results only in the formation of the 
alcohol. With the chlorinated systems the ketone is completely hydrogenated.  
 
 
Table 22. Conditions- PdCl2, TES, EtOH, reflux, 7 h. 
Entry Eq. TES X1 X2 
Yield 
191 207 
1 1 H F 94% 0% 
2 1 H Cl 71% 0% 
3 1 Cl Cl 78% 0% 
4 3 H Cl 32% 22% 
 
7.3 Methyloxime analogues 
The final step in the synthesis was the formation of the oxime. The ketone 204 was 
stirred with O-methylhydroxylamine hydrochloride and sodium acetate in ethanol at 
room temperature (Scheme 64).
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 Two stereoisomers were seen in the 
1
H NMR 
spectrum of the crude material as two singlets at 3.90 ppm and 3.74 ppm 
corresponding to the methyl groups. The two isomers were isolated by column 
chromatography due to the slightly different polarities of the two compounds. The 
major compound was the less polar isomer. The 
1
H NMR spectrum of the less polar 
isomer showed the singlet at 3.90 ppm corresponding to the methyl group and two 
separate multiplets at 2.73−2.79 ppm and 3.00−3.06 ppm corresponding to the CH2 
groups. The signals in the 
1
H NMR spectrum for the more polar isomer are more 
shielded. The methyl signal was seen at 3.74 ppm and the CH2 signals were merged 
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into one large multiplet at 2.72−2.77 ppm. The high resolution mass spectrometry 
showed that both compounds have the same accurate mass, thus indicating both 
isomers were synthesised. 
 
 
Scheme 64 
 
The identification of the E and Z isomers proved to be difficult, however they were 
assigned based on evidence obtained from the polarity of previous compounds 
synthesised and NOE experiments. The pyrifenox series suggested the E isomer was 
the less polar isomer and the Z isomer was the more polar isomer. It could be thought 
the less polar isomer of compound 210 could be the E isomer and the more polar 
isomer could be the Z isomer. NOE experiments were conducted to investigate this 
further. All of the enhancements were very small, however they suggest a slight 
difference in the enhancements. The irradiation of HA in the less polar isomer 
showed NOE effects with HC (1.2%) and HD (0.2%) whilst in the more polar isomer 
showed a NOE effect of 0.9% (Figure 44). This suggested that in the less polar 
isomer the phenyl ring was closer to the alkyl chain and the more polar isomer is 
perpendicular to the pyridine ring. Irradiation of HA showed no enhancements to the 
methyl group in the less polar isomer but a slight enhancement (0.1%) in the more 
polar isomer. This suggested the more polar isomer could be the Z isomer. Irradiation 
of HC showed a slight signal enhancement for the less polar isomer (0.2%) but there 
was no effect with the more polar isomer.  This suggested that the less polar isomer 
could be the E isomer. 
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Figure 44. NOE effects of the two isomers used to determine the configuration. 
 
The same conditions were used to synthesise the methyloximes for the chloro- and 
dichloro-substituted compounds. The ketone 191 was stirred with O-
methylhydroxylamine hydrochloride and sodium acetate in ethanol (Table 23). The 
1
H NMR spectra for the chloro- and dichloro-substituted methyl oximes showed 
similar peaks to the fluoro substituted methyl oxime. This was used to identify the E 
and Z isomers. In all three cases the E isomer was the major product. 
 
 
Table 23 
Compound X1 X2 E Z 
210 H F 47% 19% 
211 H Cl 42% 11% 
212 Cl Cl 38% 13% 
 
 
. 
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7.4 Longer chain oximes 
Having successfully synthesised the methyl oximes 210, 211 and 212, more 
complicated oximes were sought. The butyl and isopropyl alkoxyamine precursors 
83 that were synthesised in Section 3.3 were used. As already mentioned in Section 
3.3, the alkoxyamines were volatile and were difficult to isolate. A one-pot synthesis 
was used to convert the alkoxyamine precursors to the alkoxyamines before the 
addition of the ketone (Scheme 65). N-Butoxyphthalimide 134 and hydrazine hydrate 
in dichloromethane were heated under reflux until a white precipitate formed.
118
 A 
solution of the fluoro ketone 204 in acetic acid and ethanol was added to the reaction 
mixture with continued heating under reflux. The 
1
H NMR spectrum of the crude 
material showed mainly the ketone 204 and trace amounts of the oxime as two 
isomers. Separation of the crude material by column chromatography afforded the 
starting material 204 (67% yield) and one isomer (2% yield). The 
1
H NMR spectrum 
of the isolated product 213 showed two multiplets at 2.80−2.87 ppm and 2.97−3.05 
ppm corresponding to the linker. The CH2 next to the oxime appeared as a triplet at 
4.14 ppm. This was shifted downfield compared to the free hydroxyl amine and was 
in a similar region to the methyl group of the previous methyl oximes. Based on the 
CH2 groups of the linker between the pyridyl ring and the oxime being seen as two 
multiplets, it was concluded that the E isomer was synthesised. As the yield was very 
low (2%), the initial solvent was changed from dichloromethane to ethanol.
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Although the yield remained low (13%), the Z isomer was also observed in the 
1
H 
NMR spectrum of the crude material (Table 24). Unfortunately the Z isomer could 
not be purified for analysis as it was not isolated from the column.  
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Scheme 65 
Entry Conditions 
Yield 
Starting 
Material 
E Z 
1 
a) NH2NH2·H2O, DCM, reflux, o/n; 
b) CH3COOH, EtOH, reflux, 1 day 
67% 2% 0% 
2 
a) NH2NH2·H2O, EtOH, reflux, 2.5 h; 
b) CH3COOH, EtOH, reflux, 2 days 
64% 9% 4% 
 
If the hydrazine hydrate was used in a large excess it would react with the ketone 204 
to form the hydrazone 214 (Scheme 66). The 
1
H NMR spectrum showed a product 
similar to the ketone except for the shifting of the peaks associated with the CH2 
linker. The signals at 2.82 ppm and 3.17 ppm had moved upfield and there was a 
larger gap between the two signals (0.35 ppm compared to 0.18 ppm for compound 
213). The mass spectrum showed a mass similar to the molecular weight of the 
hydrazine adding to the ketone. To prevent this from occurring, the hydrazine 
hydrate was used only in a slight excess (1.1 eq.). 
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Scheme 66. Conditions- a) NH2NH2·H2O, EtOH, reflux, 30 min; b) 204, CH3COOH, EtOH, reflux, 2 days. 
 
The optimised conditions were used to synthesise other analogues (Table 24). The 
precursor 132 was heated with hydrazine hydrate in ethanol for 30 minutes under 
reflux before the ketone 191 in acetic acid and ethanol were added. The isomers were 
separated by flash chromatography except for compounds 215 and 216, where the Z 
isomer was inseparable from the E isomer. Although the isolated yields for all the 
oximes were low (Table 24), sufficient product was obtained for biological testing, 
and the reaction was not optimised further. 
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Table 24 
Compound X1 X2 R 
Yield 
E Z 
213 H F 
 
9% 2% 
215 H Cl 20% 7%* 
216 Cl Cl 1.7% 4%* 
217 H F 
 
28% 4% 
218 H Cl 7% 3% 
219 Cl Cl 16% 5% 
*Mixture of isomers 
 
To investigate the impact of steric bulk on the oxime binding within the access 
tunnel, the benzyl analogue was also synthesised. The dichloro ketone 209 was 
stirred at room temperature with O-benzylhydroxylamine hydrochloride and sodium 
acetate in ethanol (Scheme 67). The 
1
H NMR spectrum of the crude material showed 
two singlets at 4.98 ppm and 5.22 ppm indicating two isomers were formed. The E 
isomer was isolated but, unfortunately, the Z isomer could not be purified. 
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Scheme 67. Conditions- a) BnONH2·HCl, NaOAc, EtOH, o/n, rt. 
 
7.5 Anti-trypanosomal activity 
All the oximes synthesised were tested for their ability to inhibit T. cruzi. The methyl 
oxime was the most structurally similar compound to pyrifenox. The E isomer of the 
dicholoro methyl oxime 212 had an IC50 of 1.87 µM and the Z isomer had an IC50 of 
1.43 µM. In comparison, the IC50 value of pyrifenox 42 was 0.29 µM which 
suggested that increasing the carbon chain by one carbon decreases the anti-
trypanosomal activity. Although the Z isomer had a slightly lower IC50 than the E 
isomer, they were very similar. This suggested one isomer might not be favoured 
over the other, although the Z isomer had a greater cytotoxicity (77.73 µM, SI = 54). 
On changing the phenyl ring to the 4-chloro-substituted ring (compound 211), the 
inhibition also decreased. The E isomer had an inhibition of 3.18 µM whilst the Z 
isomer had an inhibition of 4.56 µM. The E isomer of the fluoro methyl oxime 210 
also had a lower IC50 value (6.01 µM) as compared to the Z isomer which a slightly 
better inhibition of 3.62 µM.  
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Table 25 
Structure 
IC50 (toxicity) 
E Z 
 
0.29 µM 
 
1.87 µM (>100 µM) 
1.43 µM (77.43 µM) 
SI = 54 
 
3.18 µM (>100 µM) 4.57 µM (100 µM) 
 
6.01 µM (>100 µM) 3.62 µM (>100 µM) 
 
The length of the oxime was also investigated (Table 26). The fluoro isopropyl 
oxime 217 had an IC50 of 1.57 µM and 6.80 µM for the E and Z isomers respectively. 
This was an increase in activity for the E isomer but a decrease for the Z isomer. On 
changing the oxime to a butyl chain (compound 213), only the E isomer was isolated. 
This showed an IC50 of 1.23 µM which was an improvement on the biological 
activity as compared to the methyl oxime. This suggested that the butyl chain 
interacts better into the CYP51 pocket. The chloro isopropyl oxime 218 IC50 for the 
E isomer was 1.45 µM and the Z isomer was 1.17 µM. Both the E and Z isomers 
showed very similar IC50 to the fluoro E isomer (217 IC50 1.57 µM). The chloro 
butyl oxime 215 showed a slightly better inhibition. The E isomer had an IC50 of 0.49 
µM and the Z isomer an IC50 of 2.10 µM. In this case the E isomer had a better 
inhibition which was approaching the activity of pyrifenox 42 (0.29 µM). The 
dichloro isopropyl oxime 219 had a similar inhibition to the chloro compound. The E 
isomer had an IC50 of 1.82 µM and the Z isomer had an IC50 of 1.17 µM. On 
increasing the length of the oxime chain to a butyl chain the inhibition was also 
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similar to the chloro. The E isomer had an IC50 of 0.55 µM and the Z isomer had an 
IC50 of 0.90 µM. This suggested that compounds with chloro substituents have a 
slightly better activity than compounds with fluoro substituents; however, there was 
not much difference between the chloro and dichloro derivatives.  
 
In comparing the toxicities, all the fluoro and chloro compounds had a toxicity 
greater than 100 µM except for the fluoro butyl oxime 213. The dichloro compounds 
were starting to show some toxicity with the dichloro butyl oxime having a toxicity 
of 83.52 µM for both isomers. Although some compounds had a slight toxicity, the 
SI values were very large. 
 
A benzyl oxime was also synthesised for the dichloro substituted compound to 
investigate the steric bulk required to fit into the access tunnel. The E isomer of 
compound 220 produced an IC50 of 0.24 µM which was similar to pyrifenox (0.29 
µM). Although the longer chain between the phenyl and pyridyl rings decreased the 
biological activity, having a larger oxime gave a compound with similar inhibition. 
This suggested that the access tunnel requires a bulky group on the oxime to increase 
the binding affinity.  
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Table 26 
Structure 
IC50 (toxicity) 
E Z 
 
1.57 µM (>100 µM) 6.80 µM (>100 µM) 
 
1.23 µM (75.09 µM) 
SI = 61 
− 
 
1.45 µM (>100 µM) 1.17 µM (>100 µM) 
 
0.49 µM (>100 µM) 2.10 µM (>100 µM)* 
 
1.82 µM (>100 µM) 1.17 µM (>100 µM) 
 
0.55 µM (83.52 µM) 
SI = 151 
0.90 µM (83.52 µM)* 
SI = 93 
 
0.24 µM (>100 µM) − 
*Mixture of isomers 
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As a comparison the ketones were analysed against T. cruzi to see if the oxime was 
required. As can be seen in Table 27, the inhibitions of the ketones were similar to 
the methyl oximes. The fluoro ketone 204 had an IC50 of 6.20 µM compared with the 
E isomer which had an IC50 of 6.01 µM. The dichloro ketone 209 had an IC50 of 1.54 
µM compared with the methyl oxime 212 which had an IC50 of 1.87 µM and 1.43 
µM. The chloro ketone 208 is still awaiting results but from the other ketones 
analysed it can be predicted that it will be similar in activity to the methyl oxime 211. 
The fully hydrogenated chloro compound 207 was also analysed. It had an IC50 of 
2.77 µM which was slightly better than the chloro methyl oxime (3.18 µM and 4.57 
µM). This could be due to the compound being more flexible than the methyl oxime 
or the compounds are more lipophilic. 
 
Table 27 
Structure IC50 (toxicity) 
 
6.20 µM (>100 µM) 
 
In testing 
 
1.54 µM (>100 µM) 
 
2.77 µM (>100 µM) 
 
The chalcones inhibition of T. cruzi was also investigated (Table 28). In most cases 
the chalcone was more active than the ketone. This could be due to the chalcone 
being more rigid than the ketone and therefore binding differently. Although the 
chalcones are more active, they are also more toxic. The double bond makes the 
compound a good Michael acceptor and therefore it may be reacting indiscriminately 
with proteins within the cell causing a higher cytotoxicity. Previously the dichloro-
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substituted compounds appeared to be the most toxic. With the chalcones, the fluoro 
chalcone 197 was shown to be the most toxic (16.33 µM, SI = 8). This was most 
likely due to the fluoro substituent being more electron withdrawing than the chloro 
substituents making it a better Michael acceptor. Therefore it can react more readily 
with the biomolecules in the parasite and in human cells. 
 
Table 28 
Structure IC50 (toxicity) 
 
2.12 µM (16.33 µM) 
SI = 8 
 
0.69 µM (17.46 µM) 
SI = 25 
 
1.88 µM (19.14 µM) 
SI = 10 
 
Chalcones have recently been reported to show good inhibition against T. cruzi 
(Figure 45).
144,145
 Lunardi et al. reported the unhalogenated chalcone showed the best 
activity of their series with an IC50 of 24.8 µM.
144
 The chalcones synthesised in this 
chapter showed a better inhibition than those reported with the IC50 ten times that in 
the literature. This could be due to the pyridine ring making the compound more 
water soluble. The nitrogen in the pyridine ring can interact with enzymes either 
through hydrogen bonding or through coordination with metal centres, such as iron 
in the heme.   
 
Figure 45. Chalcones that showed good inhibition against T. cruzi.144 
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7.6 Conclusions 
The longer linker series was successfully synthesised via a condensation reaction, 
hydrogenation and finally the oxime formation. All compounds were tested in vitro 
against T. cruzi cell lines. Biological testing showed that overall one extra carbon in 
the linker between the phenyl and pyridyl rings retained but decreased the anti-
trypanosomal activity. The substituent was also shown to be important. A chloro 
substituent was more potent than a fluoro substituent. The chalcone appeared more 
reactive than the ketone most likely due to the unsaturated alkene undergoing 
indiscriminate Michael addition in the cell. Finally the size of the oxime also 
appeared important. Having a longer, bulkier group improved the biological activity. 
The dichloro benzyl compound was synthesised and had a similar activity as 
pyrifenox. 
 
Figure 46. Diagram of key findings. 
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8 Development of a new trypanosomal lead 
 
 
 
 
 
 
In the previous chapter, the initial lack of potency of the hydrogenated chalcone was 
overcome by using bulky oximes (e.g. compound 220). One of the side products in 
the preparation of the chalcones was the Michael addition product 195. Compounds 
such as 195 will be referred to as dimers as there are two symmetrical acetophenones 
attached to the pyridyl ring. This compound looked similar to the benzyl oxime 220 
(Figure 47). They both have a similar backbone of the hydrogenated chalcone where 
the nitrogen on the pyridine ring could bind to the heme iron in CYP51 and the 
substituted phenyl ring would fit into the hydrophobic pocket. The main difference 
between the two compounds would be the oxime. Compound 220 has a benzyl oxime 
adjacent to the substituted phenyl ring whereas the dimer 195 lacks the oxime. 
Instead, compound 195 has a similar phenyl ring that can orientate towards the 
access tunnel on the carbon next to the pyridyl ring. This also removes the 
problematic stereochemistry that was in the oxime compounds. 
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Figure 47 
 
8.1 Proof of concept studies 
The dimers could be readily synthesised in one step by stirring 3-
pyridinecarboxaldehyde 106 and a substituted acetophenone 189 in the presence of a 
base with a longer reaction time than used to synthesise the chalcones in Section 7.1 
(Scheme 68). The substituents X on the phenyl ring would be varied. The use of 
fluorine and chlorine substituents would help explore the steric bulk required to fit 
better into the access tunnel. 
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Scheme 68 
  
3-Pyridinecarboxaldehyde 106 and 4ʹ-chloroacetophenone 225 were stirred with a 
solution of sodium hydroxide in ethanol and minimal water and the reaction was 
cooled for 14 hours. When additional water was added a precipitate formed. The 
1
H 
NMR spectrum showed a complex mixture of degradation by-products. The longer 
reaction time appeared to degrade the product. Therefore the reaction times were 
changed. 3-Pyridinecarboxaldehyde and 4ʹ-chloroacetophenone were reacted with a 
solution of sodium hydroxide in ethanol and water at room temperature (Scheme 69). 
After 5 minutes a precipitate started to form in the solution. Excess water was added 
after 10 minutes to precipitate the rest of the product. Column chromatography 
separated minimal degradation by-products and a mixture of the chalcone 198 (27%), 
dimer 226 (29%) and starting material (13%). The 
1
H NMR spectrum of the dimer 
showed two signals at 7.42 ppm and 7.87 ppm each with the integration of four 
hydrogens which corresponded to the chlorophenyl rings. There were two apparent 
doublet of doublets at 3.35 ppm and 3.51 ppm corresponding to two methylenes and 
a quintet at 4.06 ppm corresponding to the CH. 
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Scheme 69  
 
Using the optimised conditions, the fluoro dimer was also synthesised (Scheme 70). 
3-Pyridinecarboxaldehyde 166 and 4ʹ-fluoroacetophenone 227 were stirred with a 
solution of sodium hydroxide in ethanol and minimal water. Additional water was 
added after 30 minutes until a precipitate had formed. The 
1
H NMR spectrum of the 
product showed the key signals at 3.37, 3.54 and 4.10 ppm. Although the yield was 
low (4.7%) there was sufficient sample for biological testing.  
 
 
Scheme 70 
 
Compounds 226 and 228 were tested for their ability to inhibit T. cruzi (Table 29). 
Surprisingly, these compounds showed excellent inhibition against T. cruzi. The 
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chloro dimer 226 had an IC50 of 0.022 µM and the fluoro dimer 228 had an IC50 of 
0.029 µM. This was ten times more potent than pyrifenox (0.29 µM). Although they 
are slightly toxic (40.35 µM and 67.22 µM), the SI values are large. This means the 
drug dose can be low. These compounds establish a new class of compounds for 
further research. They can be synthesised in one step, using cheap starting materials 
and eliminated the problem of the separation of the stereoisomers in the oxime 
analogues. 
 
Table 29 
Structure IC50 (toxicity) 
 
0.022 µM (40.35 µM) 
SI = 1834 
 
0.029 µM (67.22 µM) 
SI = 2317 
 
As these compounds were derived from a known antifungal, they were also tested 
against Candida albicans by Eurofins Panlabs Inc. Taiwan.
*
 Candida albicans 
(ATCC 10231) is a common yeast infection in humans. Both compounds were 
shown to be inactive at concentrations less than 128 µg/mL. This suggested that 
these compounds are selective for Chagas disease, unlike other azole antifungals that 
are active in yeast samples. 
 
                                               
*
 Screening was done according to CLSI. Reference Method for Broth Dilution Antifungal 
Susceptibility Testing of Yeasts; Approved Standard -Second Edition. CLSI document M27-A2 
(ISBN 1-56238-469-4). Vol. 22 No. 15. Clinical and Laboratory Standards Institute; Wayne, PA 
19087 USA, 2002. 
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8.2 Further investigations into the 1,5-diaryl-3-pyridyl-pentane-1,5-
dione system 
Due to the surprising effectiveness of the fluoro and chloro substituted dimers at 
inhibiting T. cruzi, further investigations were conducted. Using the conditions 
outlined in Section 8.1, 3-pyridinecarboxaldehyde 106 and disubstituted 
acetophenones 229 were stirred with a solution of sodium hydroxide in ethanol and 
water (Table 30). The 3,4-difluoro dimer 230 produced a complex mixture. Column 
chromatography isolated the desired product 230 in 7.5% yield. As only a small 
amount of compound was required for biological testing the reaction was not 
optimised further. The 2,4-dichloro dimer 195 was observed in trace quantities in the 
1
H NMR spectrum of the crude material, however it was not possible to isolate the 
desired product. As it has been shown the dichloro analogues were the most 
biologically active, the synthesis of the dichloro dimer was investigated further. 
 
 
Table 30 
Compound X1 X2 X3 Yield 
230 H F F 7.5% 
195 Cl H Cl Trace 
 
As the previous synthesis produced the dichloro dimer 195 in trace amounts that 
could not be purified, alternative methods were sought. 2ʹ,4ʹ-Dichloroacetophenone 
193 was dissolved in methanol and sodium hydride was added at 0 °C before 3-
pyridinecarboxaldehyde 106 was added dropwise. Water was added until the solution 
became cloudy and stirred for 1 hour. The 
1
H NMR spectrum of the crude material 
showed that only the chalcone had formed. The chalcone appeared to be precipitating 
out of solution before the Michael addition occurred. 
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Scheme 71 
 
Another method to synthesise the dimer was to start with the chalcone. The dichloro 
chalcone 194 was stirred with a solution of 2ʹ,4ʹ-dichloroacetophenone 193 and 
sodium ethoxide in ethanol at 0 °C for 2 hours (Scheme 72). The 
1
H NMR spectrum 
of the crude material showed a complex mixture and the key signals for the 
methylene and the CH were not observed. Sodium ethoxide was substituted for 
sodium hydride and methanol. The use of sodium ethoxide mainly returned 
unreacted chalcone but trace amounts of the dimer were visible in the 
1
H NMR 
spectrum.  
 
 
Scheme 72 
 
The last method investigated was based on a procedure by Kudernac et al.
146
 3-
Pyridinecarboxaldehyde 106, 2ʹ,4ʹ-dichloroacetophenone 193 (2 eq.) and powdered 
sodium hydroxide were ground together in methanol for 10 minutes (Scheme 73). 
The colour changed overtime from a blood red to brown. The 
1
H NMR spectrum of 
the crude material showed a complex mixture of compounds. Column 
chromatography isolated the desired dichloro dimer 195 in 42% yield and 
degradation by-products. The 
1
H NMR spectrum showed the key signals at 3.34 ppm 
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and 3.44 ppm corresponding to the methylenes and at 3.96 ppm corresponding to the 
CH. 
 
 
Scheme 73 
 
The dimers 195 and 230 were successfully synthesised and were tested for their 
ability to inhibit T. cruzi (Table 31). As already mentioned the chloro dimer 226 and 
the fluoro dimer 228 were ten times more potent than pyrifenox. The difluoro dimer 
230 had an IC50 of 0.011 µM which was slightly better than compound 228. 
Although the results for the dichloro dimer 195 have not been obtained, it would be 
expected, based on previous results, that it would have similar activity or better than 
the other dimers. 
 
Table 31 
Structure IC50 (toxicity) 
 
0.011 µM (53.35 µM) 
SI = 4850 
 
In testing 
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Compounds 195 and 230 were also tested against the yeast Candida albicans (ATCC 
10231).
*
 As with the other dimers, these compounds were also shown to be inactive 
at concentrations less than 128 µg/mL. 
 
The dichloro dimer 195 was also tested against another parasite, Trypanosoma 
brucei. T. brucei is another vector borne parasitic disease known as Human African 
trypanosomiasis, or sleeping sickness. The dichloro dimer 195 showed only less than 
100% activity at the highest dose in the assay (69.8% activity at 83.33 µM)
†
. The 
inactivity of compound 195 against Candida albicans and T. brucei suggest that this 
series of compounds could be selective to CYP51 in T. cruzi. 
 
8.3 Conclusions 
A series of four dimers were successfully synthesised and tested in whole cell assays 
for their ability to inhibit T. cruzi. All four dimers showed surprising results at 
inhibiting T. cruzi with IC50 in the nano molar range and were inactive against 
Candida albicans and T. brucei. The substituents on the phenyl ring show slightly 
different inhibitions and the two substituents proved to be the most effective. The 
most biologically active molecule synthesised was 230 and it would be expected the 
dichloro dimer 195 would show equal or better activity. These compounds have 
provided a new lead compound for future investigations. 
  
                                               
* Screening was done according to CLSI. Reference Method for Broth Dilution Antifungal 
Susceptibility Testing of Yeasts; Approved Standard -Second Edition. CLSI document M27-A2 
(ISBN 1-56238-469-4). Vol. 22 No. 15. Clinical and Laboratory Standards Institute; Wayne, PA 
19087 USA, 2002. 
† The compound activity against T. brucei was assessed in an Alamar blue® viability assay as 
previously descrived by Sykes and Avery.161 
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9 Conclusions  
 
 
 
 
 
 
A new synthetic method was designed to synthesise pyrifenox 42 and its analogues. 
The ketone intermediate was identified as the key compound to synthesising the 
analogues. Sequential Sonogashira reactions were utilised to obtain an alkyne which 
was hydrated to form the ketone. A variety of different conditions were investigated 
which involved the hydration of an alkyne and alkene, a Curtius rearrangement, a 
condensation reaction and a cross coupling reaction. The hydration of an alkyne 
using a gold catalyst, Au(PPh3)Me, provided the optimum procedure in synthesising 
the key ketone intermediate. Analogues were then synthesised using a simple 
condensation reaction of a variety of alkoxyamines and were tested for their ability to 
inhibit T. cruzi. Out of 24 different analogues synthesised, it was shown the chloro 
substituents on the phenyl ring were the most active compared to hydrogen and 
fluorine. The stereochemistry of the oxime was also shown to be important. The E 
isomer is the synthetically and biologically favoured isomer. The analogues of 
pyrifenox were improved by adding an oxime with a phenyl ring to give compound 
153 that was ten times more potent than pyrifenox 42 (Figure 48). 
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Figure 48 
 
The rigidity of the backbone of pyrifenox was also explored. The attempt at trying to 
remove the stereochemistry to create a more flexible compound by incorporating a 
nitrogen between the two rings was unsuccessful. The anti-trypanosomal activity of 
the compounds tested showed a decrease in activity. The increased rigidity was also 
investigated and was shown to decrease the biological activity.  
 
The linker between the substituted phenyl ring and the pyridyl ring was shown to be 
important. Increasing the carbon chain by an extra CH2 decreased the biological 
activity in comparison to pyrifenox. The analogues synthesised showed a similar 
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trend to the initial pyrifenox analogues. The substituents on the phenyl ring showed 
the best activity with the bulkier chlorine groups and the bulkier oxime was also 
preferred. The preferred stereochemistry of these compounds was not fully identified 
and requires further investigations. 
 
Finally, a new lead compound was identified from a by-product in the chalcone 
reaction. The dimers showed excellent activity against T. cruzi and were shown to be 
inactive against Candida albicans and T. brucei. This suggested that these 
compounds could be selective in their activity to T. cruzi. The dimers could be 
synthesised in one step from inexpensive starting materials. This class of compounds 
provide a new area of investigation to provide a new drug for the treatment of 
Chagas disease.  
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10 Experimental 
 
 
 
 
 
 
10.1 General procedure 
Reactions were conducted under a positive pressure of nitrogen at room temperature 
unless otherwise stated. Materials were obtained from commercial sources and used 
without further purification unless otherwise stated. Dry solvents were prepared 
according to Armarego and Chai.
147
 Melting points were determined using Barnstead 
Electrothermal 9100 melting point apparatus. NMR spectra were recorded on a 
Bruker AVANCE III 400 MHz spectrometer. All 
1
H NMR spectra were recorded at a 
frequency of 400.1 MHz, 
13
C NMR spectra were recorded at a frequency of 100.6 
MHz and 
31
P NMR spectra were recorded at a frequency of 161.9 MHz. NMR 
spectra were referenced to their respective solvents: chloroform-d (CDCl3, 
1H δ 7.26 
ppm, 
13C δ 77.16 ppm); acetone d6 (
1H δ 2.05 ppm, 13C δ 29.84 ppm); 
dimethylsulfoxide-d6 (DMSO-d6, 
13C δ 39.5). Multiplicity was assigned as follows: s 
= singlet, d = doublet, t = triplet, q = quarter, m = multiplet and br = broad. Infra-red 
(IR) spectra were obtained on a Perkin Elmer Spectrometer 100 using an attenuated 
total reflectance attachment with a ZnSe/diamond composite crystal. High resolution 
ESI and ASAP ionisation (HRMS) mass measurements were carried were recorded 
in positive mode on a Walters Xovo Q-TOF instrument and were carried out at the 
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University of Wollongong or in positive and negative ionisation mode on a LTQ 
Orbitrap XL instrument carried out at Curtin University. Thin layer chromatography 
(TLC) was run on Merck aluminium backed silica gel 60 F254 sheets and visualised 
under ultraviolet light. Compounds were purified by flash chromatography on 
Davisil silica gel 40−63 µm or on a Flashmaster II system using cartridges prepared 
in house. Petroleum spirits refers to the fraction of boiling point 40−60 °C. All 
organic extracts were dried using anhydrous magnesium sulfate. Microwave 
reactions were carried out using a Biotage Initiator EXP machine. 
 
10.2 Synthesis 
10.2.1 Synthesis of dichlorobis(triphenylphosphine)palladium(II) complex 
A solution of palladium chloride (2.003 g, 11.30 mmol) and triphenylphosphine 
(6.904 g, 26.32 mmol) in N,N-dimethylformamide (70 mL) was heated under reflux 
for 3 hours under nitrogen. Yellow crystals formed upon cooling and were collected 
by vacuum filtration, washed with ether and dried under vacuum (1 mmHg) to give 
dichlorobis(triphenylphosphine)palladium(II) as yellow crystals (7.795 g, 96%): m.p. 
270 °C decomp. (lit.
148
 m.p. 288−290 °C); 1H NMR (CDCl3) δ 7.34−7.47 (18H, m), 
7.67−7.76 (12H, m); 31P NMR (CDCl3) δ 23.24 ppm; IR 3051, 1481, 1435, 1097, 
744, 691 cm
−1
. 
 
10.2.2 Synthesis of 2-methyl-4-(3-pyridinyl)-3-butyn-2-ol (72) 
 
3-Bromopyridine 68 (0.525 g, 3.3 mmol) and 2-methyl-3-butyn-2-ol 71 (0.279 g, 3.3 
mmol) were dissolved in diethylamine (12 mL). The reaction mixture was stirred 
under nitrogen for 1 hour before PdCl2(PPh3)2 (0.074 g, 0.11 mmol) and copper(I) 
iodide (0.010 g, 0.052 mmol) were added and the reaction mixture was heated under 
reflux overnight. The reaction mixture was cooled to room temperature and 
concentrated under reduced pressure. The residue was dissolved in ethyl acetate (10 
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mL), washed with 10% citric acid solution (10 mL), brine (10 mL) and water (3 × 10 
mL). The organic layer was dried over anhydrous magnesium sulfate and 
concentrated under reduced pressure. The resulting oil was subjected to flash 
chromatography. Elution with 15% ethyl acetate in petroleum afforded 2-methyl-4-
(3-pyridinyl)-3-butyn-2-ol 72 as a brown solid (0.195 g, 37%): m.p. 42−43 °C (lit.149 
m.p. 55−56 °C). The spectroscopic properties were similar to those reported.149 1H 
NMR (CDCl3) δ 1.58 (6H, s), 7.21 (1H, dd, J = 7.9, 5.0 Hz), 7.66 (1H, ddd, J = 7.9, 
1.8, 1.8), 8.46 (1H, br. s), 8.70 (1H, br. s); 
13
C NMR (CDCl3) δ 31.4 (CH3), 65.0 (C), 
78.3 (C), 98.5 (C), 120.5 (CH), 123.3 (C), 139.0 (CH), 148.0 (CH), 151.9 (CH); IR 
3258, 2981, 2933, 1587, 1568, 1477, 1165 cm
−1
. 
 
10.2.3 Synthesis of 3-ethynylpyridine (73) 
 
2-Methyl-4-(3-pyridinyl)-3-butyn-2-ol 72 (0.195 g, 1.21 mmol) was dissolved in dry 
toluene (4 mL) and stirred under nitrogen for 30 minutes. Sodium hydride (60% in 
mineral oil) (50 mg) was added and the reaction mixture was heated under reflux for 
20 minutes. The reaction mixture was allowed to cool to room temperature before 
hydrochloric acid (1 M, 10 mL) was added. The acidic layer was extracted with ethyl 
acetate (2 × 10 mL), basified with a solution of sodium hydrogen carbonate (1 M, 10 
mL) and extracted with dichloromethane (2 × 10 mL). The combined extracts were 
dried over anhydrous magnesium sulfate and concentrated under reduced pressure to 
give 3-ethynylpyridine 73 as a brown oil (0.075 g, 53%). The spectroscopic 
properties were similar to those reported.
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1
H NMR (CDCl3) δ 3.20 (1H, s), 7.23 
(1H, dd, J = 7.7, 4.6 Hz) 7.73 (1H, d, J = 7.8 Hz), 8.54 (1H, br. s), 8.70 (1H, br. s); 
13
C NMR (CDCl3) 80.1, 80.8, 119.0, 123.1, 139.1, 149.2, 152.8. 
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10.2.4 Synthesis of 4-(2,4-difluorophenyl)-2-methyl-3-butyn-2-ol (79) 
 
1-Bromo-2,4-difluorobenzene 75 (16.762 g, 86.85 mmol) and 2-methyl-3-butyn-2-ol 
71 (7.266 g, 86.77 mmol) were dissolved in diethylamine (120 mL) and stirred under 
nitrogen. After 1 hour, PdCl2(PPh3)2 (0.801 g, 1.14 mmol) and copper(I) iodide 
(0.060 g, 0.32 mmol) were added and the reaction mixture was heated under reflux 
for 4 days. The reaction mixture was concentrated under reduced pressure. The 
residue was subjected to flash chromatography. Elution with 20% ethyl acetate in 
petroleum spirits produced 4-(2,4-difluorophenyl)-2-methyl-3-butyn-2-ol 79 as a 
brown oil (14.043 g, 83%): 
1
H NMR (CDCl3) δ 1.62 (6H, s), 2.30 (1H, s), 6.77−6.85 
(2H, m), 7.33−7.41 (1H, m); 13C NMR (CDCl3) δ 31.4 (CH3), 65.7 (C), 74.6 (C), 
99.0 (C, dd, J = 3.5, 1.9 Hz), 104.2 (CH, dd, J = 24.9, 0.7 Hz), 107.8 (C, dd, J = 15.8, 
4.0 Hz), 111.5 (CH, dd, J = 18.2, 3.7 Hz), 134.4 (CH, dd, J = 9.6, 2.9 Hz), 162.7 (C, 
dd, J = 240.7, 11.1 Hz), 163.1 (C, dd, J = 241.7, 12.8 Hz); IR 3371, 2983, 1615, 
1589, 1502, 1142 cm
−1
. 
 
10.2.5 Synthesis of 3-(2,4-difluorophenylethynyl)pyridine (76) 
 
4-(2,4-Difluorophenyl)-2-methyl-3-butyn-2-ol 79 (2.107 g, 10.7 mmol) and 
potassium hydroxide (0.814 g, 14.5 mmol) were mixed with benzene (6 mL) and the 
reaction mixture was heated under reflux overnight. 3-Bromopyridine 68 (1.40 mL, 
2.30 g, 14.53 mmol) in diethylamine (80 mL) was added to the reaction mixture. The 
resulting mixture was degassed with nitrogen by the freeze-pump-thaw method. 
PdCl2(PPh3)2 (0.097 g) and copper(I) iodide (0.026 g) were added and the mixture 
was degassed with nitrogen again. The reaction mixture was heated under reflux for 
2 days. After cooling to room temperature the reaction mixture was concentrated 
147 
 
under reduced pressure. The residue was subjected to flash chromatography. Elution 
with 25% ethyl acetate in petroleum spirits afforded 3-(2,4-
difluorophenylethynyl)pyridine 76 as a brown oil (0.983 g, 41%) and 1,4-Bis(2,4-
difluorophenyl)buta-1,3-diyne 82 as a brown oil (0.580 g, 19%). 
3-(2,4-Difluorophenylethynyl)pyridine (76): HRMS m/z Calcd for C13H8F2N 
216.0625, found 216.0617; 
1
H NMR (CDCl3) δ 6.84−6.95 (2H, m), 7.29 (1H, m), 
7.46−7.54 (1H, m), 7.81 (1H, d, J = 7.8 Hz), 8.59 (1H, br. s), 8.79 (1H, br. s); 13C 
NMR (CDCl3) 85.0 (C), 90.7 (C), 104.4 (CH, dd, J = 24.6, 1.0 Hz), 107.5 (C, d, J = 
4.0 Hz), 107.7 (C, d, J = 4.0 Hz), 111.6 (CH, d, J = 3.7), 111.8 (CH, d, J = 3.7 Hz), 
134.3 (CH, dd, J = 9.8, 2.4 Hz), 138.4 (CH), 148.9 (CH), 152.2 (CH), 163.0 (C, dd, J 
= 255.1, 4.4 Hz), 163.12 (C, dd, J = 249.8, 5.7 Hz); IR 3064, 2228 1588, 1500, 1266, 
806 cm
−1
. 
1,4-Bis(2,4-difluorophenyl)buta-1,3-diyne 82: 
1
H NMR (CDCl3) δ 6.83−6.95 (4H, 
m), 7.46−7.56 (2H, m). 
 
10.2.6 Synthesis of 4-(2,4-dichlorophenyl)-2-methyl-3-butyn-2-ol (85) 
 
1-Bromo-2,4-dichlorobenzene 84 (15.260 g, 67.55 mmol) and 2-methyl-3-butyn-2-ol 
71 (5.75 g, 68.35 mmol) were dissolved in diethylamine (110 mL) and stirred under 
nitrogen. After 1 hour, PdCl2(PPh3)2 (0.760 g, 1.08 mmol) and copper(I) iodide 
(0.060 g) were added and the reaction mixture was heated under reflux for 3 days. 
The reaction mixture was concentrated under reduced pressure. The residue was 
subjected to flash chromatography. Elution with 20% ethyl acetate in petroleum 
spirits produced 4-(2,4-dichlorophenyl)-2-methyl-3-butyn-2-ol 85 as a brown oil 
(14.48 g, 94%): 
1
H NMR (CDCl3) δ 1.62 (6H, s), 2.32 (1H, s), 7.16 (1H, dd, J = 8.3, 
2.1 Hz), 7.34 (1H, d, J = 8.3 Hz) 7.38 (1H, d, J = 2.1 Hz); 
13
C NMR (CDCl3) δ 31.4 
(CH3), 65.7 (C), 78.1 (C), 100.2 (C), 121.4 (C), 127.0 (CH), 129.3 (CH), 133.9 (CH), 
134.6 (C), 136.8 (C); IR 3362, 2982, 2933, 2233, 1583, 1545, 1474, 1100 cm
−1
. 
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10.2.7 Synthesis of 3-(2,4-dichlorophenylethynyl)pyridine (87) 
 
4-(2,4-Dichlorophenyl)-2-methyl-3-butyn-2-ol 85 (0.857 g, 3.74 mmol) and 
potassium hydroxide (0.385 g, 6.86 mmol) were dissolved in benzene (10 mL) and 
the reaction mixture was heated under reflux overnight. 3-Bromopyridine 68 (0.36 
mL, 0.590 g, 3.74 mmol) in diethylamine (40 mL) was added to the reaction mixture 
and the reaction mixture was degassed with nitrogen. PdCl2(PPh3)2 (0.047 g, 0.067 
mmol) and copper(I) iodide (0.013 g, 0.068 mmol) were added and the reaction 
mixture was heated under reflux for 2 days. The reaction mixture was filtered 
through Celite and the filtrate was concentrated under reduced pressure. The residue 
was subjected to flash chromatography. Elution with 25% ethyl acetate in petroleum 
spirits afforded 3-(2,4-dichlorophenylethynyl)pyridine 87 as a brown oil (0.297 g, 
32%): HRMS m/z Calcd for C13H8Cl2N requires 248.0034, found 248.0027; 
1
H NMR 
(CDCl3) δ 7.14−7.24 (2H, m), 7.36−7.43 (2H, m), 7.71−7.78 (1H, m), 8.50 (1H, dd, 
J = 4.8, 1.5 Hz), 8.71 (1H, br. s);
 13
C NMR (CDCl3) δ 88.6 (C), 91.9 (C), 119.9 (C), 
121.2 (C), 123.3 (CH), 127.2 (CH), 129.5 (CH), 133.9 (CH), 135.3 (C), 136.9 (C), 
138.8 (CH), 149.0 (CH), 152.2 (CH); IR 3062, 3025, 1577, 1558, 1542, 1478, 1101, 
803, 698 cm
−1
. 
 
10.2.8 Synthesis of 3-(2-phenylethynyl)-pyridine (89) 
 
3-Bromopyridine 68 (1.057 g, 6.69 mmol) and phenyl acetylene 88 (0.661 g, 6.47 
mmol) were dissolved in diethylamine (40 mL) and the solution was degassed with 
nitrogen. PdCl2(PPh3)2 (0.127 g, 0.181 mmol) and copper(I) iodide (0.049 g, 0.252 
mmol) were added and the mixture was heated under reflux for 2 days. The reaction 
mixture was filtered through Celite and concentrated under reduced pressure. The 
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residue was subjected to flash chromatography. Elution with 25% ethyl acetate in 
petroleum spirits produced 3-(2-phenylethynyl)pyridine 89 as brown solid (1.025g, 
88%): m.p. 37 °C. The spectroscopic properties were similar to those reported.
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1
H 
NMR (CDCl3) δ 7.24−7.31 (1H, m), 7.34−7.41 (3H, m), 7.53−7.60 (2H, m), 7.81 
(1H, ddd, J = 7.9, 1.9, 1.9 Hz), 8.56 (1H, d, J = 3.8 Hz), 8.80 (1H, br. s); 
13
C NMR 
(CDCl3) δ 86.0 (C), 92.7 (C), 120.5 (C), 122.5 (C), 123.1 (CH), 128.4 (CH), 128.8 
(CH), 131.6 (CH), 138.2 (CH), 148.3 (CH), 152.1 (CH); IR 3048, 3007, 2956, 2220, 
1963, 1819, 1560, 1489, 1021, 756, 689 cm
−1
. 
 
10.2.9 Synthesis of methyltriphenylphosphine gold 
A mixture of concentrated nitric acid (2 mL) and concentrated hydrochloric acid (8 
mL) were added to a gold ingot (1.00 g, 5.08 mmol). The mixture was allowed to 
stand at room temperature overnight until all the gold had dissolved.  
The acid solution was diluted with methanol (25 mL) and was added dropwise to a 
solution of triphenylphosphine (2.630 g, 10.03 mmol) in methanol (75 mL) with a 
white precipitate forming immediately. The reaction mixture was left to stand at 0 °C 
for 1 hour. The precipitate was collected by vacuum filtration to give 
triphenylphosphine gold(I) chloride as white crystals (2.222 g, 44%): m.p. 201 °C 
decomp; 
1
H NMR (CDCl3) δ 7.45−7.55 (m); 
31
P NMR (161 MHz, CDCl3) δ 33.75; 
IR 3058, 1479, 1433, 1101, 747, 690 cm
−1
.  
Triphenylphosphinegold(I) chloride (2.220 g, 4.5 mmol) was suspended in dry 
tetrahydrofuran (50 mL) and nitrogen was bubbled through the mixture. A solution 
of methylmagnesium iodide (3 M in THF) (10 mL, 30 mmol, 6.7 eq.) was added 
dropwise to the reaction mixture over 10 minutes. The resulting mixture was heated 
under reflux for 3 hours and then allowed to cool to room temperature before cooling 
to 0 °C. A degassed and cooled (0 °C) solution of sulfuric acid (0.5%, 100 mL) was 
added to the reaction mixture to form a purple precipitate. Tetrahydrofuran (30 mL) 
was added and the solid was removed by vacuum filtration and the residue was 
washed with toluene (10 mL). The filtrate was separated and the organic layer was 
washed with water, dried over anhydrous magnesium sulfate and concentrated under 
reduced pressure until about 10 mL of solvent remained. Hexanes (15 mL) was 
added slowly to the surface of the reaction mixture and the reaction mixture was 
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cooled (−20 °C) overnight. The resulting precipitate was collected to give white 
crystals (1.499 g, 70%): m.p. 259 °C decomp. (lit.
101
 m.p. 173−175 °C); 1H NMR 
(CDCl3) δ 0.54 (3H, d, J = 7.9), 7.41−7.47 (9H, m), 7.51−7.56 (6H, m); 
13
C NMR 
(CDCl3)
*
 δ 7.3 (CH3, d, J = 95.3 Hz), 129.0 (CH), 129.1 (CH), 130.9 (CH), 131.0 
(CH), 131.5 (C), 134.4 (CH), 134.5 (CH); 
31
P NMR (CDCl3) δ 47.96; IR 3053, 2928, 
2869, 1477, 1432, 1098, 742, 690 cm
−1
. 
 
10.2.10 Synthesis of ethyltriphenylphosphine gold 
Triphenylphosphinegold(I) chloride (0.499 g, 1.01 mmol) was suspended in 
anhydrous ether (12 mL). A solution of ethylmagnesium bromide (3 M in ether) (2 
mL, 6 mmol, 6 eq.) was added dropwise and the resulting mixture was heated under 
reflux for 3 hours. The reaction was cooled to room temperature and a solution of 
sulfuric acid (0.5%, 12 mL) was added. The resulting precipitate was vacuum filtered 
and washed with toluene (3 mL). The filtrate was separated and the organic layer was 
washed with water (30 mL). The organics were dried over anhydrous magnesium 
sulfate and concentrated under reduced pressure until 5 mL remained. Hexanes (12 
mL) were added to the surface of the reaction mixture and the mixture was cooled 
(−20 °C) for 7 days. The resulting precipitate was collected to give white crystals 
(0.310 g, 62%): m.p. 125.5 °C (lit.
100
 m.p. 134.5−135.5 °C); 1H NMR (CDCl3) δ 
1.34−1.48 (5H, m), 7.40−7.49 (9H, m), 7.49−7.57 (6H, m); 13C NMR (CDCl3)
†
 δ 
16.5 (CH3), 22.1 (CH2), 23.0 (CH2), 129.0 (CH), 129.1 (CH), 130.9 (CH), 131.7 (C), 
132.2 (C), 134.4 (CH), 134.5 (CH); 
31
P NMR (CDCl3) δ 45.61 ppm; IR 2872, 2853, 
1477, 1433, 1099, 742, 691 cm
−1
. 
 
 
 
                                               
*
 This is a description of the spectra. The peaks were not assigned. 
†
 This is a description of the spectra. The peaks were not assigned. 
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10.2.11 Synthesis of 1-phenyl-2(3-pyridinyl)ethanone (93) 
 
Procedure 1 
3-(2-Phenylethynyl)pyridine 89 (0.163 g, 0.91 mmol) was dissolved in methanol (3 
mL), water (1 mL) and concentrated sulfuric acid (0.5 mL). Au(PPh3)Me (0.033 g, 
0.069 mmol, 7.6 eq.) was added and nitrogen was bubbled through the solution. The 
reaction mixture was heated under reflux for 1 hour. The reaction mixture was 
cooled to room temperature and poured into a solution of sodium hydrogen carbonate 
(1 M, 25 mL) and extracted with dichloromethane (3 × 20 mL). The combined 
extracts were washed with brine (25 mL), dried over anhydrous magnesium sulfate 
and concentrated under reduced pressure. The residue was subjected to flash 
chromatography. Elution with 50% ethyl acetate in petroleum spirits afforded 1-
phenyl-2-(3-pyridinyl)ethanone 93 as a colourless oil (0.174 g, 97%). The 
spectroscopic properties were similar to those reported.
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1
H NMR (CDCl3)  4.27 
(2H, s), 7.23 (1H, ddd, J = 7.8, 4.8, 0.7 Hz), 7.42−7.48 (2H, m), 7.52−7.60 (2H, m), 
7.96−8.01 (2H, m), 8.46−8.51 (2H, m); 13C NMR (CDCl3) δ 42.3 (CH2), 123.5 
(CH), 128.4 (CH), 128.8 (CH), 130.3 (C), 133.6 (CH), 136.2 (C), 137.4 (CH), 148.2 
(CH), 150.6 (CH), 196.4 (C); IR 3058, 1679, 1579, 1209, 687 cm
−1
. 
 
Procedure 2 
3-(2-Phenylethynyl)pyridine 89 (0.055 g, 0.329 mmol) was dissolved in 
trifluoroacetic acid (1 mL) and water (0.10 mL) and the reaction mixture was heated 
under reflux overnight. The reaction mixture was cooled to room temperature and 
poured into a solution of sodium hydrogen carbonate (1 M, 10 mL). The aqueous 
layer was extracted with dichloromethane (2 × 10 mL). The combined extracts were 
washed with brine (15 mL), dried over anhydrous magnesium sulfate and 
concentrated under reduced pressure. The residue was subjected to flash 
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chromatography. Elution with 25% ethyl acetate in petroleum spirits produced 1-
phenyl-2(3-pyridinyl)ethanone 93 as a colourless oil (0.021 g, 34 %).  
 
Procedure 3 
Sodium dodecyl sulfate (0.015 g, 0.05 mmol, 0.13 eq.) was added to a solution of 3-
(2-phenylethynyl)pyridine 89 (0.072 g, 0.40 mmol) in a solution of hydrochloric acid 
(2 M, 0.25 mL) and water (1.75 mL). The reaction mixture was heated in a 
microwave oven at 170 °C for 20 minutes with 10 seconds prestirring. The reaction 
mixture was cooled to room temperature and poured into a solution of sodium 
carbonate (1 M, 10 mL). The aqueous layer was extracted with dichloromethane (5 × 
10 mL). The combined extracts were dried over anhydrous magnesium sulfate and 
concentrated under reduced pressure. The residue was subjected to flash 
chromatography. Elution with 50% ethyl acetate in petroleum spirits afforded 1-
phenyl-2(3-pyridinyl)ethanone 93 as a colourless oil (0.021 g, 27%). 
 
10.2.12 Synthesis of 1-phenyl-2-(3-pyridinyl)ethanone (93) 
 
3-Chloropyridine 116 (0.1 mL, 0.121 g, 1.06 mmol), acetophenone 57 (0.15 mL, 
0.15 g, 1.25 mmol) and dry toluene (4 mL) were added via syringe to chloro(2-
dicyclohexylphosphino-2ʹ,4ʹ,6ʹ-tri-iso-propyl-1,1ʹ-biphenyl)[2-(2-aminoethyl)-
phenyl]Pd(II) methyl-tert-butylether adduct 59 (0.008 g) and potassium tert-butoxide 
(0.262 g, 2.33 mmol) under nitrogen. The reaction mixture was heated under reflux 
overnight. Upon cooling, the reaction mixture was poured into a solution of 
ammonium chloride (1 M, 40 mL) and extracted with ethyl acetate (3 × 40 mL). The 
combined extracts were dried over anhydrous magnesium sulfate and concentrated 
under reduced pressure. The residue was subjected to flash chromatography. Elution 
with 0−40% ethyl acetate in hexanes afforded 1-phenyl-2-(3-pyridinyl)ethanone 93 
as a colourless oil (0.181 g, 87%). 
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10.2.13 Synthesis of 1-(2,4-difluorophenyl)-2-(3-pyridinyl)ethanone (99) 
 
Au(PPh3)Me (0.082 g, 0.17 mmol) was added to a solution of 4-(2,4-
Difluorophenyl)ethynylpyridine 76 (0.454 g, 2.11 mmol) in methanol (9 mL), water 
(3 mL) and concentrated sulfuric acid (1.5 mL) and nitrogen was bubbled through 
the solution. The reaction mixture was heated under reflux overnight. The reaction 
mixture was cooled to room temperature and poured into a solution of sodium 
hydrogen carbonate (1 M, 25 mL) and extracted with dichloromethane (3 × 20 mL). 
The combined extracts were washed with brine (25 mL), dried over anhydrous 
magnesium sulfate and concentrated under reduced pressure. The residue was 
subjected to flash chromatography. Elution with 50% ethyl acetate in petroleum 
spirits afforded 1-(2,4-difluorophenyl)-2-(3-pyridinyl)ethanone 99 as a yellow oil 
(0.470 g, 96%): HRMS m/z Calcd for C13H9F2NO requires 234.0730, found 
234.0732; 
1
H NMR (CDCl3) δ 4.19 (2H, s), 7.17−7.22 (2H, m), 7.26−7.41 (1H, m), 
7.49−7.54 (1H, m), 7.8−7.88 (1H, m), 8.43−8.46 (2H, m); 13C NMR (CDCl3) δ 46.6 
(CH2, d, J = 8.4 Hz), 104.8 (CH, dd, J = 25.2, 2.4 Hz), 112.4 (CH, dd, J = 18.2, 3.4 
Hz), 121.5 (C, dd, J = 13.1, 3.7), 123.3 (CH), 129.6 (C, d, J = 1.7 Hz), 133.0 (CH, J 
= 10.6, 4.2 Hz), 137.3 (CH), 148.3 (CH), 150.6 (CH), 162.6 (C, dd, J = 244.4, 12.8 
Hz), 166.0 (C, dd, J = 245.4, 11.8 Hz), 193.2 (C, d, J = 5.0 Hz); IR 3100, 2476, 
1664, 1608, 1589, 1428 cm
−1
. 
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10.2.14 Synthesis of 1-(2,4-dichlorophenyl)-2-(3-pyridinyl)ethanone (48) 
 
Au(PPh3)Me (0.136 g, 0.29 mmol) was added to a solution of 3-(2,4-
dichlorophenylethynyl)pyridine 87 (0.700 g, 2.82 mmol) was dissolved in methanol 
(10 mL), water (3 mL) and concentrated sulfuric acid (1.5 mL). Nitrogen was 
bubbled through the solution and the reaction mixture was heated under reflux 
overnight. The reaction was cooled to room temperature and poured into a solution 
of sodium hydrogen carbonate (1 M, 25 mL) and extracted with dichloromethane (3 
× 20 mL). The combined extracts were washed with brine (25 mL), dried over 
anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The 
residue was subjected to flash chromatography. Elution with 50% ethyl acetate in 
petroleum spirits afforded 1-(2,4-dichlorophenyl)-2(3-pyridinyl)-ethanone 42 as a 
yellow oil (0.662 g, 88%): 
1
H NMR (CDCl3)  4.25 (2H, s), 7.24−7.29 (1H, m), 7.31 
(1H, d, J = 1.9 Hz), 7.41 (1H, d, J = 8.2 Hz), 7.44 (1H, d, J = 1.9 Hz), 7.59 (1H, m), 
8.49 (2H, br. s); 
13
C NMR (CDCl3)  46.5 (CH2), 123.5 (CH), 127.5 (CH), 129.4 (C), 
130.4 (CH), 130.5 (CH), 132.1 (C), 136.8 (C), 137.4 (CH), 137.8 (C), 148.4 (CH), 
150.4 (CH), 198.3 (C); IR 3086, 2922, 1683, 1580, 1552, 1102 cm
−1
. 
 
10.2.15 Synthesis of 3-bromopyridine N-oxide (94) 
 
3-Chloroperoxybenzoic acid (0.292 g, 1.27 mmol) was added to a solution of 3-
bromopyridine 68 (0.166 g, 1.05 mmol) in dichloromethane (1 mL) and the reaction 
mixture was stirred at room temperature overnight. The reaction mixture was poured 
into a solution of sodium hydrogen carbonate (1 M, 5 mL) and extracted with 
dichloromethane (3 × 5 mL). The combined extracts were dried over anhydrous 
magnesium sulfate and concentrated under reduced pressure to give 3-bromopyridine 
N-oxide 94 as a yellow oil (0.149 g, 82%): 
1
H NMR (CDCl3) δ
 
7.13 (1 H, dd, J = 8.2, 
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6.6 Hz), 7.35−7.39 (1 H, m), 8.09−8.14 (1 H, m), 8.31−8.33 (1 H, m); IR 3390, 
3098, 1592, 1466, 1421 cm
−1
. 
 
10.2.16 Synthesis of 2-methyl-4-(3-pyridinyl)-3-butyn-2-ol N-oxide (95) 
 
3-Bromopyridine N-oxide 94 (0.149 g, 0.86 mmol) and 2-methyl-3-butyn-2-ol 71 
(0.081 g, 0.96 mmol) were dissolved in diethylamine (10 mL) and the solution was 
degassed with nitrogen. PdCl2(PPh3)2 (0.021 g) and copper(I) iodide (0.010 g, 0.052 
mmol) were added and the reaction mixture was heated under reflux for 1 day. The 
reaction mixture was filtered through Celite and concentrated under reduced 
pressure. The residue was subjected to flash chromatography. Elution with 50% ethyl 
acetate in petroleum spirits before increasing to methanol afforded 2-methyl-4-(3-
pyridinyl)-3-butyn-2-ol N-oxide 95 as a brown oil (0.150 g, 98%): HRMS m/z Calcd 
for C10H11NO2 requires 178.0868, found 178.0869; 
1
H NMR (CDCl3) δ 1.59 (6H, s), 
3.47 (1H, s), 7.21 (2H, br. s), 8.12 (1H, br. s), 8.22 (1H, br. s); IR 3398, 3129, 3073, 
2979, 1627, 1594, 1477, 1150, 984, 880 cm
−1
. 
 
10.2.17 Synthesis of 1-phenyl-2-(3-pyridinyl)ethanone N-oxide (97) 
 
3-Chloroperoxybenzoic acid (0.300 g, 1.74 mmol) was added to a solution of 3-(2-
phenylethynyl)pyridine 89 (0.188 g, 1.049 mmol) in dichloromethane (1 mL) and the 
reaction mixture was stirred at room temperature for 1 day. The reaction mixture was 
poured into a solution of sodium hydrogen carbonate (1 M, 10 mL) and extracted 
with dichloromethane (3 × 10 mL). The combined extracts were dried over 
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magnesium sulfate and concentrated under reduced pressure. The residue was 
subjected to flash chromatography. Elution with 25% ethyl acetate in petroleum 
spirits and increasing gave the product 97 as a brown oil (0.089 g, 43%): HRMS m/z 
Calcd for C13H10NO requires 196.0762, found 196.0762; 
1
H NMR (CDCl3) δ 
7.21−7.28 (1H, m), 7.33−7.41 (4H, m), 7.49−7.56 (2H, m), 8.18 (1H, d, J = 6.3 
Hz), 8.34 (1H, s); 
13
C NMR (CDCl3) δ 83.2 (C), 94.9 (C), 121.6 (C),  128.5 (CH), 
128.7 (CH), 129.1 (CH), 129.7 (CH), 132.0 (CH), 132.2 (CH); IR 3406, 2219, 1598, 
1558, 1494, 1213 cm
−1
.  
 
10.2.18 Synthesis of 3-(2-phenylethynyl)pyridine (101) 
 
Acetylacetone 100 (0.10 mL, 0.97 mmol), Pd(OAc)2 (0.004 g, 0.018 mmol) and 
potassium carbonate (5.102 g, 36.92 mmol) were added to a solution of 3-
bromopyridine 68 (2.856 g, 18.08 mmol) and styrene (2.847 g, 27.34 mmol) in dry 
N,N-dimethylformamide (38 mL). The reaction mixture was heated to 130 °C for 2.5 
hours. The reaction mixture was cooled to room temperature. A solution of sodium 
hydroxide (1 M, 10 mL) was added to the reaction mixture and extracted with ethyl 
acetate (3 × 10 mL). The combined extracts were washed with water (20 mL), dried 
over anhydrous magnesium sulfate and concentrated under reduced pressure. The 
residue was subjected to flash chromatography. Elution with 50% ethyl acetate in 
petroleum spirits gave 3-(2-phenylethenyl)pyridine 101 as a pale brown solid (2.566 
g, 78%): m.p. 72 °C (lit.
107
 m.p. 81−83 °C). The spectroscopic properties were 
similar to those reported.
107
 
1
H NMR (CDCl3) δ 7.06 (1H, d, J = 16.4 Hz), 7.16 (1H, 
d, J = 16.4 Hz), 7.25−7.32 (2H, m), 7.35−7.41 (2H, m), 7.53 (2H, m), 7.82 (1H, m), 
8.49 (1H, d, J = 3.7 Hz), 8.73 (1H, br. s); 
13
C NMR (CDCl3) δ 123.7 (CH), 125.0 
(CH), 126.8 (CH), 128.3 (CH), 128.9 (CH), 131.0 (CH), 132.8 (CH), 133.1 (C), 
136.8 (C), 148.7 (CH); IR 3054, 3025, 2999, 1636, 1565, 1492, 1479, 1448, 962 
cm
−1
. 
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10.2.19 Synthesis of 3-(2-phenylethyl)pyridine (105) 
 
3-(2-Phenylethenyl)pyridine 101 (0.088 g, 0.486 mmol) and potassium iodide (1.388 
g, 8.06 mmol) were mixed in phosphoric acid (2 mL) and the reaction mixture was 
heated to 150 °C for 48 hours. The reaction mixture was poured into a solution of 
sodium hydrogen carbonate (1 M, 10 mL) and extracted with dichloromethane (2 × 
10 mL). The combined extracts were washed with brine (10 mL), dried over 
anhydrous magnesium sulfate and concentrated under reduced pressure. The residue 
was subjected to flash chromatography. Elution with 50% ethyl acetate in petroleum 
spirits gave 3-(2-phenylethyl)pyridine 105 as a colourless oil (0.064 g, 72%). The 
spectroscopic properties were similar to those reported.
109
 
1
H NMR (CDCl3)  
2.94−2.96 (4H, m), 7.14−7.18 (2H, m), 7.19−7.25 (2H, m), 7.27−7.33 (2H, m), 
7.47 (1H, ddd, J = 7.8, 1.7, 1.7 Hz), 8.47 (2H, br. s); 
13
C NMR (CDCl3) δ 34.9 
(CH2), 37.5 (CH2), 123.4 (CH), 126.2 (CH), 128.5 (CH), 136.4 (CH), 137.1 (C), 
140.7 (C), 147.1 (CH), 149.6 (CH); IR 3027, 2924, 2858, 1602, 1575, 1494, 1478, 
1453, 1422, 697 cm
−1
. 
 
10.2.20 Synthesis of 2,4-dichloro-α-(3-pyridinylmethylene)phenylacetic acid 
(108) 
 
3-Pyridinecarboxaldehyde 106 (5.6 mL, 6.39 g, 59.65 mmol), 2,4-
dichlorophenylacetic acid 107 (12.102 g, 59.02 g) and triethylamine (6 mL) were 
suspended in acetic anhydride (48 mL) and heated under reflux for 5 hours. The 
reaction mixture was cooled to room temperature and water (200 mL) was added. 
The resulting mixture was left to crystallise for 3 days. The resulting precipitate was 
filtered. Recrystallisation with ethanol afforded the product 108 as a pale brown solid 
(10.704 g, 62%): m.p. 205−207°C (lit.113 m.p. 208−211 °C); 1H NMR (d6-acetone)  
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7.11−7.16 (1H, m), 7.19 (1H, d, J = 8.3 Hz), 7.27 (1H, m), 7.28−7.30 (1H, m), 7.31 
(1H, d, J = 2.1 Hz), 7.50 (1H, d, J = 2.0 Hz), 7.86 (1H, s), 8.29 (1H, d, J = 2.1 Hz), 
8.34 (1H, dd, J = 4.8, 1.7 Hz);
 13
C NMR (d6-acetone) δ 124.3 (CH), 128.7 (CH), 
130.2 (CH), 131.2 (C), 132.8 (C), 133.5 (CH), 135.3 (C), 135.3 (C), 135.6 (C), 137.0 
(CH), 139.2 (CH), 151.0 (CH), 151.8 (CH), 167.0 (C); IR 2446, 1694, 1610, 1244, 
1192, 801, 695 cm
−1
. 
 
10.2.21 Synthesis of 2,4-dichloro-α-(3-pyridinylmethylene)benzeneacetyl 
chloride hydrochloride (109) 
 
2,4-Dichloro-α-(3-pyridinylmethylene)phenylacetic acid 108 (4.40 g, 14.96 mmol) 
was suspended in thionyl chloride (26 mL) and heated under reflux for 3 hours. The 
solvent was distilled off leaving a brown solid. The residue was washed with ether 
and collected via vacuum filtration to give the product 109 as a pale brown solid 
(5.043 g, 97%). 
 
10.2.22 Synthesis of 1-(2,4-dichlorophenyl)-2-(3-pyridinyl)-1,2-ethanedione 
(112) 
 
2,4-Dichloro-α-(3-pyridinylmethylene)phenylacetyl chloride hydrochloride 109 (2.05 
g, 5.87 mmol) was dissolved in acetone (5 mL) and cooled to 0 °C. A solution of 
sodium azide (0.467 g, 7.18 mmol, 1.2 eq.) in water (5 mL) was added and the 
reaction mixture was stirred at 0 °C for 10 minutes and at room temperature for 5 
minutes. A solution of sodium carbonate (0.85 g) in water (40 mL) was added until a 
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cloudy precipitate formed. The aqueous phase was extracted with toluene (3 × 30 
mL). The combined extracts were dried over anhydrous magnesium sulfate and 
filtered. The filtrate was heated under reflux for 2 hours. The reaction mixture was 
cooled to room temperature and concentrated under reduced pressure. The residue 
was dissolved in acetic acid (12 mL) and water (6 mL) and heated under reflux for 2 
hours. The reaction was cooled to room temperature and concentrated under reduced 
pressure until half its volume remained. A solution of saturated sodium hydrogen 
carbonate (250 mL) was added until pH 8 and was extracted with dichloromethane (4 
× 40 mL). The combined extracts were dried over anhydrous magnesium sulfate and 
concentrated under reduced pressure. The residue was subjected to flash 
chromatography. Elution with 50% ethyl acetate in petroleum spirits afforded 1-(2,4-
dichlorophenyl)-2(3-pyridinyl)ethanone 48 as an oil (0.700 g). 
After 1 week under normal atmospheric conditions was converted to 1-(2,4-
dichlorophenyl)-2-(3-pyridinyl)-1,2-ethanedione 112 as a yellow oil (0.682 g, 44%): 
HRMS m/z Calc for C13H7Cl2NO2 requires 280.9824, found 279.9922; 
1
H NMR 
(CDCl3) δ 7.46 (1H, d, J = 1.8 Hz), 7.47−7.49 (1H, m), 7.52 (1H, ddd, J = 7.8, 4.9, 
0.8 Hz), 7.86 (1H, dd, J = 7.8, 0.5 Hz), 8.35 (1H, ddd, J = 8.1, 2.0, 2.0 Hz), 8.90 (1H, 
dd, J = 4.9, 1.7 Hz), 9.24 (1H, d, J = 1.5 Hz); 
13
C NMR (CDCl3) δ 124.0 (CH), 128.1 
(C), 128.3 (CH), 130.5 (CH), 132.2 (C), 133.1 (CH), 134.8 (C), 137.3 (CH), 141.0 
(C), 151.7 (CH), 154.8 (CH), 190.2 (C), 191.8 (C); IR 3088, 2924, 1677, 1578, 1206, 
871 cm
−1
. 
 
10.2.23 Synthesis of 2,4dichlorobenzoic acid methyl ester (114) 
 
2,4-Dichlorobenzoic acid (1.524 g, 7.98 mmol) and concentrated sulfuric acid (3.6 
mL) in methanol (20 mL) were heated under reflux overnight. The reaction mixture 
was cooled to room temperature, poured onto water (10 mL) and made basic with a 
solution of sodium carbonte (1 M, 130 mL). The aqueous layer was extracted with 
dichloromethane (5 × 25 mL). The combined extracts were dried over anhydrous 
160 
 
magnesium sulfate and concentrated under reduced pressure to give 2,4-
dichlorobenzoic acid methyl ester 114 as a colourless oil (1.549 g, 94%): 
1
H NMR 
(CDCl3) δ 3.84 (3H, s), 7.21 (1H, dd, J = 8.4, 2.0 Hz), 7.38 (1H, d, J = 2.0 Hz), 7.71 
(1H, d, J = 8.4 Hz); 
13
C NMR (CDCl3) δ 52.5 (CH3), 127 (CH), 128.2 (C), 131.0 
(CH), 132.0 (CH), 134.9 (C), 138.3 (C), 165.2 (C). 
 
10.2.24 Synthesis of 1-phenyl-2-(3-pyridinyl)ethanone methyloxime (117) 
 
O-Methylhydroxylamine hydrochloride (0.084 g, 1.01 mmol) and sodium acetate 
(0.195 g, 2.38 mmol) were added to a solution of 1-phenyl-2-(3-pyridinyl)ethanone 
93 (0.180 g, 0.91 mmol) in ethanol (4 mL). The reaction mixture was stirred at room 
temperature for 3 days. The reaction mixture was poured into a solution of sodium 
hydrogen carbonate (1 M, 20 mL). The aqueous layer was extracted with 
dichloromethane (4 × 20 mL). The combined extracts were dried over anhydrous 
magnesium sulfate and concentrated under reduced pressure. The residue was 
subjected to flash chromatography. Elution with 0−25% ethyl acetate in hexanes 
afforded the two isomers as an oil (0.142 g, 69%, E:Z 3:1). 
E isomer (colourless oil, 0.070 g, 34%) HRMS m/z Calcd for C14H15N2O requires 
227.1184, found 227.1186; 
1
H NMR (CDCl3) δ 4.02 (3H, s), 4.12 (2H, s), 7.18 (1H, 
dd, J = 7.8, 4.8 Hz), 7.31−7.35 (3H, m), 7.51 (1H, d, J = 7.8 Hz), 7.59−7.65 (2H, 
m), 8.43 (1H, br. s), 8.52 (1H, br. s); 
13
C NMR (CDCl3) δ 30.1 (CH2), 62.3 (CH3), 
123.7 (CH), 126.5 (CH), 128.7 (CH), 129.5 (CH), 132.8 (C), 135.2 (C), 136.3 (CH), 
147.5 (CH), 149.8 (CH), 155.1 (C); IR 2936, 1574, 1423, 1043, 893, 691 cm
−1
. 
Z isomer (colourless oil, 0.072 g, 35%) HRMS m/z Calcd for C14H15N2O requires 
227.1184, found 227.1183; 
1
H NMR (CDCl3  3.86 (2H, s), 3.88 (3H, s), 7.19 (1H, 
dd, J = 7.8, 4.8 Hz), 7.27−7.37 (5H, m), 7.54 (1H, d, J = 7.8 Hz), 8.41−8.47 (2H, br. 
s); 
13
C NMR (CDCl3) δ 39.1 (CH2), 62.1 (CH3), 123.5 (CH), 128.1 (CH), 128.3 
(CH), 129.1 (CH), 132.7 (C), 133.0 (C), 136.6 (CH), 148.0 (CH), 150.2 (CH), 155.3 
(C); IR 3056, 2935, 2817, 1677, 1575, 1423, 1036, 1021, 696 cm
−1
. 
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10.2.25 Synthesis of 1-(2,4-fluorophenyl)-2-(3-pyridinyl)ethanone methyloxime 
(119) 
 
O-Methylhydroxylamine hydrochloride (0.094 g, 1.13 mmol) and sodium acetate 
(0.195 g, 2.38 mmol) were added to a solution of 1-(2,4-difluorophenyl)-2-(3-
pyridinyl)-ethanone 99 (0.221 g, 0.95 mmol) in ethanol (4 mL). The reaction mixture 
was stirred at room temperature for 4 days. The reaction mixture was poured into a 
solution of sodium hydrogen carbonate (1 M, 20 mL) and extracted with 
dichloromethane (4 × 20 mL). The combined extracts were dried over anhydrous 
magnesium sulfate and concentrated under reduced pressure. The residue was 
subjected to flash chromatography. Elution with 25% ethyl acetate in petroleum 
spirits afforded the two isomers as oils (0.153 g, 64%, E:Z 1.5:1).  
E isomer (colourless oil, 0.103 g, 40%) HRMS m/z Calcd for C14H13F2N2O requires 
263.0996, found 263.0989; 
1
H NMR (CDCl3)  4.00 (3H, s), 4.08 (2H, s), 6.73−6.83 
(2H, m), 7.14 (1H, dd, J = 7.8, 4.8 Hz), 7.35 (1H, m), 7.41−7.46 (1H, m), 8.39 (2H, 
br. s); 
13
C NMR (CDCl3) δ 32.1 (CH2, d, J = 4.7 Hz), 62.4 (CH3), 104.6 (CH, dd, J = 
25.6, 25.6 Hz), 111.8 (CH, dd, J = 18.9, 4.0 Hz), 119.9 (C, dd, J = 9.1, 4.0 Hz) 123.4 
(CH), 131.5 (CH, dd, J = 9.8, 5.0 Hz), 132.1 (C), 136.4 (CH), 147.8 (CH), 150.1 
(CH), 153.0 (C, d, J = 2.0 Hz), 160.6 (C, dd, J = 240.7, 12.7 Hz), 163.6 (C, dd, J = 
239.7, 12.5 Hz); IR 2940, 2821, 1673, 1609, 1503, 1479, 1421, 1042, 968 cm
−1
. 
Z isomer (colourless oil, 0.020 g, 8%) HRMS m/z Calcd for C14H13F2N2O requires 
263.0996, found 263.0993; 
1
H NMR (CDCl3)  3.83 (2H, s), 3.87 (3H, s), 6.74−6.83 
(2H, m), 6.96−7.03 (1H, m), 7.21 (1H, dd, J = 7.5, 4.8 Hz), 7.53 (1H, d, J = 7.8 Hz), 
8.43 (2H, br. s);
 13
C NMR (CDCl3) δ 38.7 (CH2), 62.3 (CH3), 104.5 (CH, dd, J = 
25.0, 25.0 Hz), 107.9 (C), 111.6 (CH, dd, J = 17.3, 4.2 Hz), 117.3 (CH, dd, J = 13.5, 
3.5 Hz), 130.4 (CH, dd, J = 9.8, 6.0 Hz), 137.8 (CH), 147.3 (CH), 149.2 (CH), 150.4 
(C), 158.0 (C, dd, J = 239.3, 13.1 Hz), 163.3 (C, dd, J = 242.0, 13.9 Hz); IR 2939, 
2820, 1611, 1592, 1503, 1478, 1422, 1026, 966 cm
−1
. 
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10.2.26 Synthesis of 1-phenyl-2-(3-pyridinyl)ethanone ethyloxime (123) 
 
O-Ethylhydroxylamine hydrochloride 122 (0.078 g, 0.80 mmol) and sodium acetate 
(0.195 g, 2.38 mmol) were added to a solution of 1-phenyl-2-(3-pyridinyl)ethanone 
93 (0.140 g, 0.71 mmol) in ethanol (4 mL). The reaction mixture was stirred at room 
temperature for 3 days. The reaction mixture was poured into a solution of sodium 
hydrogen carbonate (1 M, 20 mL) and was extracted with dichloromethane (4 × 20 
mL). The combined extracts were dried over anhydrous magnesium sulfate and 
concentrated under reduced pressure. The residue was subjected to flash 
chromatography. Elution with 0−25% ethyl acetate in hexanes afforded the two 
isomers as an oil (0.093 g, 55%, E:Z 2:1).  
E isomer (colourless oil, 0.062 g, 43%) HRMS m/z Calcd for C15H17N2O requires 
241.1341, found 241.1340; 
1
H NMR (CDCl3)  1.32 (3H, t, J = 7.0 Hz), 4.12 (2H, s), 
4.29 (2H, q, J = 7.0 Hz), 7.16 (1H, dd, J = 7.7, 4.8 Hz), 7.29−7.35 (3H, m), 
7.48−7.53 (1H, m), 7.60−7.65 (2H, m), 8.42 (1H, d, J = 4.1 Hz), 8.53 (1H, s); 13C 
NMR (CDCl3) δ 14.8 (CH3), 30.1 (CH2), 70.1 (CH2), 123.5 (CH), 126.4 (CH), 123.6 
(CH), 129.3 (CH), 132.8 (C), 135.4 (C), 136.1 (CH), 147.7 (CH), 150.1 (CH), 154.7 
(C); IR 3030, 2977, 2931, 1669, 1574, 1042, 691 cm
−1
. 
Z isomer (colourless oil, 0.012 g, 7%) 
1
H NMR (CDCl3)  1.26 (3H, t, J = 7.0 Hz), 
3.86 (2H, s), 4.14 (2H, q, J = 7.0 Hz), 7.20 (1H, dd, J = 7.6, 5.0 Hz), 7.27−7.34 (5H, 
m), 7.53−7.57 (1H, m), 8.41−8.47 (2H, m); 13C NMR (CDCl3) δ 14.8 (CH3), 39.1 
(CH2), 69.9 (CH2), 123.7 (CH), 128.3 (CH), 129.1 (CH), 133.2 (C), 133.4 (C), 137.2 
(CH), 147.5 (CH), 149.7 (CH), 154.5 (C); IR 3031, 2978, 2932, 1666, 1575, 1041, 
693 cm
−1
. 
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10.2.27 Synthesis of 1-phenyl-2-(3-pyridinal)ethanone benzyloxime (125) 
 
O-Benzylhydroxylamine hydrochloride 124 (0.142 g, 0.89 mmol) and sodium acetate 
(0.183 g, 2.23 mmol) were added to a solution of 1-phenyl-2-(3-pyridinyl)ethanone 
93 (0.162 g, 0.82 mmol) in ethanol (4 mL). The reaction mixture was stirred at room 
temperature for 2 days. The reaction mixture poured into a solution of sodium 
hydrogen carbonate (1 M, 20 mL) and was extracted with dichloromethane (4 x 20 
mL). The combined extracts were dried over anhydrous magnesium sulfate and 
concentrated under reduced pressure. The residue was subjected to flash 
chromatography. Elution with 50% ethyl acetate in petroleum spirits afforded the 
two isomers as an oil (0.083 g, 33%, E:Z 2.8:1). 
E isomer (colourless oil, 0.063 g, 25%) HRMS m/z Calcd for C20H18N2O requires 
303.1497, found 303.1498; 
1
H NMR (CDCl3)  4.16 (2H, s), 5.28 (2H, s), 7.12 (1H, 
dd, J = 7.8, 4.7 Hz), 7.29−7.38 (8H, m), 7.42−7.47 (1H, m), 7.60−7.66 (2H, m), 
8.43 (1H, d, J = 3.7 Hz), 8.52 (1H, br. s); 
13
C NMR (CDCl3) δ 30.2 (CH2), 76.7 
(CH2), 123.6 (CH), 126.5 (CH), 128.1 (CH), 128.4 (CH), 128.5 (CH), 128.7 (CH), 
129.5 (CH), 132.7 (C), 135.2 (C), 136.1 (CH), 137.7 (C), 147.7 (CH), 150.1 (CH), 
155.5 (C); IR 3030, 2917, 2849, 1701, 1574, 1014, 692 cm
-1
. 
Z isomer (colourless oil, selected peaks)
*
 C20H18N2O requires 303.1497, found 
303.1486;
 1
H NMR (CDCl3)  3.83 (2H, s), 5.14 (2H, s), 7.14 (1H, dd, J = 7.7, 4.6 
Hz), 7.28−7.38 (8 H, m), 7.46 (1H, d, J = 7.7 Hz), 7.60−7.65 (2H, m), 8.43 (2H, br. 
s). 
 
 
                                               
*
 The Z isomer was not isolated. Peaks were assigned based on the integration in the 
1
H NMR 
spectrum. 
164 
 
10.2.28 Synthesis of 1-phenyl-2-(3-pyridinal)ethanone pentafluorobenzyloxime 
(127) 
 
O-Pentafluorobenzylhydroxylamine hydrochloride 126 (0.074 g, 0.291 mmol) and 
sodium acetate (0.076 g, 0.93 mmol) were added to a solution of 1-phenyl-2-(3-
pyridinyl)ethanone 93 (0.083 g, 0.42 mmol) in ethanol (3 mL). The mixture was 
stirred at room temperature for 3 days. The reaction mixture was poured into a 
solution of sodium hydrogen carbonate (1 M, 20 mL). The aqueous layer was 
extracted with dichloromethane (4 × 20 mL). The combined extracts were dried over 
anhydrous magnesium sulfate and concentrated under reduced pressure. The residue 
was subjected to flash chromatography. Elution with 40% ethyl acetate in petroleum 
spirits afforded the product 127 as an oil (0.047 g, 40%, E:Z 2.9:1). 
E isomer (colourless oil, selected peaks)
*
 
1
H NMR (CDCl3)  4.09 (2H, s), 5.32 (2H, 
t, J = 1.6 Hz), 8.47 (1H, br. s.), 8.50 (1H, br. s.). 
Z isomer (colourless oil, selected peaks)
*
 
1
H NMR (CDCl3) 3.81 (2H, s), 5.14 (2H, 
t, J = 1.6 Hz), 8.37 (2H, br. s.). 
 
10.2.29 Synthesis of N-butoxyphthalimide (134) 
 
Sodium carbonate (0.952 g, 8.98 mmol) and 1-bromobutane 132 (15.39 g, 112 
mmol) were added to a solution of N-hydroxyphthalimide 131 (18.01 g, 110 mmol) 
in N,N-dimethylformamide (25 mL) and the reaction mixture heated to 90 °C for 5 
days. The reaction mixture was cooled to room temperature and water (50 mL) was 
                                               
*
 Isomers were not isolated. Peaks were assigned based on the integration in the 
1
H NMR spectrum 
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added. The resulting precipitate was collected by vacuum filtration and dried under 
vacuum to give N-butoxyphthalimide 134 as a cream solid (19.03 g, 79%): m.p. 
193.2−194 °C (lit.121 m.p. 29.2−30.0 °C). The spectroscopic properties were similar 
to those reported.
121
 
1
H NMR (CDCl3)  0.97 (3H, t, J = 7.4 Hz), 1.51 (2H, q, J = 7.4 
Hz), 1.72−1.81 (2H, m), 4.20 (2H, t, J = 6.8 Hz), 7.71−7.76 (2H, m), 7.79−7.85 
(2H, m); 
13
C NMR (DMSO-d6) δ 13.6 (CH3), 18.4 (CH2), 29.7 (CH2), 77.4 (CH2), 
123.0 (CH), 128.8 (C), 134.6 (CH), 164.1 (C); IR 3128, 2959, 1787, 1705, 1607, 
1463 cm
−1
.
 
 
 
10.2.30 Synthesis of N-propoxyphthalimide (135) 
 
N-Hydroxyphthalimide 131 (8.919 g, 54.67 mmol) was dissolved in N,N-
dimethylformamide (20 mL). Sodium carbonate (0.460 g, 4.34 mmol) and 1-
bromopropane (7.581 g, 61.64 mmol) were added and the mixture was heated to 90 
°C for 3 days. The reaction mixture was cooled to room temperature and water (50 
mL) was added. The resulting precipitate was collected by vacuum filtration and 
dried under vacuum to give N-propoxyphthalimide 135 as an off-white powder 
(7.720 g, 69%): m.p. 210−216 °C (lit. m.p. 57.1−58.3 °C). The spectroscopic 
properties were similar to those reported.
121,150
 
1
H NMR (CDCl3) δ 1.06 (3H, t, J = 
7.5 Hz), 1.78−1.87 1.82 (2H, m), 4.17 (2H, t, J = 6.5 Hz), 7.75 (2H, m), 7.84 (2H, 
m); 
13
C NMR (CDCl3) δ 10.0 (CH3), 21.6 (CH2), 80.1 (CH2), 123.5 (CH), 129.0 (C), 
134.4 (CH), 163.7 (C); IR 3128, 2971, 1786, 1706, 1607, 1463 cm
−1
. 
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10.2.31 Synthesis of N-isopropoxyphthalimide (136) 
 
Sodium carbonate (0.977 g, 9.22 mmol) and 2-bromopropane (13.184 g, 112 mmol) 
were added to a solution of N-hydroxyphthalimide 131 (18.042 g, 111 mmol) in N,N-
dimethylformamide (25 mL) and the reaction mixture was heated to 90 °C for 5 
days. The reaction mixture was cooled to room temperature and water (75 mL) was 
added. The resulting precipitate was collected by vacuum filtration and dried under 
vacuum to give N-isopropoxyphthalimide 136 as a white powder (15.37 g, 68%): 
m.p. 188.5−191 °C (lit.150 m.p. 58−59 °C). The spectroscopic properties were 
similar to that reported.
150
  
1
H NMR (CDCl3) δ 1.38 (6H, d, J = 6.2 Hz), 4.55 (1H, 
hept, J = 6.2 Hz), 7.75 (2H, m), 7.84 (2H, m); 
13
C NMR (CDCl3) δ 21.0 (CH3), 80.9 
(CH), 123.6 (CH), 129.2 (C), 134.6 (CH), 164.5 (C); IR 3477, 3132, 2983, 1787, 
1705, 1607, 1463 cm
−1
. 
 
10.2.32 Synthesis of N-isopentoxyphthalimide (137) 
 
Sodium carbonate (0.527 g, 4.97 mmol) and 1-bromo-3-methylbutane (1.00 g, 6.67 
mmol) were added to a solution of N-hydroxyphthalimide 131 (1.12 g, 6.87 mmol) in 
N,N-dimethylformamide (10 mL) and the mixture was heated to 90 °C for 2 days. 
The reaction mixture was cooled to room temperature and water (50 mL) was added. 
The aqueous layer was extracted with dichloromethane (3 × 25 mL). The combined 
extracts were dried over anhydrous magnesium sulfate and concentrated under 
reduced pressure. Water was added to the residue and cooled to −23 °C overnight. 
The resulting precipitate was collected by vacuum filtration and dried under vacuum 
to give N-isopentoxyphthalimide 137 as white powder (0.919 g, 59%): m.p. 
48.1−48.5 °C (lit.151 m.p. 42−43 °C); HRMS m/z Calcd for C13H16NO3 requires 
234.1130, found 234.1132; 
1
H NMR (CDCl3)  0.97 (6H, d, J = 6.6 Hz), 1.69 (2H, q, 
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J = 6.9 Hz), 1.82−187 (1H, m), 4.23 (2H, t, J = 6.8 Hz), 7.73−7.76 (2H, m), 
7.82−7.85 (2H, m); 13C NMR (CDCl3) δ 22.5 (CH3), 24.9 (CH), 36.7 (CH2), 76.7 
(CH2), 123.5 (CH), 129.0 (C), 134.4 (CH), 163.7 (C); IR 2958, 1786, 1726 cm
−1
. 
 
10.2.33 Synthesis of N-(4-fluorobenzyloxy)phthalimide (138) 
 
Sodium carbonate (0.506 g, 4.77 mmol) and 4-fluorobenzyl bromide (1.000 g, 5.29 
mmol) were added to a solution of N-hydroxyphthalimide 131 (0.909 g, 5.57 mmol) 
in N,N-dimethylformamide (10 mL) and the reaction mixture was heated to 90 °C for 
2 days. The reaction mixture was cooled to room temperature and water (50 mL) was 
added. The resulting precipitate was collected by vacuum filtration and dried under 
vacuum to give N-(4-fluorobenzyloxy)phthalimide 138 as an off-white powder 
(0.733 g, 51%): m.p. 154−156 °C (lit.152 m.p. 155−156 °C). The spectroscopic 
properties were similar to those reported.
152
 
1
H NMR (CDCl3)  5.18 (2H, s), 
7.02−7.10 (2H, m), 7.50−7.55 (2H, m), 7.71−7.77 (2H, m), 7.78−7.85 (2H, m); 13C 
NMR (CDCl3) δ 79.2 (CH2), 115.7 (CH, d, J = 21.2 Hz), 123.7 (CH), 129.0 (C), 
129.8 (C, d, J = 3.0 Hz), 132.0 (CH, d, J = 8.0 Hz), 134.6 (CH), 163.5 (C, d, J = 
248.1 Hz), 163.6 (C); IR 1776, 1722, 1604 cm
−1
. 
 
10.2.34 Synthesis of N-cyclohexylmethoxyphthalimide (139) 
 
Sodium carbonate (0.247 g, 2.33 mmol) and bromomethylcyclohexane (0.500 g, 2.84 
mmol) were added to a solution of N-hydroxyphthalimide 131 (0.525 g, 3.22 mmol) 
in N,N-dimethylformamide (10 mL) and the reaction mixture was heated to 90 °C for 
2 days. The reaction mixture was cooled to room temperature and water (50 mL) was 
added. The resulting precipitate was collected by vacuum filtration and dried under 
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vacuum to give N-cyclohexylmethoxyphthalimide 139 as an off-white powder (0.548 
g, 85%): m.p. 95.3−96.2 °C (lit.153 m.p. 91−93 °C). The spectroscopic properties 
were similar to those reported.
154
 
1
H NMR (CDCl3)  1.00−1.36 (5H, m), 1.64−1.98 
(6H, m), 4.00 (2H, d, J = 6.6 Hz), 7.70−7.76 (2H, m), 7.79−7.86 (2H, m); 13C NMR 
(CDCl3) δ 25.7 (CH2), 26.5 (CH2), 29.6 (CH2), 37.0 (CH), 84.0 (C), 123.6 (CH), 
129.2 (C), 134.5 (CH), 163.8 (C); IR 3388, 2925, 2854, 1781, 1720 cm
−1
. 
 
10.2.35 Synthesis of N-(3-phenylpropoxy)phthalimide (140) 
 
Sodium carbonate (1.017 g, 9.60 mmol) and 3-bromopropylbenzene (1.8 mL, 2.358 
g, 11.84 mmol) were added to a solution of N-hydroxyphthalimide 131 (1.962 g, 
12.02 mmol) in N,N-dimethylformamide (20 mL) and the reaction mixture was 
heated to 90 °C for 4 days. The reaction mixture was cooled to room temperature and 
water (50 mL) was added. The resulting precipitate was collected by vacuum 
filtration and dried under vacuum to give N-(3-phenylpropoxy)phthalimide 140 as an 
off-white powder (1.590 g, 48%): m.p. 59.5−61 °C; HRMS m/z Calcd for 
C17H16NO3 requires 282.1130, found 282.1133. The spectroscopic properties were 
similar to those reported.
155
  
1
H NMR (CDCl3)  2.06−2.15 (2H, m), 2.84−2.91 (2H, 
m), 4.23 (2H, t, J = 6.4 Hz), 7.17−7.22 (1H, m), 7.24−7.32 (4H, m), 7.72−7.77 (2H, 
m), 7.81−7.87 (2H, m); 13C NMR (CDCl3) δ 30.1 (CH2), 31.9 (CH2), 77.7 (CH2), 
123.6 (CH), 126.2 (CH), 128.6 (CH), 128.7 (CH), 129.1 (C), 134.6 (CH), 141.3 (C), 
163.8 (C); IR 2951, 1790, 1717 cm
−1
. 
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10.2.36 Synthesis of Ethyl 4-[(1,3-dihydro-1,3-dioxo-2-isoindol-2-yl)oxy]-
butanoate (141) 
 
Sodium carbonate (1.043 g, 9.84 mmol) and ethyl-4-bromobutyrate (1.8 mL, 2.45 g, 
12.58 mmol) were added to a solution of N-hydroxyphthalimide 131 (1.976 g, 12.11 
mmol) in N,N-dimethylformamide (20 mL) and the reaction mixture was heated to 
90 °C for 4 days. The reaction mixture was cooled to room temperature and water 
(50 mL) was added. The aqueous layer was extracted with dichloromethane (3 × 25 
mL). The combined extracts were dried over anhydrous magnesium sulfate and 
concentrated under reduced pressure. Water was added to the residue and cooled to 
−23 °C overnight. The resulting precipitate was collected by vacuum filtration and 
dried under vacuum to give the product 141 as white crystals (1.129 g, 34%): m.p. 
44.8 °C; HRMS m/z Calcd for C14H15NO5 requires 278.1028, found 278.1030; 
1
H 
NMR (CDCl3)  1.27 (3H, t, J = 7.2 Hz), 2.05−2.14 (2H, m), 2.64 (2H, t, J = 7.3 
Hz), 4.16 (2H, q, J = 7.2 Hz), 4.27 (2H, t, J = 6.1 Hz), 7.72−7.77 (2H, m), 
7.81−7.86 (2H, m); 13C NMR (CDCl3) δ 14.4 (CH3), 23.7 (CH2), 30.4 (CH2), 60.7 
(CH2), 77.5 (CH2), 123.7 (CH), 129.1 (C), 134.6 (CH), 163.7 (C); IR 1979, 1786, 
1722 cm
−1
. 
 
10.2.37 Synthesis of O-butylhydroxylamine (142) 
 
Hydrazine hydrate (600 μL, 0.613 g, 19.13 mmol) was added to a solution of N-
butoxyoxyphthalimide 134 (0.982 g, 4.48 mmol) in dichloromethane (17 mL) and 
the mixture was heated under reflux for 2 days. The reaction mixture was cooled to 
room temperature and filtered. Quantitative 
1
H NMR experiments of the reaction 
mixture showed 90% yield of product 142. 
1
H NMR (CDCl3) δ
 
0.87 (3H, t, J = 7.6 
Hz), 1.25−1.37 (2H, m), 1.46−1.55 (2H, m), 3.61 (2H, t, J = 6.6 Hz). 
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10.2.38 Synthesis of 1-phenyl-2-(3-pyridinyl)ethanone butyloxime (144) 
 
Hydrazine hydrate (0.15 mL, 0.015 g, 0.31 mmol) was added to a solution of N-
butoxyphthalimide 134 (0.501 g, 2.28 mmol) in ethanol (6 mL) and the reaction 
mixture was heated under reflux for 30 minutes. A solution of 1-phenyl-2-(3-
pyridinyl)-ethanone 93 (0.200 g, 1.01 mmol) in acetic acid (0.5 mL) and ethanol (1 
mL) was added to the reaction mixture and the reaction mixture was heated under 
reflux for 1 day. The reaction mixture was cooled to room temperature and poured 
into a solution of sodium hydrogen carbonate (1 M, 20 mL). The aqueous layer was 
extracted with dichloromethane (3 × 20 mL). The combined extracts were dried over 
anhydrous magnesium sulfate and concentrated under reduced pressure. The residue 
was subjected to flash chromatography. Elution with 0−25% ethyl acetate in hexanes 
afforded the E isomer as a colourless oil (0.009 g, 3.4%): 
1
H NMR (CDCl3)  0.92 
(3H, t, J = 7.8 Hz), 1.32−1.43 (2H, m), 1.65−1.75 (2H, m), 4.13 (2H, s), 4.23 (2H, t, 
J = 6.7 Hz), 7.18 (1H, dd, J = 7.8, 4.8 Hz), 7.31−7.36 (3H, m), 7.49−7.53 (1H, m), 
7.60−7.66 (2H, m), 8.43 (1H, d, J = 3.5 Hz), 8.53 (1H, br. s); 13C NMR (CDCl3) δ 
14.1 (CH3), 19.3 (CH2), 30.2 (CH2), 31.4 (CH2), 74.6 (CH2), 123.9 (CH), 126.4 
(CH), 128.8 (CH), 129.5 (CH), 132.3 (C), 135.4 (C), 136.9 (CH), 146.9 (CH), 149.3 
(CH), 154.5 (C). 
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10.2.39 Synthesis of 1-phenyl-2-(3-pyridinyl)ethanone propyloxime (145) 
 
Hydrazine hydrate (0.15 mL, 0.015 g, 0.309 mmol) was added to a solution of N-
propoxyphthalimide 135 (0.507 g, mmol) in ethanol (6 mL) and the reaction mixture 
was heated under reflux for 30 minutes. A solution of 1-phenyl-2-(3-pyridinyl)-
ethanone 93 (0.200 g, 1.01 mmol) in acetic acid (0.5 mL) and ethanol (1 mL) was 
added to the reaction mixture and the reaction mixture was heated under reflux for 1 
day. The reaction mixture was cooled to room temperature and poured into a solution 
of sodium hydrogen carbonate (1 M, 20 mL). The aqueous layer was extracted with 
dichloromethane (3 × 20 mL). The combined extracts were dried over anhydrous 
magnesium sulfate and concentrated under reduced pressure. The residue was 
subjected to flash chromatography. Elution with 0−25% ethyl acetate in hexanes 
afforded the product as the E isomer as a colourless oil (0.005 g, 2%): 
1
H NMR 
(CDCl3) t, J = 7.3 Hz), 1.69−1.78 (1H, m), 4.14 (2H, s), 4.19 (2H, t, J = 
6.7 Hz), 7.19−7.22 (1H, m), 7.32−7.37 (3H, m), 7.55 (1H, d, J = 7.9 Hz), 7.61−7.65 
(2H, m), 8.44 (1H, br. s), 8.54 (1H, br. s). 
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10.2.40 Synthesis of 1-phenyl-2-(3-pyridinyl)ethanone isopropyloxime (146) 
 
Hydrazine hydrate (0.15 mL, 0.015 g, 0.31 mmol) was added to a solution of N-
isopropoxyphthalimide 136 (0.496 g, 2.42 mmol) in ethanol (6 mL) and the reaction 
mixture was heated under reflux for 30 minutes. A solution of 1-phenyl-2-(3-
pyridinyl)ethanone 93 (0.200 g, 1.01 mmol) in acetic acid (0.5 mL) and ethanol (1 
mL) was added to the reaction mixture and the reaction mixture was heated under 
reflux for 1 day. The reaction mixture was cooled to room temperature and poured 
into a solution of sodium hydrogen carbonate (1 M, 20 mL). The aqueous layer was 
extracted with dichloromethane (3 × 20 mL). The combined extracts were dried over 
anhydrous magnesium sulfate and concentrated under reduced pressure. The residue 
was subjected to flash chromatography. Elution with 0−25% ethyl acetate in hexanes 
afforded the product 146 as the E isomer as a colourless oil (0.009 g, 4%): 
1
H NMR 
(CDCl3)  1.30 (6H, d, J = 6.2 Hz), 4.12 (2H, s), 4.51 (1H, sept, J = 6.2 Hz), 7.19 
(1H, dd, J = 7.7, 5.1 Hz), 7.32−7.35 (3H, m), 7.52−7.56 (1H, m), 7.62−7.66 (2H, 
m), 8.43 (1H, d, J = 4.6 Hz), 8.54 (1H, s). 
 
10.2.41  Synthesis of 1-phenyl-2-(3-pyridinyl)ethanone isopentyloxime (147) 
 
Hydrazine hydrate (0.1 mL) was added to a solution of N-isopentoxyphthalimide 137 
(0.247 g, 1.06 mmol) in ethanol (5 mL) and the reaction mixture was heated to 80 °C 
for 1 hour. The reaction mixture was cooled to room temperature. A solution of 1-
phenyl-2-(3-pyridinyl)-ethanone 93 (0.169 g, 0.86 mmol) in acetic acid (0.5 mL) and 
ethanol (1 mL) was added to the reaction mixture and the reaction mixture was 
heated to 80 °C for 2 days. The reaction mixture was then cooled to room 
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temperature and poured into a solution of sodium hydrogen carbonate (1 M, 20 mL). 
The aqueous layer was extracted with dichloromethane (3 × 20 mL). The combined 
extracts were dried over anhydrous magnesium sulfate and concentrated under 
reduced pressure. The residue was subjected to flash chromatography. Elution with 
50% ethyl acetate in petroleum spirits with 1% triethylamine afforded the product 
147 as the E isomer as a colourless oil (0.077g, 32%): HRMS m/z Calcd for 
C18H23N2O requires 283.1810, found 283.1802;
 1
H NMR (CDCl3)  0.92 (6H, d, J = 
6.7 Hz), 1.56−1.65 (2H, m), 4.11 (2H, s), 4.26 (2H, t, J = 6.7 Hz), 7.13−7.17 (1H, 
m), 7.30−7.34 (3H, m), 7.47−7.52 (1H, m), 7.60−7.65 (2H, m), 8.39−8.44 (1H, m), 
8.52 (1H, d, J = 1.3 Hz); 
13
C NMR (CDCl3) δ 22.7 (CH3), 25.2 (CH), 30.2 (CH2), 
38.1 (CH2), 73.2 (CH2), 123.5 (CH), 126.4 (CH), 128.7 (CH), 129.3 (CH), 132.9 (C), 
135.5 (C), 136.0 (CH), 147.7 (CH), 150.1 (CH), 154.7 (C); IR 2955, 2932, 1574, 
1052, 691 cm
−1
. 
 
10.2.42 Synthesis of 1-phenyl-2-(3-pyridinyl)ethanone 4-fluorobenzyloxime 
(148) 
 
Hydrazine hydrate (0.07 mL) was added to a solution of N-(4-
fluorobenzyloxy)phthalimide 138 (0.228 g, 0.84 mmol) in ethanol (4 mL) and the 
reaction mixture was heated to 80 °C for 30 minutes. The reaction mixture was 
cooled to room temperature. A solution of 1-phenyl-2-(3-pyridinyl)-ethanone 93 
(0.150 g, 0.76 mmol) in acetic acid (0.5 mL) and ethanol (1 mL) was added to the 
reaction mixture and the reaction mixture was heated to 80 °C for 3 days. The 
reaction mixture was cooled to room temperature and poured into a solution of 
sodium hydrogen carbonate (1 M, 20 mL). The aqueous layer was extracted with 
dichloromethane (3 × 20 mL). The combined extracts were dried over anhydrous 
magnesium sulfate and concentrated under reduced pressure. The residue was 
subjected to flash chromatography. Elution with 50% ethyl acetate in petroleum 
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spirits with 1% triethylamine afforded the product 148 as two isomers (0.131 g, 53%, 
E:Z 7.5:1) 
E isomer (colourless oil, 0.108 g, 44%) HRMS m/z Calcd for C20H18FN2O requires 
321.1403, found 321.1390;
 1
H NMR (CDCl3) δ 4.03 (2H, s), 5.12 (2H, s), 6.90−6.96 
(2H, m), 7.00−7.05 (1H, m), 7.19−7.26 (5H, m), 7.31−7.34 (1H, m), 7.49−7.56 
(2H, m), 8.31 (1H, d, J = 4.0 Hz), 8.40 (1H, s); 
13
C NMR (CDCl3) δ 30.1 (CH2), 75.8 
(CH2), 115.3 (CH, d, J = 21.5 Hz), 123.5 (CH), 126.4 (CH), 128.6 (CH), 129.5 (CH), 
130.2 (CH, d, J = 8.1 Hz), 132.5 (C), 133.4 (C, d, J = 3.4 Hz), 135.0 (C), 135.9 (CH), 
147.6 (CH), 149.9 (CH), 155.6 (C), 162.6 (C, d, J = 246.0 Hz); IR 3055, 2927, 1603, 
1509, 1220, 692 cm
−1
. 
Z isomer (colourless oil, 0.008 g, 3%) HRMS m/z Calcd for C20H18FN2O requires 
321.1403, found 321.1389; 
1
H NMR (CDCl3)  3.77 (2H, s), 5.00 (2H, s), 6.91−6.98 
(2H, m), 7.12 (1H, dd, J = 7.8, 5.0 Hz), 7.17−7.26 (7H, m), 7.39−7.42 (1H, m), 8.33 
(1H, br. s), 8.37 (1H, d, J = 4.1 Hz); 
13
C NMR (CDCl3) δ 39.0 (CH2), 75.4 (CH2), 
115.2 (CH, d, J = 21.2 Hz), 123.6 (CH), 127.9 (CH), 128.2 (CH), 129.1 (CH), 129.8 
(CH, d, J = 8.1 Hz), 132.9 (C), 133.8 (C, d, J = 3.0 Hz), 134.9 (C), 137.2 (CH), 147.3 
(CH), 149.4 (CH), 155.7 (C), 162.4 (C, d, J = 245.0 Hz); IR 3055, 2927, 2869, 1603, 
1509, 1220, 695 cm
−1
. 
 
10.2.43 Synthesis of 1-phenyl-2-(3-pyridinyl)ethanone cyclohexylmethyloxime 
(149) 
 
Hydrazine hydrate (0.07 mL) was added to a solution of N-
cyclohexylmethoxyphthalimide 139 (0.253 g, 0.98 mmol) in ethanol (4 mL) and the 
reaction mixture was heated to 80 °C for 30 minutes. The reaction mixture was 
cooled to room temperature. A solution of 1-phenyl-2-(3-pyridinyl)-ethanone 93 
(0.150 g, 0.76 mmol) in acetic acid (0.5 mL) and ethanol (1 mL) was added to the 
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reaction mixture and the reaction mixture was heated to 80 °C for 3 days. The 
reaction mixture was cooled to room temperature and poured into a solution of 
sodium hydrogen carbonate (1 M, 20 mL). The aqueous layer was extracted with 
dichloromethane (3 × 20 mL). The combined extracts were dried over anhydrous 
magnesium sulfate and concentrated under reduced pressure. The residue was 
subjected to flash chromatography. Elution with 50% ethyl acetate in petroleum 
spirits with 1% triethylamine afforded the product 149 as two isomers (0.103 g, 45%, 
E:Z, 4:1) 
E isomer (colourless oil, 0.083 g, 36%) HRMS m/z Calcd for C20H25N2O requires 
309.1967, found 309.1952; 
 1
H NMR (CDCl3)  0.82−1.03 (2H, m), 1.05−1.32 (4H, 
m), 1.60−1.80 (5H, m), 4.04 (2H, d, J = 6.3 Hz), 4.11 (2H, s), 7.15 (1H, ddd, J = 7.9, 
4.8, 0.7 Hz), 7.29−7.34 (3H, m), 7.46−7.51 (1H, m), 7.58−7.65 (2H, m), 8.40 (1H, 
dd, J = 4.8, 1.5 Hz), 8.52 (1H, d, J = 1.6 Hz); 
13
C NMR (CDCl3) δ 25.8 (CH2), 26.6 
(CH2), 29.9 (CH2), 30.1 (CH2), 37.6 (CH), 80.2 (CH2), 123.4 (CH), 126.3 (CH), 
128.6 (CH), 129.2 (CH), 132.8 (C), 135.4 (C), 135.9 (CH), 147.6 (CH), 150.0 (CH), 
154.5 (C); IR 2921, 2851, 1574, 1023, 691 cm
−1
. 
Z isomer (colourless oil, 0.020 g, 9%) HRMS m/z Calcd for C20H25N2O requires 
309.1967, found 309.1953; 
1
H NMR (CDCl3)  0.81−1.00 (2H, m), 1.10−1.32 (4H, 
m), 1.62−1.76 (4H, m), 3.85 (2H, s), 3.90 (2H, d, J = 6.3 Hz), 7.16 (1H, ddd, J = 7.8, 
4.8, 0.6 Hz), 7.20−7.35 (6H, m), 7.47−7.53 (1H, m), 8.40−8.46 (2H, m); 13C NMR 
(CDCl3) δ 25.8 (CH2), 26.6 (CH2), 29.8 (CH2), 37.5 (CH), 38.9 (CH2), 80.0 (CH2), 
123.3 (CH), 127.8 (CH), 128.1 (CH), 128.9 (CH), 132.9 (C), 133.1 (C), 136.3 (CH), 
148.0 (CH), 150.2 (CH), 154.3 (C); IR 2921, 2851, 1574, 1023, 691 cm
−1
. 
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10.2.44 Synthesis of 1-phenyl-2-(3-pyridinyl)ethanone phenylpropyloxime (150) 
 
Hydrazine hydrate (0.15 mL, 0.30 g, 0.31 mmol) was added to a solution of N-(3-
phenylpropoxy)phthalimide 140 (0.490 g, 1.74 mmol) in ethanol (5 mL) and the 
reaction mixture was heated to 80 °C in a sealed vessel for 1 hour. The reaction 
mixture was cooled to room temperature. A solution of 1-phenyl-2-(3-pyridinyl)-
ethanone 93 (0.205 g, 1.04 mmol) in acetic acid (0.5 mL) and ethanol (1 mL) was 
added to the reaction mixture and the reaction mixture was heated to 80 °C for 5 
days. The reaction mixture was cooled to room temperature and poured into a 
solution of sodium hydrogen carbonate (1 M, 20 mL). The aqueous layer was 
extracted with dichloromethane (3 × 20 mL). The combined extracts were dried over 
anhydrous magnesium sulfate and concentrated under reduced pressure. The residue 
was subjected to flash chromatography. Elution with 50% ethyl acetate in petroleum 
spirits with 1% triethylamine afforded the product 150 as two isomers (0.182 g, 57%, 
E:Z, 5.5:1).  
E isomer (colourless oil, 0.154 g, 48%) HRMS m/z Calcd for C22H23N2O requires 
331.1810, found 331.1793;
 1
H NMR (CDCl3)  1.91−2.00 (2H, m), 2.58 (2H, t, J = 
7.5 Hz), 4.02 (2H, s), 4.17 (2H, t, J = 6.5 Hz), 7.04−7.12 (4H, m), 7.15−7.21 (3H, 
m), 7.22−7.27 (3H, m), 7.39−7.47 (1H, m), 7.52−7.58 (1H, m), 8.33 (1H, d, J = 3.8 
Hz), 8.45 (1H, s); 
13
C NMR (CDCl3) δ 30.1 (CH2), 30.9 (CH2), 32.3 (CH2), 73.8 
(CH2), 123.5 (CH), 125.9 (CH), 126.4 (CH), 128.4 (CH), 128.5 (CH), 128.6 (CH), 
129.4 (CH), 132.8 (C), 135.3 (CH), 136.0 (C), 141.7 (C), 147.6 (CH), 150.0 (CH), 
154.9 (C); IR 3026, 2931, 1602, 1574, 1025, 692 cm
−1
. 
Z isomer (colourless oil, 0.028 g, 9%) HRMS m/z Calcd for C22H23N2O requires 
331.1810, found 331.1791;
 1
H NMR (CDCl3) δ 1.96−2.06 (2H, m), 2.63−2.70 (2H, 
m), 3.89 (2H, s), 4.14 (2H, t, J = 6.6 Hz), 7.14−7.23 (4H, m), 7.26−7.37 (7H, m), 
7.52−7.57 (1H, m), 8.47 (2H, br. s); 13C NMR (CDCl3) δ 30.8 (CH2), 32.2 (CH2), 
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39.0 (CH2), 73.4 (CH2), 123.4 (CH), 125.8 (CH), 128.1 (CH), 128.2 (CH), 128.4 
(CH), 128.5 (CH), 129.0 (CH), 132.9 (C), 133.1 (C), 136.6 (CH), 141.8 (C), 147.8 
(CH), 150.1 (CH), 154.9 (C); IR 3026, 2927, 1601, 1575, 1024, 695 cm
−1
. 
 
10.2.45 Synthesis of ethyl-4-(((1-phenyl-2-(3-pyridinyl)ethylidene)amino)oxy)- 
butanoate (151) 
 
Hydrazine hydrate (0.14 mmol) was added to a solution of ethyl 4-[(1,3-dihydro-1,3-
dioxo-2-isoindol-2-yl)oxy]-butanoate 141 (0.520 g, 1.88 mmol) in ethanol (5 mL) 
and the reaction mixture was heated to 80 °C for 1 hour. The reaction mixture was 
then cooled to room temperature. A solution of 1-phenyl-2-(3-pyridinyl)-ethanone 93 
(0.224 g, 1.14 mmol) in acetic acid (0.5 mL) and ethanol (1 mL) was added to the 
reaction mixture and the reaction mixture was heated to 80 °C for 5 days. The 
reaction mixture was cooled to room temperature and poured into a solution of 
sodium hydrogen carbonate (1 M, 20 mL). The aqueous layer was extracted with 
dichloromethane (3 × 20 mL). The combined extracts were dried over anhydrous 
magnesium sulfate and concentrated under reduced pressure. The residue was 
subjected to flash chromatography. Elution with 50% ethyl acetate in petroleum 
spirits with 1% triethylamine afforded the product 151 as two isomers (0.085 g, 14%, 
E:Z, 10:1). 
E isomer (colourless oil, 0.073 g, 12%) HRMS m/z Calcd for C19H23N2O3 requires 
327.1709, found 327.1700; 
1
H NMR (CDCl3)  1.19−1.26 (3H, m), 1.98−2.08 (2H, 
m), 2.32−2.37 (2H, m), 4.05−4.13 (4H, m), 4.25 (2H, t, J = 6.2 Hz), 7.14−7.20 (1H, 
m), 7.29−7.33 (3H, m), 7.50 (1H, d, J = 7.8 Hz), 7.59−7.62 (2H, m), 8.42 (1H, br. 
s), 8.51 (1H, br. s); 
13
C NMR (CDCl3) δ 14.3 (CH3), 24.7 (CH2), 30.1 (CH2), 30.9 
(CH2), 60.5 (CH2), 73.4 (CH2), 123.7 (CH), 126.4 (CH), 128.7 (CH), 129.5 (CH), 
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132.8 (C), 135.2 (C), 136.2 (CH), 147.5 (CH), 149.8 (CH), 155.1 (C), 173.3 (C); IR 
2953, 1729, 1176, 1026, 693 cm
−1
. 
Z isomer (colourless oil, 0.007 g, 1.1%) 
1
H NMR (CDCl3) δ 1.20−1.27 (3H, m), 
1.93−2.04 (2H, m), 2.30−2.36 (2H, m), 3.89 (2H, s), 4.08−4.14 (4H, m), 7.27−7.37 
(6H, m), 7.68 (1H, d, J = 7.8 Hz), 8.48 (2H, br. s); 
13
C NMR (CDCl3) δ 14.2 (CH3), 
24.5 (CH2), 30.9 (CH2), 38.9 (CH2), 60.4 (CH2), 73.2 (CH2), 126.4 (CH), 128.0 
(CH), 128.3 (CH), 128.9 (CH), 129.2 (CH), 132.7 (C), 138.6 (CH), 143.5 (CH), 
154.5 (C), 173.2 (C). 
 
10.2.46 Synthesis of 1-(2,4-dichlorophenyl)-2-(3-pyridinyl)ethanone 
benzyloxime (152) 
 
O-Benzylhydroxylamine hydrochloride 124 (0.137 g, 0.86 mmol) and sodium acetate 
(0.183 g, 2.23 mmol) were added to a solution of 1-(2,4-dichlorophenyl)-2-(3-
pyridinyl)-ethanone 42 (0.217 g, 0.82 mmol) in ethanol (4 mL). The reaction mixture 
was stirred at room temperature for 2 days. The reaction mixture poured into a 
solution of sodium hydrogen carbonate (1 M, 20 mL). The aqueous layer was 
extracted with dichloromethane (4 × 20 mL). The combined extracts were dried over 
anhydrous magnesium sulfate and concentrated under reduced pressure. The residue 
was subjected to flash chromatography. Elution with 50% ethyl acetate in petroleum 
spirits afforded the two isomers as an oil (0.211 g, 70 %, E:Z, 1.5:1). 
 E isomer (colourless oil, 0.093 g, 31%) HRMS m/z Calcd for C20H17Cl2N2O requires 
372.0718, found 371.0708; 
1
H NMR (CDCl3)  3.79 (2H, s), 5.09 (2H, s), 6.66 (1H, 
d, J = 8.2 Hz), 7.13 (1H, dd, J = 8.2, 1.9 Hz), 7.18 (1H, dd, J = 7.3, 4.9 Hz), 
7.23−7.46 (7H, m), 8.34 (1H, br. s), 8.47 (1H, br. s); 13C NMR (CDCl3) δ 38.6 
(CH2), 76.4 (CH2), 123.5 (CH), 127.1 (CH), 127.9 (CH), 128.2 (CH), 128.4 (CH), 
129.7 (CH), 129.9 (CH), 132.1 (C), 132.3 (C), 135.2 (C), 137.3 (CH), 137.8 (C), 
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148.2 (CH), 150.4 (CH), 153.9 (C) ; IR 3031, 2924, 1585, 1554, 1472, 1424, 997, 
696 cm
−1
. 
Z isomer (colourless oil, 0.059 g, 18%) HRMS m/z Calcd for C20H17Cl2N2O requires 
372.0718, found 371.0710; 
1
H NMR (CDCl3)  3.80 (2H, s), 5.06 (2H, s), 6.67 (1H, 
d, J = 8.3 Hz), 7.12 (1H, dd, J = 8.3, 2.1 Hz), 7.20−7.38 (6H, m), 7.51 (2H, d, J = 
7.6 Hz), 8.69 (2H, br. s); 
13
C NMR (CDCl3) δ 24.0 (CH2), 76.4 (CH2), 123.5 (CH), 
127.2 (CH), 127.9 (CH), 128.2 (CH), 128.4 (CH), 129.7 (CH), 129.8 (CH), 131.6 
(C), 132.2 (C), 132.3 (C), 135.3 (C), 137.3 (CH), 137.7 (C), 148.2(CH), 150.4 (CH), 
153.7 (C). 
 
10.2.47 Synthesis of 1-(2,4-difluorophenyl)-2-(3-pyridinyl)ethanone 
benzyloxime (153) 
 
O-Benzylhydroxylamine hydrochloride 124 (0.115 g, 0.72 mmol) and sodium acetate 
(0.189 g, 2.30 mmol) were added to a solution of 1-(2,4-difluorophenyl)-2-(3-
pyridinyl)-ethanone 99 (0.170 g, 0.73 mmol) in ethanol (4 mL). The reaction mixture 
was stirred at room temperature for 4 days. The reaction mixture was poured into a 
solution of sodium hydrogen carbonate (1 M, 20 mL). The aqueous layer was 
extracted with dichloromethane (4 × 20 mL). The combined extracts were dried over 
anhydrous magnesium sulfate and concentrated under reduced pressure. The residue 
was subjected to flash chromatography. Elution with 25% ethyl acetate in petroleum 
spirits afforded the E isomer as a colourless oil (0.053 g, 21%): HRMS m/z Calcd for 
C20H17F2N2O requires 339.1309, found 339.1304; 
1
H NMR (CDCl3) δ 4.13 (2H, s), 
5.25 (2H, s), 6.74−6.85 (2H, m), 7.13 (1H, dd, J = 7.8, 4.8 Hz), 7.30−7.44 (7H, m), 
8.41 (2H, br. s); 
13
C NMR (CDCl3) δ 32.4 (CH2, d, J = 5.0 Hz), 76.8 (CH2), 104.6 
(CH, t, J = 25.9), 111.9 (CH, dd, J = 17.8, 3.4 Hz), 119.9 (C, dd, J = 12.8, 3.7 Hz), 
123.6 (CH), 128.2 (CH), 128.4 (CH), 128.6 (CH), 131.6 (CH, dd J = 9.6, 4.9 Hz), 
132.5 (C), 136.7 (CH), 137.3 (C), 147.3 (CH), 149.6 (CH), 153.4 (C, d, J = 2.0 Hz), 
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160.7 (C, dd, J = 240.7, 12.1 Hz), 163.7 (C, dd, J = 240.0, 12.5 Hz); IR 3032, 2930, 
1610, 1575, 1502, 1478, 1421, 968, 696 cm
−1
. 
 
10.2.48 Synthesis of N-phenyl-N-(3-pyridinemethyl)amine (156) 
 
Anhydrous magnesium sulfate (0.330 g, 2.74 mmol) was added to a solution of 
aniline 155 (0.195 mL, 0.199 g, 2.14 mmol) and 3-pyridinecarboxaldehyde 106 
(0.175 mL, 0.20 g, 1.86 mmol) in dry 1,2-dichloroethane (25 mL) and the reaction 
mixture was heated under reflux for 6 hours. Upon cooling, the reaction mixture was 
filtered and the filtrate was concentrated under reduced pressure.
 1
H NMR (CDCl3) δ
 
7.17−7.30 (3H, m), 7.34−7.44 (3H, m), 8.27 (1H, m), 8.47 (1H, s), 8.69 (1H, d, J = 
3.81 Hz), 9.01 (1H, br. s). The residue was dissolved in methanol (6 mL) and sodium 
borohydride (0.527 g, 13.93 mmol) was added in portions. The reaction mixture was 
stirred at room temperature for 3 hours. The reaction mixture was acidified with a 
solution of hydrochloric acid (5 M) and then adjusted to pH 9 with a solution of 
sodium hydrogen carbonate. The aqueous layer was extracted with dichloromethane 
(3 × 20 mL). The combined extracts were dried over anhydrous magnesium sulfate 
and concentrated under reduced pressure. The residue was subjected to flash 
chromatography. Elution with 25% ethyl acetate in petroleum spirits with 1% 
triethylamine gave the product 156 as a colourless oil (0.308 g, 90%). The 
spectroscopic properties were similar to those reported.
156
 
1
H NMR (CDCl3) δ
 
4.09 
(1H, br. s), 4.35 (2H, s), 6.60−6.65 (2H, m), 6.74 (1H, m), 7.15−7.21 (2H, m), 
7.23−7.28 (1H, m), 7.68−7.71 (1H, m), 8.52 (1H, d, J = 4.1 Hz), 8.63 (1H, s); 13C 
NMR (CDCl3) δ 45.9 (CH2), 113.1 (CH), 118.2 (CH), 123.7 (CH), 129.4 (CH), 135.1 
(C), 135.3 (CH), 147.7 (C), 148.6 (CH), 149.1 (CH); IR 3248, 3110, 3030, 2921, 
1917, 1600, 1578, 1497, 1423, 1311 cm
−1
. 
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10.2.49 Synthesis of 3-phenyl-2-propenol 163 
 
Anhydrous magnesium sulfate (0.309 g, 2.57 mmol) was added to a solution of N-
phenyl-N-(3-pyridinemethyl)amine 156 (0.347 g, 1.88 mmol) and trans-
cinnamaldehyde 161 (0.256 g, 1.94 mmol) in dry 1,2-dichloroethane (15 mL) and the 
reaction mixture was heated under reflux for 4 days. Upon cooling, the reaction 
mixture was filtered and the filtrate was concentrated under reduced pressure. The 
residue was dissolved in methanol (6 mL) and sodium borohydride (0.406 g, 10.73 
mmol) was added in portions. The reaction mixture was stirred at room temperature 
for 4 days. The reaction mixture was acidified with a solution of hydrochloric acid (5 
M) and then adjusted to pH 9 with a solution of sodium hydrogen carbonate. The 
aqueous layer was extracted with dichloromethane (3 × 20 mL). The combined 
extracts were dried over anhydrous magnesium sulfate and concentrated under 
reduced pressure. The residue was subjected to flash chromatography. Elution with 
50% ethyl acetate in petroleum spirits with 1% triethylamine afforded the starting 
material 156 (0.209 g, 60%) and 3-phenyl-2-propenol 163 as a colourless oil (0.069 
g, 27%). 
1
H NMR (CDCl3) δ
 
1.87 (1H, br. s.), 4.35 (2H, dd, J = 5.7, 1.3 Hz), 6.34−6.44 (1 H, 
m), 6.64 (1 H, d, J = 15.9 Hz), 7.23−7.45 (H, m); 13C NMR (CDCl3) δ 63.8 (CH2), 
112.8 (CH), 126.6 (CH), 127.8 (CH), 128.7 (CH), 131.2 (CH), 136.8 (C).  
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10.2.50 Synthesis of N-(3-phenyl-2-propen-1-yl)-benzenamine (164) 
 
Anhydrous magnesium sulfate (0.330 g, 2.74 mmol) was added to a solution of 
aniline 155 (0.20 mL, 0.204 g, 2.19 mmol) and trans-cinnamaldehyde 161 (0.28 mL, 
0.294 g, 2.22 mmol) in dry 1,2-dichloroethane (25 mL) and the reaction mixture was 
heated under reflux for 1 day. Upon cooling the reaction was filtered and the filtrate 
was concentrated under reduced pressure. The residue was dissolved in methanol (7 
mL) and sodium borohydride (0.620 g, 16.39 mmol) was added in portions. The 
reaction mixture was stirred at room temperature for 4 hours. The reaction mixture 
was acidified with a solution of hydrochloric acid (5 M) and then adjusted to pH 9 
with a solution of sodium hydrogen carbonate. The organics were extracted with 
dichloromethane (3 × 20 mL), dried over anhydrous magnesium sulfate and 
concentrated under reduced pressure. The residue was subjected to flash 
chromatography. Elution with 25% ethyl acetate in petroleum spirits with 1% 
triethylamine gave the product 164 as a colourless oil (0.122 g, 27%). The 
spectroscopic properties were similar to those reported.
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1
H NMR (CDCl3)  3.85 
(2H, dd, J = 5.7, 1.6 Hz), 4.24 (1H, s), 6.25 (1H, dt, J = 15.9, 5.7 Hz), 6.51−6.68 
(5H, m), 7.06−7.31 (6H, m); 13C NMR (CDCl3) δ 46.4 (CH2), 113.2 (CH), 117.8 
(CH), 126.5 (CH), 127.1 (CH), 127.7 (CH), 128.7 (CH), 129.4 (CH), 131.7 (CH), 
137.0 (C), 148.1 (C); IR 3404, 3054, 3025, 1683, 1599, 1501, 689 cm
−1
. 
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10.2.51 Synthesis of N-phenyl-N-(3-pyridylmethyl)cinnamamide (166) 
 
N-Phenyl-N-(3-pyridinemethyl)amine 156 (0.255 g, 1.38 mmol) and DMAP (0.003 
g, 0.03 mmol) were dissolved in dry dichloromethane (3 mL) and the reaction 
mixture was cooled to 0 °C. Cinnamoyl chloride 165 (0.320 g, 1.92 mmol) was 
added and the  reaction mixture was stirred at room temperature for 5 days. The 
reaction mixture was concentrated under reduced pressure and a solution of sodium 
hydrogen carbonate (1 M) was added. The aqueous layer was extracted with 
dichloromethane (2 × 10 mL). The combined extracts were dried over anhydrous 
magnesium sulfate and concentrated under reduced pressure. The residue was 
subjected to flash chromatography. Elution with 50% ethyl acetate in petroleum 
spirits with 1% triethylamine afforded the product 166 as a yellow oil (0.395 g, 
91%): HRMS m/z Calcd for C21H19N2O requires 315.1497, found 315.1499; 
1
H 
NMR (CDCl3)  5.03 (2H, s), 6.30 (1H, d, J = 15.6 Hz), 7.02−7.08 (2H, m), 
7.20−7.32 (6H, m), 7.33−7.41 (3H, m), 7.69−7.77 (2H, m), 8.41 (1H, br. s), 8.50 
(1H, d, J = 3.1 Hz); 
13
C NMR (CDCl3) δ 50.9 (CH2), 118.4 (CH), 123.7 (CH), 128.0 
(CH), 128.3 (CH), 128.4 (CH), 128.8 (CH), 129.8 (CH), 197.9 (CH), 133.3 (C), 
135.1 (C), 136.8 (CH), 141.7 (C), 142.9 (CH), 148.9 (CH), 149.9 (CH), 166.3 (C); IR 
3057, 3028, 2927, 1651, 1492, 1380, 760, 698 cm
−1
. 
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10.2.52 Synthesis of N-phenyl-N-(3-pyridinylmethyl)dihydrocinnamamide (168) 
 
N-Phenyl-N-(3-pyridylmethyl)cinnamamide 166 (0.147 g, 0.47 mmol) was dissolved 
in dry ethanol (6 mL) under nitrogen. Triethylsilane (0.20 mL, 0.146 g, 1.25 mmol, 
2.65 eq.) and palladium(II) chloride (0.020 g, 0.17 mmol) were added and the 
mixture was heated under reflux for 3 hours under nitrogen. The reaction mixture 
was poured into a solution of hydrochloric acid (3 M, 20 mL) and washed with ethyl 
acetate (2 × 20 mL). The aqueous layer was made basic with a solution of sodium 
hydroxide (3 M, 20 mL). The organics were extracted with dichloromethane (3 × 20 
mL), dried over anhydrous magnesium sulfate and concentrated under reduced 
pressure. The residue was subjected to flash chromatography. Elution with 50% ethyl 
acetate in petroleum spirits afforded the product 168 as a colourless oil (0.068 g, 
48%): HRMS m/z Calcd for C21H21N2O requires 317.1654, found 317.1641; 
1
H 
NMR (CDCl3)  2.29 (2H, t, J = 7.6 Hz), 2.85 (2H, t, J = 7.6 Hz), 4.77 (2H, s), 
6.64−6.71 (2H, m), 6.94−6.99 (2H, m), 7.04−7.16 (4H, m), 7.17−7.23 (3H, m), 
7.48 (1H, d, J = 7.8 Hz), 8.25 (1H, br. s), 8.41 (1H, br. s); 
13
C NMR (CDCl3) δ 31.7 
(CH2), 36.0 (CH2), 50.6 (CH2), 123.9 (CH), 126.3 (CH), 128.4 (CH), 128.5 (CH), 
128.6 (CH), 130.0 (CH), 133.7 (CH), 137.6 (CH), 141.0 (C), 141.9 (C), 148.2 (CH), 
149.3 (C), 172.4 (C); IR 3028, 2927, 1651, 1593, 1494, 1264, 698 cm
−1
. 
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10.2.53 Synthesis of 3-(2-(naphthoxy)methyl)pyridine (175) 
 
3-Chloromethylpyridine 49 (0.378 g, 2.30 mmol) and 2-naphthol 170 (0.334g, 2.32 
mmol) were dissolved in a solution of sodium hydroxide (0.190 g, 4.75 mmol) and 
water (3 mL) and the mixture was stirred at room temperature overnight. The 
mixture was poured into a solution of hydrochloric acid (1 M, 10 mL) and made 
basic to pH 8 with a solution of sodium hydrogen carbonate (1 M). The aqueous 
layer was extracted with dichloromethane (5 × 20 mL). The combined extracts were 
dried over anhydrous magnesium sulfate and concentrated under reduced pressure. 
The residue was subjected to flash chromatography. Elution with 50% ethyl acetate 
in petroleum spirits with 1% triethylamine afforded starting material 170 as a white 
solid (0.098 g, 30%) and compound 175 as a colourless oil (0.087 g, 16%). 
3-(2-(naphthoxy)methyl)pyridine (175): 
1
H NMR (CDCl3)  5.18 (2H, s), 7.19−7.25 
(2H, m), 7.31−7.40 (2H, m), 7.46 (1H, ddd, J = 8.2, 6.9, 1.2 Hz), 7.71−7.80 (3H, 
m), 7.81−7.86 (1H, m), 8.62 (1H, dd, J = 4.8, 1.3 Hz), 8.76 (1H, d, J = 1.7 Hz); 13C 
NMR (CDCl3) δ 67.5 (CH2), 107.3 (CH), 118.8 (CH), 123.6 (CH), 124.0 (CH), 126.6 
(CH), 126.9 (CH), 127.7 (CH), 129.3 (C), 129.7 (CH), 132.6 (C), 134.5 (C), 135.5 
(CH), 148.9 (CH), 149.4 (CH), 158.4 (C); IR 3027, 1625, 1597, 1255, 1212, 1177, 
1021, 838 cm
−1
. 
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10.2.54 Synthesis of 3-((2-(pyridin-3-ylmethoxy)naphthalen-1-yl)methyl)-
pyridine (176) 
 
2-Napthol 170 (0.694 g, 4.814 mmol) and 3-chloromethylpyridine hydrochloride 
(0.789 g, 4.81 mmol) were added to a solution of sodium hydroxide (0.393 g, 9.83 
mmol) in water (5 mL). The reaction mixture was stirred at room temperature for 60 
hours. The reaction mixture was poured onto a solution of hydrochloric acid (1 M, 10 
mL) and made basic to pH 8 with a solution of sodium hydrogen carbonate (1 M). 
The aqueous layer was extracted with dichloromethane (2 × 15 mL), dried over 
anhydrous magnesium sulfate and concentrated under reduced pressure. The residue 
was subjected to flash chromatography. Elution with 50% ethyl acetate in petroleum 
spirits afforded naphthol 170 (0.349 g, 50%) and 3-((2-(pyridin-3-
ylmethoxy)naphthalen-1-yl)methyl)pyridine 176 as a brown oil (0.296 g, 19 %). 
3-((2-(pyridin-3-ylmethoxy)naphthalen-1-yl)methyl)pyridine 176: 
1
H NMR (CDCl3) 
 4.56 (2H, s), 5.22 (2H, s), 7.08−7.13 (3H, m), 7.15−7.25 (2H, m), 7.29−7.35 (2H, 
m), 7.45 (1H, d, J = 7.8 Hz), 7.55−7.61 (3H, m), 7.65 (2H, d, J = 9.1 Hz), 8.46 (1H, 
dq, J = 2.6, 0.7 Hz), 8.51 (1H, d, J 4.3 Hz); 13C NMR (CDCl3) δ 46.7 (CH2), 70.6 
(CH2), 118.8 (CH), 121.4 (CH), 122.7 (CH), 122.8 (CH), 123.1 (CH), 123.9 (CH), 
126.4 (CH), 126.9 (CH), 127.6 (CH), 129.1 (C), 129.6 (CH), 134.5 (C), 136.9 (CH), 
137.1 (CH), 149.2 (CH), 149.4 (CH), 156.3 (C), 156.5 (C), 157.1 (C). 
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10.2.55 Synthesis of 1-(3-pyridinylmethyl)-2-naphthol (171) 
 
3-Pyridine carboxaldehyde 106 (0.55 mL, 0.628 g, 5.86 mmol) and β-tetralone 177 
(0.66 mL, 0.73 g, 4.99 mmol) were dissolved in acetic acid (20 mL). Freshly 
prepared anhydrous hydrogen chloride gas was bubbled through the reaction mixture 
until saturated. The mixture was stirred at room temperature overnight and then 
concentrated under reduced pressure. The residue was dissolved in ethyl acetate (20 
mL) and washed with a solution of sodium hydrogen carbonate (1 M, 20 mL). The 
aqueous layer was extracted with ethyl acetate (3 × 20 mL). The combined extracts 
were dried over anhydrous magnesium sulfate and concentrated under reduced 
pressure. Diethyl ether was added to the residue and the resulting crystals were 
collected by vacuum filtration and dried under vacuum to give 1-(3-
pyridinylmethyl)-2-naphthol 171 as yellow crystals (0.876 g, 75%): m.p. 202−203 
°C (lit.
128
 m.p. 197−200 °C). The spectroscopic properties were similar to those 
reported.
128
 
1
H NMR (CDCl3) δ
 
4.47 (2H, s), 7.20 (1H, d, J = 8.6 Hz), 7.27−7.33 
(2H, m), 7.44 (1H, ddd, J = 8.6, 6.9, 1.3 Hz), 7.62 (1H, d, J = 8.6 Hz), 7.74−7.80 
(2H, m), 7.87 (1H, d, J = 8.6 Hz), 8.42 (1H, d, J = 4.4 Hz), 8.65 (1H, s); 
13
C NMR 
(CDCl3) δ 28.3 (CH2), 117.9 (C), 118.4 (CH), 122.8 (CH), 123.1 (CH), 123.7 (CH), 
126.8 (CH), 128.5 (CH), 128.8 (CH), 129.3 (C), 133.5 (CH), 136.7 (CH), 137.5 (C), 
146.3 (CH), 149.5 (CH), 150.8 (C); IR 3041, 2868, 2598, 1626, 1578, 1435, 1273, 
997, 706 cm
−1
. 
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10.2.56 Synthesis of 2-butoxy-1-(pyridylmethyl)naphthalene (178) 
 
1-(3-Pyridinylmethyl)-2-naphthol 171 (0.146 g, 0.62 mmol) was dissolved in N,N- 
dimethylformamide (11 mL). Potassium carbonate (0.264 g, 1.91 mmol) was added 
to the solution followed by 1-bromobutane 133 (0.2 mL, 0.253 g, 1.85 mmol). The 
reaction mixture was heated to 80 °C for 4 days under nitrogen. The reaction mixture 
was cooled to room temperature and concentrated under reduced pressure. The 
residue was subjected to flash chromatography. Elution with 5% methanol in 
dichloromethane afforded the product 178 as a pale brown oil (0.153 g, 84%): 
HRMS m/z Calcd for C20H22NO requires 292.1701, found 292.1697; 
1
H NMR 
(CDCl3) δ 0.96 (3H, t, J = 7 Hz), 1.40−1.54 (2H, m), 1.73−1.84 (2H, m), 4.12 (2H, 
t, J = 6.5 Hz), 4.46 (2H, s), 7.09 (1H, dd, J = 7.6, 4.8 Hz), 7.28−7.36 (2H, m), 
7.40−7.47 (2H, m), 7.76−7.82 (2H, m), 7.86−7.92 (1H, m), 8.38 (1H, br. s), 8.60 
(1H, br. s); 
13
C NMR (CDCl3) δ 13.9 (CH3), 19.4 (CH2), 28.2 (CH2), 31.7 (CH2), 
68.9 (CH2), 114.3 (CH), 120.5 (C), 123.2 (CH), 123.4 (CH), 126.8 (CH), 128.7 (CH), 
128.8 (CH), 129.3 (C), 133.2 (C), 136.0 (CH), 137.1 (C), 147.0 (CH), 150.0 (CH), 
154.4 (C); IR 2951, 2935, 2869, 1623, 1594, 1262, 1250, 1079, 803, 750 cm
−1
. 
 
10.2.57 Synthesis of 3-((2-butoxynaphthalen-1-yl)methyl)-1-butylpyridin-1-
ium (179)
 
1-(3-Pyridinylmethyl)-2-naphthol 171 (0.148 g, 0.63 mmol) was dissolved in 
dimethylformamide (15 mL). Potassium carbonate (0.238 g, 1.70 mmol) was added 
to the solution followed by 1-bromobutane (1.5 mL, 1.905 g, 13.9 mmol). The 
reaction mixture was heated to 80 °C for 3 days under nitrogen. The reaction mixture 
was cooled to room temperature and concentrated under reduced pressure. The 
189 
 
residue was subjected to flash chromatography. Elution with 5% methanol in 
dichloromethane afforded 2-butoxy-1-(pyridylmethyl)naphthalene 178 as a pale 
brown oil (0.006 g, 3.3%) and 3-((2-butoxynaphthalen-1-yl)methyl)-1-butylpyridin-
1-ium 179 as a pale brown oil (0.186 g, 85%). 
3-((2-butoxynaphthalen-1-yl)methyl)-1-butylpyridin-1-ium 179: 
1
H NMR (CDCl3) δ 
0.86 (3H, t, J = 7.3 Hz), 0.92 (3H, t, J = 7.3 Hz), 1.24−1.47 (4H, m), 1.68−1.78 (2H, 
m), 1.89−2.00 (2H, m), 4.10 (2H, t, J = 6.5 Hz), 4.68 (2H, s), 4.85 (2H, t, J = 7.3 
Hz), 7.26−7.31 (2H, m), 7.45 (1H, ddd, J = 8.4, 7.0, 1.2 Hz), 7.76 (1H, d, J = 7.9 
Hz), 7.80 (1H, d, J = 9.1 Hz), 7.83−7.92 (2H, m), 8.03 (1H, d, J = 8.1 Hz), 9.35 (1H, 
s), 9.41 (1H, d, J = 6.0 Hz);
 13
C NMR (CDCl3) δ 13.4 (CH3), 13.8 (CH3), 19.2 
(CH2), 19.3 (CH2), 27.8 (CH2), 31.5 (CH2), 33.7 (CH2), 61.5 (CH2), 68.9 (CH2), 
113.8 (CH), 117.5 (C), 122.6 (CH), 123.8 (CH), 127.6 (CH), 128.0 (CH), 128.8 
(CH), 129.1 (C), 129.9 (CH), 132.5 (C), 142.8 (CH), 143.3 (C), 143.7 (CH), 144.5 
(CH), 154.2 (C). 
 
10.2.58 Synthesis of nicotinic acid methyl ester (182) 
 
Nicotinic acid 185 (1.064 g, 7.87 mmol) and concentrated sulfuric acid (3.4 mL) in 
methanol (17 mL) were heated under reflux overnight. The reaction mixture was 
cooled to room temperature, poured into water (10 mL) and made basic with a 
solution of sodium carbonate (1 M). The aqueous layer was extracted with 
dichloromethane (5 × 25 mL). The combined extracts were dried over anhydrous 
magnesium sulfate and concentrated under reduced pressure to give nicotinic acid 
methyl ester 182 as a white solid (0.939 g, 80%): 
1
H NMR (CDCl3) δ 3.81 (3H, s), 
7.26 (1H, ddd, J = 7.9, 4.8, 0.88 Hz), 8.14 (1H, m), 8.63 (1H, dd, J = 4.8, 1.8 Hz), 
9.07 (1H, dd, J = 2.2, 0.9 Hz); 
13
C NMR (CDCl3) δ 51.9 (CH3), 122.9 (CH), 125.6 
(C), 136.5 (CH), 150.4 (CH), 153.0 (CH), 165.2 (C). 
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10.2.59 Synthesis of 2-(2,4-dichlorophenyl)-1-(3-pyridinyl)ethanone (184) 
 
Nicotinic acid methyl ester 182 (0.147 g, 0.99 mmol) and 2,4-dichlorophenylacetic 
acid 183 (0.206 g, 1.00 mmol) were dissolved in anhydrous N,N-dimethylformamide 
(3 mL). The mixture was cooled to −8 °C and sodium bis(trimethylsilyl)amide (1 M 
in THF, 2 mL) was added dropwise. The resulting mixture was stirred for 3.5 hours. 
The reaction mixture was poured into a solution of ammonium chloride (1 M, 20 
mL). The aqueous layer was extracted with dichloromethane (4 × 20 mL). The 
combined extracts were dried over anhydrous magnesium sulfate and concentrated 
under reduced pressure. The residue was subjected to flash chromatography. Elution 
with 20% ethyl acetate in hexanes afforded the ketone 184 as a yellow oil (0.158 g, 
60%): 
1
H NMR (CDCl3) δ 4.39 (2H, s), 7.10−7.20 (2H, m), 7.35 (1H, d, J = 2.0 Hz), 
7.40−7.46 (1H, m), 8.20−8.24 (1H, m), 8.80 (1H, d, J = 3.5 Hz), 9.24 (1H, s); 13C 
NMR (CDCl3) δ 43.0 (CH2), 124.0 (CH), 127.5 (CH), 129.5 (CH), 130.9 (C), 131.9 
(C), 132.2 (CH), 134.1 (C), 135.2 (C), 135.9 (CH), 149.6 (CH), 153.7 (CH), 194.7 
(C); IR 3071, 1692, 1548, 1473, 1228, 1100, 823, 699 cm
−1
. 
 
10.2.60 Synthesis of 2-(2,4-dichlorophenyl)-1-(3-pyridinyl)methyloxime 
ethanone (180) 
 
A mixture of 2-(2,4-dichlorophenyl)-1-(3-pyridinyl)ethanone 184 (0.150 g, 0.56 
mmol), O-methylhydroxylamine hydrochloride (0.054 g, 0.65 mmol) and sodium 
acetate (0.186 g, 22.27 mmol) in ethanol (4 mL) was stirred at room temperature for 
4 days. The reaction mixture was poured into a solution of sodium hydrogen 
carbonate (1 M, 20 mL) and extracted with dichloromethane (4 × 20 mL). The 
combined extracts were dried over anhydrous magnesium sulfate and concentrated 
under reduced pressure. The residue was subjected to flash chromatography. Elution 
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with 25% ethyl acetate in petroleum spirits afforded the two isomers as a coloulress 
oil (0.021 g, 13%). 
Data for major isomer (selected peaks)
*
 
1
H NMR (CDCl3) δ 3.99 (3H, s), 4.12 (2H, 
s), 6.92 (1H, d, J = 8.4 Hz), 7.88 (1H, m), 8.58 (1H, br. s.), 8.78 (1H, br. s.).  
Data for minor isomer (selected peaks)
*
 
1
H NMR (CDCl3) δ 3.82 (3H, s), 3.92 (2H, 
s), 7.62−7.67 (1H, m), 8.50 (2H, br. s.). 
 
10.2.61 Synthesis of 1-benzoyl-1-(3-pyridyl)cyclopropane (181) 
 
Potassium t-butoxide (0.106 g, 0.94 mmol) was added to a cooled (0 °C) solution of 
1-phenyl-2-(3-pyridinyl)ethanone 93 (0.153 g, 0.78 mmol) in anhydrous N,N-
dimethylformamide (4 mL). The reaction mixture was stirred at 0 °C under nitrogen 
for 30 minutes. 1,2-Dibromoethane 187 (0.1 mL, 0.22 g, 1.16 mmol) was added to 
the reaction mixture and the reaction mixture was stirred at 0 °C for 2.5 hours. 
Additional potassium t-butoxide (0.110 g, 0.98 mmol) was added and the reaction 
mixture was stirred at room temperature overnight. The reaction mixture was 
concentrated under reduced pressure to give an oil. The residue was dissolved in 
ethyl acetate (20 mL) and washed with water. The organic layer was dried over 
anhydrous magnesium sulfate and concentrated under reduced pressure. The residue 
was subjected to flash chromatography. Elution with 50% ethyl acetate in hexanes 
afforded the product 188 as a colourless oil (0.034 g, 20%): HRMS m/z Calcd for 
C15H14NO requires 224.1075, found 224.1064; 
1
H NMR (CDCl3) δ 1.32 (2H, dd, J = 
4.5, 2.6 Hz), 1.68 (2H, dd, J = 4.4, 2.6 Hz), 7.08 (1H, ddd, J = 7.9, 4.8, 0.8 Hz), 
7.18−7.24 (2H, m), 7.31 (1H, m), 7.40−7.44 (1H, m), 7.60−7.65 (2H, m), 8.33 (1H, 
dd, J = 4.8, 1.7 Hz), 8.42 (1H, d, J = 1.8 Hz); 
13
C NMR (CDCl3) δ 16.2 (CH2), 33.1 
(C), 123.3 (CH), 128.2 (CH), 129.2 (CH), 132.2 (CH), 135.7 (CH), 136.7 (C), 136.8 
(C), 147.9 (CH), 149.5 (CH), 199.5 (C); IR 3035, 1719, 1670, 1284, 988, 707 cm
−1
. 
                                               
*
 Isomers were not to be isolated. Peaks were assigned based on the integration in the 
1
H NMR 
spectrum 
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10.2.62 Synthesis of 1-(2,4-dichlorophenyl)-3-(3-pyridinyl)-2-propen-1-one 
(194) 
 
A solution of sodium hydroxide (2.264 g, 56.6 mmol) in water (80 mL) and ethanol 
(80 mL) was added to a solution of 3-pyridinecarboxaldehyde 106 (4.38 mL, 4.9 g, 
46.7 mmol) and 2ʹ,4ʹ-dichloroacetophenone 193 (6.69 mL, 8.82 g, 46.7 mmol) in 
ethanol (160 mL). Water (600 mL) was added immediately until a solid precipitated 
out. The solid was collected via vacuum filtration and dried under vacuum to give 1-
(2,4-dichlorophenyl)-3-(3-pyridinyl)-2-propen-1-one 194 as a pale yellow solid 
(9.544 g, 99%): m.p. 115.5−116.5 °C (lit.131 m.p. 120−122 °C). The spectroscopic 
properties were similar to those reported.
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1
H NMR (CDCl3) δ 7.20 (1H, d, J = 16.1 
Hz), 7.33−7.40 (2H, m), 7.45−7.53 (3H, m), 7.90 (1H, m), 8.64 (1H, dd, J = 4.8, 1.4 
Hz), 8.78 (1H, d, J = 1.6 Hz); 
13
C NMR (CDCl3) δ 124.0 (CH), 127.6 (CH), 127.6 
(CH), 130.3 (C), 130.5 (CH), 130.8 (CH), 132.6 (C), 134.7 (CH), 137.2 (C), 137.6 
(C), 142.3 (CH), 150.4 (CH), 151.7 (CH), 191.9 (C); IR 3087, 3060, 3034, 1678, 
1608, 1582, 1568, 1551, 1211 cm
−1
. 
 
10.2.63 Synthesis of 1-(4-fluorophenyl)-3-(3-pyridinyl)-2-propen-1-one (197) 
 
A solution of sodium hydroxide (2.27 g, 56.7 mmol) in water (80 mL) and ethanol 
(80 mL) was added to a solution of 3-pyridinecarboxaldehyde 106 (4.38 mL, 5 g, 
46.7 mmol) and 4ʹ-fluoroacetophenone (5.67 mL, 6.45 g, 46.7 mmol) in ethanol (160 
mL). Water (600 mL) was added immediately until a solid precipitated out. The solid 
was collected via vacuum filtration and dried under vacuum to give 1-(4-
fluorophenyl)-3-(3-pyridinyl)-2-propen-1-one 197 as a pale yellow solid (9.35 g, 
90%): m.p. 125 °C (lit.
158
 m.p. 126−127 °C). The spectroscopic properties were 
similar to those reported.
131,158
 
1
H NMR (CDCl3) δ 7.13−7.21 (2H, m), 7.35 (1H, dd, 
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J = 7.9, 4.8 Hz), 7.56 (1H, d, J = 15.8 Hz), 7.78 (1H, d, J = 15.8 Hz), 7.93 (1H, m), 
8.01−8.09 (2H, m), 8.62 (1H, br. s), 8.85 (1H, br. s); 13C NMR (CDCl3) δ 116.0 
(CH, d, J = 21.9 Hz), 123.5 (CH), 123.9 (CH), 130.7 (C), 131.2 (CH, d, J = 9.1 Hz), 
134.2 (C, d, J = 3.0 Hz), 134.7 (CH), 141.3 (CH), 150.1 (CH), 151.3 (CH), 165.9 (C, 
d, J = 255.1 Hz), 188.2 (C); IR 3069, 1686, 1664, 1603, 1587, 1567, 1217 cm
−1
. 
 
10.2.64 Synthesis of 1-(4-chlorophenyl)-3-(3-pyridinyl)-2-propen-1-one (198) 
 
A solution of sodium hydroxide (2.27 g, 56.7 mmol) in water (80 mL) and ethanol 
(80 mL) was added to a solution of 3-pyridinecarboxaldehyde 106 (4.38 mL, 5 g, 
46.7 mmol) and 4ʹ-chloroacetophenone (6 mL, 7.152 g, 46.2 mmol) in ethanol (160 
mL). Water (600 mL) was added immediately until a solid precipitated out. The solid 
was collected via vacuum filtration and dried under vacuum to give 1-(4-
chlorophenyl)-3-(3-pyridinyl)-2-propen-1-one 198 as a pale yellow solid (10.47 g, 
92%): m.p. 120 °C; HRMS Calcd for C14H11ClNO requires 244.0529, found 
244.0520; 
1
H NMR (CDCl3) δ 7.37 (1H, dd, J = 7.9, 4.8 Hz), 7.46−7.51 (2H, m), 
7.55 (1H, d, J = 15.8 Hz), 7.79 (1H, d, J = 15.8 Hz), 7.93−7.99 (3H, m), 8.64 (1H, d, 
J = 3.8 Hz), 8.86 (1H, br. s); 
13
C NMR (CDCl3) δ 123.6 (CH), 124.0 (CH), 129.2 
(CH), 130.1 (CH), 130.7 (C), 134.9 (C), 136.2 (C), 139.8 (C), 141.5 (CH), 150.0 
(CH), 151.3 (CH), 188.6 (C); IR 3063, 3032, 1666, 1604, 1580, 1568, 796 cm
−1
. 
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10.2.65 Synthesis of ((1R,2R,3S,4S)-2,4-di(pyridin-3-yl)cyclobutane-1,3-diyl)bis-
(phenylmethanone) (200) 
 
A solution of sodium hydroxide (0.113 g, 2.83 mmol) in water (1.5 mL) and ethanol 
(1.5 mL) was added to a solution of 3-pyridinecarboxaldehyde 106 (0.512 g, 4.78 
mmol) and acetophenone (0.579 g, 4.82 mmol) in ethanol (1.5 mL). Water (10 mL) 
was added immediately. The aqueous layer was extracted with dichloromethane (5 × 
10 mL). The combined organics were dried over anhydrous magnesium sulfate and 
concentrated under reduced pressure. The residue was subjected to flash 
chromatography. Elution with 50% ethyl acetate in petroleum spirits afforded 1-
phenyl-3-(3-pyridinyl)-2-propen-1-one 199 as a white solid (0.259 g, 26 %): 
1
H 
NMR (CDCl3) δ 7.34−7.39 (1H, m), 7.49−7.56 (2H, m), 7.57−7.64 (2H, m), 7.79 
(1H, d, J = 15.3 Hz), 7.92−7.98 (1H, m), 8.00−8.05 (2H, m), 8.64 (1H, dd, J = 4.7, 
1.6 Hz), 8.86 (1H, d, J = 2.1 Hz);
 13
C NMR (CDCl3) δ 123.9 (CH), 124.0 (CH), 
128.7 (CH), 128.9 (CH), 130.8 (C), 133.3 (CH), 134.7 (CH), 137.9 (C), 141.1 (CH), 
150.1 (CH), 151.3 (CH), 190.0 (C); IR 3062, 3039, 1650, 1603, 1220, 679 cm
-1
. 
Recrystallisation of 1-phenyl-3-(3-pyridinyl)-2-propen-1-one 199 from 
dichloromethane and petroleum spirits afforded ((1R,2R,3S,4S)-2,4-di(pyridin-3-
yl)cyclobutane-1,3-diyl)bis-(phenylmethanone) 200 as a white solid: 
1
H NMR 
(CDCl3) δ 4.89−4.95 (2H, m), 4.97−5.03 (2H, m), 7.21 (2H, dd, J = 7.7, 5.2 Hz), 
7.34−7.41 (4H, m), 7.48−7.53 (2H, m), 7.69−7.77 (6H, m), 8.35−8.39 (2H, m), 
8.52 (2H, d, J = 1.6 Hz);
 13
C NMR (CDCl3) δ 39.8 (CH), 49.7 (CH), 123.4 (CH), 
128.1 (CH), 128.7 (CH), 133.7 (CH), 134.5 (C), 135.6 (CH), 135.9 (C), 147.9 (CH), 
149.0 (CH), 197.6 (C); IR 3059, 3037, 1660, 1595, 1579, 1428, 1025 cm
-1
. 
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10.2.66 Synthesis of 1-(4-fluorophenyl)-3-(3-pyridinyl)-1-propanone (204) 
 
Procedure 1 
Ammonium chloride (1.495 g, 27.9 mmol) in water (11 mL) was added to a solution 
of 1-(4-fluorophenyl)-3-(3-pyridinyl)-2-propen-1-one 197 (0.158 g, 0.7 mmol) in 
ethanol (70 mL). Zinc powder (0.277 g, 4.24 mmol) was added in portions over 15 
minutes whilst stirring. After 2 hours the reaction mixture was gravity filtered and 
the filtrate was concentrated under reduced pressure. The residue was subjected to 
flash chromatography. Elution with 50% ethyl acetate in petroleum spirits afforded 
1-(4-fluorophenyl)-3-(3-pyridinyl)-1-propanone 204 as a yellow oil (0.048 g, 30%): 
HRMS m/z Calcd for C14H13FNO requires 230.0981, found 230.0971; 
1
H NMR 
(CDCl3) δ 2.90 (2H, t, J = 7.3 Hz), 3.13 (2H, t, J = 7.3 Hz), 7.07−7.15 (2H, m), 7.20 
(1H, dd, J = 7.7, 4.8 Hz), 7.54−7.59 (1H, m), 7.93−7.99 (2H, m), 8.44 (1H, d, J = 
3.7 Hz), 8.51 (1H, br. s); 
13
C NMR (CDCl3) δ 27.2 (CH2), 39.7 (CH2), 115.9 (CH, d, 
J = 22.6 Hz), 123.6 (CH), 130.8 (CH, d, J = 9.1 Hz), 133.2 (C, d, J = 3.4 Hz), 136.0 
(CH), 136.4 (C), 147.6 (CH), 149.8 (CH), 165.8 (C, d, J = 254.8 Hz), 196.9 (C); IR 
3057, 2919, 1682, 1597, 1506, 1225 cm
−1
. 
 
Procedure 2 
Triethylsilane (1.11 mL, 0.808 g, 6.95 mmol) and palladium(II) chloride (0.072 g, 
0.41 mmol) were added to a solution of 1-(4-fluorophenyl)-3-(3-pyridinyl)-2-propen-
1-one 197 (0.699 g, 3.15 mmol) in dry ethanol (37 mL). The mixture was heated 
under reflux for 1 day. On cooling the mixture was filtered through Celite and 
concentrated under reduced pressure. The residue was acidified with a solution of 
hydrochloric acid (1 M, 20 mL) and washed with ethyl acetate (10 mL). The aqueous 
layer was made basic with a solution of sodium hydrogen carbonate (1 M, 30 mL) 
and extracted with dichloromethane (3 × 30 mL). The combined extracts were dried 
over anhydrous magnesium sulfate and concentrated under reduced pressure to give 
1-(4-fluorophenyl)-3-(3-pyridinyl)-1-propanone 204 as a yellow oil (0.676 g, 94%). 
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10.2.67 Synthesis of 1-(4-fluorophenyl)-3-(3-pyridinyl)-1-propanol (206) 
 
Triethylsilane (4.00 mL, 2.912 g, 25.0 mmol) and palladium(II) chloride (0.238 g, 
1.34 mmol) were added to a solution of 1-(4-fluorophenyl)-3-(3-pyridinyl)-2-propen-
1-one 197 (1.998 g, 8.99 mmol) in dry ethanol (150 mL). The mixture was heated 
under reflux for 2 days. On cooling the mixture was filtered through Celite and 
concentrated under reduced pressure. The residue was subjected to flash 
chromatography. Elution with 50% ethylacetate in petroleum spirits afforded 1-(4-
fluorophenyl)-3-(3-pyridinyl)-1-propanone 204 as a yellow oil (0.634 g, 31%) and 1-
(4-fluorophenyl)-3-(3-pyridinyl)-1-propanol 206 as a yellow oil (0.612 g, 32%). 
1-(4-fluorophenyl)-3-(3-pyridinyl)-1-propanol 206: 
1
H NMR (CDCl3) δ 1.77−2.02 
(2H, m), 2.49−2.68 (2H, m), 4.44 (1H, br. s.), 4.54 (1H, dd, J = 7.8, 5.1 Hz), 
6.86−6.93 (2H, m), 7.07 (1H, dd, J = 7.8, 5.1 Hz), 7.17−7.23 (2H, m), 7.39 (1H, dt, 
J = 7.8, 1.9 Hz), 8.16 (1H, d, J = 3.8 Hz), 8.17−8.21 (1H, m). 
 
10.2.68 Synthesis of 1-(4-chlorophenyl)-3-(3-pyridinyl)-1-propanone (208) 
 
Triethylsilane (1.3 mL, 0.946 g, 8.14 mmol) and palladium(II) chloride (0.132 g, 
0.74 mmol) were added to a solution of 1-(4-chlorophenyl)-3-(3-pyridinyl)-2-propen-
1-one 198 (1.603 g, 6.58 mmol) in dry ethanol (50 mL).. The mixture was heated 
under reflux for 2 days. The reaction mixture was filtered through Celite and 
concentrated under reduced pressure. The resulting oil was subjected to flash 
chromatography. Elution with 50% ethyl acetate in petroleum spirits afforded 1-(4-
chlorophenyl)-3-(3-pyridinyl)-1-propanone 208 as a yellow oil (1.153 g, 71%): 
HRMS m/z Calcd for C14H13ClNO requires 246.0686, found 246.0680; 
1
H NMR 
(CDCl3) δ 2.98 (2H, t, J = 7.3 Hz), 3.20 (2H, t, J = 7.3 Hz), 7.18−7.24 (1H, m), 
7.38−7.48 (2H, m), 7.52−7.61 (1H, m), 7.84−7.96 (2H, m), 8.38 (1H, d, J = 4.7 
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Hz), 8.45 (1H, br. s); 
13
C NMR (CDCl3) δ 27.1 (CH2), 39.8 (CH2), 127.9 (CH), 128.9 
(CH), 129.3 (CH), 133.4 (CH), 135.0 (C), 136.3 (C), 139.8 (C), 147.7 (CH), 149.9 
(CH), 197.3 (C); IR 3031, 2917, 2849, 1681, 1588, 1573, 1089 cm
−1
. 
 
10.2.69 Synthesis of 3-[4-(4-chlorophenyl)propyl]pyridine (207) 
 
Triethylsilane (4.0 mL, 2.912 g, 25.0 mmol) and palladium(II) chloride (0.238 g, 
1.34 mmol) were added to a solution of 1-(4-chlorophenyl)-3-(3-pyridinyl)-2-propen-
1-one 198 (2.001 g, 8.20 mmol) in dry ethanol (100 mL). The mixture was heated 
under reflux for 2 days. The reaction mixture was filtered through Celite and 
concentrated under reduced pressure. The resulting oil was subjected to flash 
chromatography. Elution with 50% ethyl acetate in petroleum spirits afforded 1-(4-
chlorophenyl)-3-(3-pyridinyl)-1-propanone 208 as a yellow oil (0.639 G, 32%) and 
3-[4-(4-chlorophenyl)propyl]pyridine 207 as an oil (0.412 g, 22%) 
3-[4-(4-chlorophenyl)propyl]pyridine 207: 
1
H NMR (CDCl3) δ 1.91−2.01 (2H, m), 
2.60−2.69 (4H, m), 7.15−7.22 (4H, m), 7.25−7.32 (2H, m), 7.44−7.50 (1H, m), 
8.41−8.49 (2H, m); 13C NMR (CDCl3) δ 32.4 (CH2), 32.6 (CH2), 35.2 (CH2), 123.3 
(CH), 125.9 (CH), 128.4 (CH), 135.9 (CH), 1317.4 (C), 141.7 (C), 147.3 (CH), 149.9 
(CH).  
 
10.2.70 Synthesis of 1-(2,4-chlorophenyl)-3-(3-pyridinyl)-1-propanone (209) 
 
Triethylsilane (1.3 mL, 0.946 g, 8.14 mmol) and palladium(II) chloride (0.136 g, 
0.77 mmol) were added to a solution of 1-(2,4-dichlorophenyl)-3-(3-pyridinyl)-2-
propen-1-one 194 (1.673 g, 6.02 mmol) in dry ethanol (50 mL).. The mixture was 
heated under reflux for 2 days. On cooling the mixture was filtered through Celite 
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and concentrated under reduced pressure. The resulting oil was subjected to flash 
chromatography. Elution with 50% ethyl acetate in petroleum spirits afforded 1-(2,4-
chlorophenyl)-3-(3-pyridinyl)-1-propanone 209 as a yellow oil (1.315 g, 78%): 
HRMS m/z Calcd for C14H12Cl2NO requires 280.0296, found 280.0291; 
1
H NMR 
(CDCl3) δ 3.07 (2H, t, J = 7.3 Hz), 3.29 (2H, t, J = 7.3 Hz), 7.26−7.31 (2H, m), 
7.38−7.44 (2H, m), 7.63 (1H, d, J = 7.3 Hz), 8.46 (1H, d, J = 3.81 Hz), 8.52 (1H, br. 
s);
 13
C NMR (CDCl3) δ 27.2 (CH2), 43.7 (CH2), 123.7 (CH), 127.5 (CH), 130.3 
(CH), 130.5 (CH), 132.1 (C), 136.5 (C), 136.9 (C), 137.0 (CH), 137.7 (C), 146.9 
(CH), 149.0 (CH), 200.1 (C); IR 3029, 2931, 1694, 1580, 1552, 1423 cm
−1
. 
 
10.2.71 Synthesis of 1-(4-fluorophenyl)-3-(3-pyridinyl)-1-propanone 
methyloxime (210) 
 
1-(4-Fluorophenyl)-3-(3-pyridinyl)-1-propanone 204 (0.661 g, 2.88 mmol), O-
methylhydroxylamine hydrochloride (0.253 g, 3 mmol) and sodium acetate (0.557 g, 
6.8 mmol) were stirred in ethanol (9 mL) at room temperature for 4 days. The 
reaction mixture was poured into a solution of sodium hydrogen carbonate (1 M, 10 
mL) and the aqueous layer was extracted with ethyl acetate (3 × 10 mL). The 
combined extracts were dried over anhydrous magnesium sulfate and concentrated 
under reduced pressure. The resulting oil was subjected to flash chromatography. 
Elution with 50% ethyl acetate in petroleum spirits with 1% triethylamine afforded 
the two isomers (0.492 g, 66%, E:Z 2.5:1). 
E isomer (colourless oil, 0.353 g, 47%) HRMS m/z Calcd for C15H16FN2O requires 
259.1247, found 259.1247; 
1
H NMR (CDCl3) δ 2.76−2.82 (2H, m), 2.95−3.01 (2H, 
m), 3.90 (3H, s), 6.97−7.04 (2H, m), 7.12−7.18 (1H, m), 7.44−7.48 (1H, m), 
7.49−7.56 (2H, m), 8.38−8.44 (2H, m); 13C NMR (CDCl3) δ 28.1 (CH2), 29.6 (CH2), 
62.0 (CH3), 115.6 (CH, d, J = 21.2 Hz), 123.3 (CH), 128.6 (CH, d, J = 8.1 Hz), 131.6 
(C, d, J = 3.4 Hz), 135.9 (CH), 147.7 (CH), 149.8 (CH), 156.1 (C), 163.4 (C, d, J = 
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249.1 Hz); IR 3393, 3058, 3042, 3021, 2938, 2823, 1630, 1608, 1510, 1457, 1222, 
1049 cm
−1
. 
Z isomer (colourless oil, 0.139 g, 19%) HRMS m/z Calcd for C15H16FN2O requires 
259.1247, found 259.1243; 
1
H NMR (CDCl3) δ 2.72−2.77 (4H, m), 3.74 (3H, s), 
6.97−7.04 (2H, m), 7.13 (1H, dd, J = 7.7, 4.8 Hz), 7.28−7.34 (2H, m), 7.47−7.50 
(1H, m), 8.41 (1H, br. s), 8.43 (1H, br. s); 
13
C NMR (CDCl3) δ 30.1 (CH2), 36.6 
(CH2), 61.9 (CH3), 115.5 (CH, d, J = 20.9 Hz), 123.5 (CH), 129.4 (C, d, J = 3.7 Hz), 
130.1 (CH, d, J = 8.4 Hz), 136.1 (CH), 147.6 (CH), 150.0 (CH), 154.8 (C), 162.8 (C, 
d, J = 249.1 Hz); IR 3386, 2937, 2818, 1685, 1601, 1576, 1507, 1423, 1227, 1045 
cm
−1
. 
 
10.2.72 Synthesis of 1-(4-chlorophenyl)-3-(3-pyridinyl)-1-propanone 
methyloxime (211) 
 
1-(4-Chlorophenyl)-3-(3-pyridinyl)-1-propanone 208 (0.134 g, 0.55 mmol), O-
methylhydroxylamine hydrochloride (0.048 g, 0.57 mmol) and sodium acetate (0.140 
g, 1.71 mmol) were stirred in ethanol (3 mL) at room temperature for 4 days. The 
reaction mixture was poured into a solution of sodium hydrogen carbonate (1 M, 10 
mL) and the aqueous layer was extracted with ethyl acetate (3 × 10 mL). The 
combined extracts were dried over anhydrous magnesium sulfate and concentrated 
under reduced pressure. The resulting oil was subjected to flash chromatography. 
Elution with 50% ethyl acetate in petroleum spirits with 1% triethylamine afforded 
the two isomers (0.081 g, 53%, E:Z 3.8 :1).  
E isomer (colourless oil, 0.069 g, 42%) HRMS m/z Calcd for C15H16ClN2O requires 
275.0951, found 275.0949; 
1
H NMR (CDCl3) δ 2.79−2.87 (2H, m), 2.97−3.06 (2H, 
m), 3.93 (3H, s), 7.14−7.21 (1H, m), 7.29−7.37 (2H, m), 7.45−7.53 (3H, m), 8.46 
(2H, br. s); 
13
C NMR (CDCl3) δ 28.7 (CH2), 30.5 (CH2), 62.2 (CH3), 123.6 (CH), 
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127.2 (CH), 129.8 (CH), 131.6 (CH), 133.6 (C), 134.0 (C), 135.5 (C), 147.1 (CH), 
149.2 (CH), 157.2 (C); IR 3029, 2936, 2817, 1563, 1575, 1046 cm
−1
. 
Z isomer (colourless oil, 0.017 g, 11%) 
1
H NMR (CDCl3) δ 2.78−2.87 (4H, m), 3.82 
(3H, s), 7.21 (1H, d, J = 1.61 Hz), 7.29−7.34 (2H, m), 7.35−7.40 (2H, m), 7.49 (1H, 
d, J = 7.6 Hz), 8.35−8.58 (2H, m); 13C NMR (CDCl3) δ 27.3 (CH2), 29.7 (CH2), 62.4 
(CH3), 126.2 (CH), 127.5 (CH), 129.0 (CH), 129.1 (CH), 129.3 (CH), 129.6 (CH), 
133.0 (C), 135.8 (C), 142.6 (C), 155.1 (C); IR 2933, 1684, 1492, 1092, 1047 cm
−1
. 
 
10.2.73 Synthesis of 1-(2,4-dichlorophenyl)-3-(3-pyridinyl)-1-propanone 
methyloxime (212) 
 
1-(2,4-Dichlorophenyl)-3-(3-pyridinyl)-1-propanone 209 (0.346 g, 1.24 mmol), O-
methylhydroxylamine hydrochloride (0.114 g, 1.36 mmol) and sodium acetate (0.173 
g, 2.11 mmol) were stirred in ethanol (4 mL) at room temperature for 3 days. The 
reaction mixture was poured into a solution of sodium hydrogen carbonate (1 M, 10 
mL) and the aqueous layer was extracted with ethyl acetate (3 × 10 mL). The 
combined extracts were dried over anhydrous magnesium sulfate and concentrated 
under reduced pressure. The resulting oil was subjected to flash chromatography. 
Elution with 50% ethyl acetate in petroleum spirits with 1% triethylamine afforded 
the two isomers (0.193 g, 51%, E:Z 2.9:1). 
E isomer (colourless oil, 0.144 g, 38%) HRMS m/z Calcd for C15H15Cl2N2O requires 
309.0561, found 309.0559; 
1
H NMR (CDCl3) δ 2.73−2.79 (2H, m), 3.00−3.06 (2H, 
m), 3.96 (3H, s), 7.03 (1H, d, J = 8.2 Hz), 7.15−7.22 (2H, m), 7.40 (1H, d, J = 1.9 
Hz), 7.43−7.48 (1H, m), 8.38 (1H, s), 8.43 (1H, d, J = 4.1 Hz); 13C NMR (CDCl3) δ 
28.8 (CH2), 30.5 (CH2), 62.2 (CH3), 123.5 (CH), 127.3 (CH), 129.8 (CH), 131.6 
(CH), 133.6 (C), 134.0 (C), 135.5 (C), 136.2 (CH), 136.5 (C), 147.3 (CH), 149.3 
(CH), 157.3 (C); IR 2936, 2818, 1587, 1552, 1473, 1043 cm
−1
. 
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Z isomer (colourless oil, 0.049 g, 13%) HRMS m/z Calcd for C15H15Cl2N2O requires 
309.0561, found 309.0554;
 1
H NMR (CDCl3) δ 2.76−2.84 (2H, m), 2.86−2.94 (2H, 
m), 3.83 (3H, s), 7.01 (1H, d, J = 8.2 Hz), 7.20−7.25 (2H, m), 7.26−7.31 (1H, m), 
7.55 (1H, d, J = 7.8 Hz), 8.47 (2H, br. s); 
13
C NMR (CDCl3) δ 29.4 (CH2), 36.0 
(CH2), 62.2 (CH3), 127.3 (CH), 128.3 (CH), 129.5 (CH), 129.8 (CH), 132.3 (C), 
132.8 (C), 135.2 (C), 136.8 (CH), 137.2 (C), 146.9 (CH), 149.2 (CH), 153.7 (C); IR 
2935, 1630, 1585, 1554, 1470, 1055, 814 cm
−1
.  
 
10.2.74 Synthesis of 1-(4-fluorophenyl)-3-(3-pyridinyl)-1-propanone butyloxime 
(213) 
 
Hydrazine hydrate (117 µL, 0.120 g, 3.76 mmol) was added to a solution of N-
butoxyphthalimide 134 (0.525 g, 2.39 mmol) in ethanol (7 mL) and the reaction 
mixture was heated under reflux for 2.5 hours. The reaction mixture was allowed to 
cool to room temperature before 1-(4-fluorophenyl)-3-(3-pyridinyl)-1-propanone 204 
(0.492 g, 2.15 mmol) in ethanol (1 mL) and acetic acid (0.270 mL) were added. The 
mixture was then heated under reflux for 3 days. The reaction mixture was poured 
into a solution of sodium hydrogen carbonate (1 M, 10 mL) and extracted with 
dichloromethane (5 × 10 mL). The combined extracts were dried over anhydrous 
magnesium sulfate and concentrated under reduced pressure. The resulting residue 
was subjected to flash chromatography. Elution with 50% ethyl acetate in petroleum 
spirits with 1% triethylamine afforded the E isomer as a colourless oil (0.061 g, 9%): 
HRMS m/z Calcd for C18H22FN2O requires 301.1716, found 301.1702; 
1
H NMR 
(CDCl3) δ 0.95 (3H, t, J = 7.4 Hz), 1.35−1.47 (2H, m), 1.62−1.71 (2H, m), 
2.80−2.87 (2H, m), 2.97−3.05 (2H, m), 4.14 (2H, t, J = 6.7 Hz), 6.99−7.07 (2H, m), 
7.18 (1H, dd, J = 7.6, 4.8 Hz), 7.48−7.50 (1H, m), 7.52−7.58 (2H, m), 8.45 (2H, br. 
s); 
13
C NMR (CDCl3) δ 14.0 (CH3), 19.4 (CH2), 28.3 (CH2), 29.7 (CH2), 31.4 (CH2), 
74.3 (CH2), 115.6 (CH, d, J = 21.2 Hz), 123.6 (CH), 128.0 (CH, d, J = 8.1 Hz), 131.7 
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(C, d, J = 3.4 Hz), 136.8 (CH), 137.0 (C) 146.9 (CH), 149.1 (CH), 155.5 (C), 163.3 
(C, d, J = 250.1 Hz); IR 2958, 2932, 2872, 1734, 1602, 1576, 1509, 1230 cm
−1
. 
 
10.2.75 Synthesis of 1-(4-chlorophenyl)-3-(3-pyridinyl)-1-propanone butyl 
oxime (215) 
 
Hydrazine hydrate (117 µL, 0.120 g, 3.76 mmol) was added to a solution of N-
butoxyphthalimide 134 (0.525 g, 2.39 mmol) in ethanol (5 mL) and the reaction 
mixture was heated under reflux for 4.5 hours. The reaction mixture was allowed to 
cool to room temperature before 1-(4-chlorophenyl)-3-(3-pyridinyl)-1-propanone 
208 (0.492 g, 2.15 mmol) in ethanol (1 mL) and acetic acid (0.270 mL) were added. 
The mixture was then heated under reflux for 3 days. The reaction mixture was 
poured into a solution of sodium hydrogen carbonate (1 M, 10 mL) and extracted 
with dichloromethane (5 × 10 mL). The combined extracts were dried over 
anhydrous magnesium sulfate and concentrated under reduced pressure. The 
resulting residue was subjected to flash chromatography. Elution with 50% ethyl 
acetate in petroleum spirits afforded two isomers (0.102 g, 39%, E:Z 6:1).  
E isomer (colourless oil, 0.065 g, 20%) HRMS m/z Calcd for C18H21ClN2O requires 
317.1421, found 317.1421; 
1
H NMR (CDCl3) δ 0.96 (3H, t, J = 7.4 Hz), 1.35−1.48 
(2H, m), 1.62−1.72 (2H, m), 2.80−2.89 (2H, m), 2.98−3.08 (2H, m), 4.12−4.19 
(2H, m), 7.19 (1H, dd, J = 7.6, 5.0 Hz), 7.29−7.38 (2H, m), 7.47−7.54 (2H, m), 
7.56−7.61 (1H, m), 8.45 (2H, br.s.); 13C NMR (CDCl3) δ 14.1 (CH3), 19.4 (CH2), 
28.2 (CH2), 29.7 (CH2), 31.4 (CH2), 74.4 (CH2), 123.7 (CH), 126.3 (CH), 127.5 
(CH), 128.9 (CH), 134.4 (C), 135.2 (C), 136.4 (CH), 149.4 (CH), 155.5 (C), 156.6 
(C); IR 3029, 2958, 2931, 2871, 1601, 1575, 1027, 712 cm
−1
. 
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Z isomer (colourless oil, selected peaks)
* 1
H NMR (CDCl3) δ 0.86−0.92 (3 H, m), 
1.27−1.35 (2 H, m), 1.51−1.62 (2 H, m), 4.01 (2 H, t, J = 6.7 Hz). 
 
10.2.76 Synthesis of 1-(2,4-dichlorophenyl)-3-(3-pyridinyl)-1-propanone 
butyloxime (216) 
 
Hydrazine hydrate (117 µL, 0.120 g, 3.76 mmol) was added to a solution of N-
butoxyphthalimide 134 (0.500 g, 2.28 mmol) in ethanol (5 mL) and the mixture was 
heated under reflux for 1 hour. The reaction mixture was allowed to cool to room 
temperature before 1-(2,4-dichlorophenyl)-3-(3-pyridinyl)-1-propanone 209 (0.250 
g, 1.02 mmol) in ethanol (1 mL) and acetic acid (0.5 mL) were added. The reaction 
mixture was then heated under reflux for 3 days. The reaction mixture was poured 
into a solution of sodium hydrogen carbonate (1 M, 10 mL) and extracted with 
dichloromethane (5 × 10 mL). The combined extracts were dried over anhydrous 
magnesium sulfate and concentrated under reduced pressure. The resulting residue 
was subjected to flash chromatography. Elution with 50% ethyl acetate in petroleum 
spirits afforded two isomers as an oil (0.028 g, 6%, E:Z 1.8:1).  
E isomer (colourless oil, 0.008 g, 2%) HRMS m/z Calcd for C18H21Cl2N2O requires 
351.1031, found 351.1024; 
1
H NMR (CDCl3) δ 0.93−1.00 (3H, m), 1.38−1.48 (2H, 
m), 1.64−1.74 (2H, m), 2.77−2.83 (2H, m), 3.01−3.07 (2H, m), 4.17 (2H, t, J = 6.7 
Hz), 7.04 (1H, d, J = 8.2 Hz), 7.21 (2H, dd, J = 8.2, 2.1 Hz), 7.41 (1H, d, J = 2.1 Hz), 
7.48−7.53 (1H, m), 8.43 (2H, br. s); 13C NMR (CDCl3) δ 14.1 (CH3), 19.4 (CH2), 
28.9 (CH2), 30.8 (CH2), 31.4 (CH2), 74.5 (CH2), 127.4 (CH), 128.9 (CH), 129.9 
(CH), 131.7 (CH), 133.8 (C), 134.4 (C), 135.5 (C), 136.4 (CH), 136.7 (C), 147.3 
(CH), 149.4 (CH), 156.9 (C); IR 2932, 2871, 1576, 1477, 1423, 1027, 908, 730 cm
−1
. 
                                               
*
 The Z isomer was not isolated. Peaks were assigned based on the integration in the 
1
H NMR 
spectrum 
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Z isomer (colourless oil, selected peaks)
*
 HRMS m/z Calcd for C18H21Cl2N2O 
requires 351.1031, found 351.1025; 
1
H NMR (CDCl3) δ 0.89 (3H, t, J = 7.2 Hz), 
1.26−1.36 (2H, m), 1.50−1.62 (2H, m), 4.01 (2H, t, J = 6.7 Hz). 
 
10.2.77 Synthesis of 1-(4-fluorophenyl)-3-(3-pyridinyl)-1-propanone 
isopropyloxime (217) 
 
Hydrazine hydrate (135 µL, 0.159 g, 4.33 mmol) was added to a solution of N-
isopropoxyphthalimide 136 (0.506 g, 2.47 mmol) in ethanol (5 mL) and the reaction 
mixture was heated under reflux for 5 hours. The reaction mixture was allowed to 
cool to room temperature before 1-(4-fluorophenyl)-3-(3-pyridinyl)-1-propanone 204 
(0.410 g, 1.79 mmol) in ethanol (1 mL) and acetic acid (0.5 mL) were added. The 
mixture was then heated under reflux for 5 days. The reaction mixture was poured 
into a solution of sodium hydrogen carbonate (1 M, 10 mL) and extracted with 
dichloromethane (5 × 10 mL). The combined extracts were dried over anhydrous 
magnesium sulfate and concentrated under reduced pressure. The resulting residue 
was subjected to flash chromatography. Elution with 50% ethyl acetate in petroleum 
spirits afforded two isomers (0.331 g, 32%, E:Z 7.4:1). 
E isomer (yellow oil, 0.141 g, 28%) HRMS m/z Calcd for C17H20FN2O requires 
287.1560, found 287.1554; 
1
H NMR (CDCl3) δ
 
1.24 (6H, d, J = 6.2 Hz), 2.78−2.86 
(2H, m), 2.96−3.03 (2H, m), 4.38 (1H, sept, J = 6.2 Hz), 6.98−7.05 (2H, m), 7.16 
(1H, dd, J = 7.8, 4.8 Hz), 7.47−7.49 (1H, m), 7.52−7.58 (2H, m), 8.43 (2H, br. s); 
13
C NMR (CDCl3) δ 21.8 (CH3), 28.2 (CH2), 29.7 (CH2), 75.9 (CH), 115.6 (CH, d, J 
= 21.5 Hz), 123.5 (CH), 128.0 (CH, d, J = 8.5 Hz), 131.9 (C, d, J = 3.4 Hz), 136.3 
(CH), 136.8 (C), 147.3 (CH), 149.6 (CH), 155.0 (C), 163.2 (C, d, J = 248.7 Hz); IR 
2974, 2931, 1734, 1602, 1576, 1509, 1226, 960 cm
−1
. 
                                               
*
 The Z isomer was not isolated. Peaks were assigned based on the integration in the 
1
H NMR 
spectrum 
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Z isomer (yellow oil, 0.019 g, 4%) 
1
H NMR (CDCl3) δ 1.18 (6H, d, J = 6.3 Hz), 
2.73−2.82 (2H, m), 2.91−2.99 (2H, m), 4.32 (1H, sept, J = 6.2 Hz), 6.92−7.00 (2H, 
m), 7.13 (1H, dd, J = 7.8, 4.7 Hz), 7.44 (1H, d, J = 7.8 Hz), 7.46−7.52 (2H, m), 8.39 
(2H, br. s);
 13
C NMR (CDCl3) δ 21.7 (CH3), 28.1 (CH2), 29.6 (CH2), 75.8 (CH), 
115.6 (CH, d, J = 21.5 Hz), 123.4 (CH), 128.0 (CH, d, J = 8.1 Hz), 131.9 (C, d, J = 
8.1 Hz), 136.2 (CH), 136.8 (C), 147.2 (CH), 149.5 (CH), 154.9 (C), 163.5 (C, d, J = 
248.7 Hz); IR 2974, 2931, 1734, 1602, 1576, 1509, 1227, 960 cm
−1
. 
 
10.2.78 Synthesis of 1-(4-chlorophenyl)-3-(3-pyridinyl)-1-propanone 
isopropyloxime (218) 
 
Hydrazine hydrate (117 µL, 0.120 g, 3.76 mmol) was added to a solution of N-
isopropoxyphthalimide 136 (0.500 g, 2.28 mmol) in ethanol (5 mL) and the reaction 
mixture was heated under reflux for 1 hour. The reaction mixture was cooled to room 
temperature before 1-(4-chlorophenyl)-3-(3-pyridinyl)-1-propanone 208 (0.250 g, 
1.02 mmol) in ethanol (1 mL) and acetic acid (0.5 mL) were added. The reaction 
mixture was then heated under reflux for 3 days. The reaction mixture was poured 
into a solution of sodium hydrogen carbonate (1 M, 10 mL) and extracted with 
dichloromethane (5 × 10 mL). The combined extracts were dried over anhydrous 
magnesium sulfate and concentrated under reduced pressure. The resulting residue 
was subjected to flash chromatography. Elution with 50% ethyl acetate in petroleum 
spirits afforded the two isomers (0.033g, 10%, 3:1).  
E isomer (colourless oil, 0.029 g, 7%) HRMS m/z Calcd for C17H20ClN2O requires 
303.1264, found 303.1267; 
1
H NMR (CDCl3) δ 1.26 (6H, d, J = 6.3 Hz), 2.84−2.90 
(2H, m), 2.97−3.08 (2H, m), 4.40 (1H, sept, J = 6.1 Hz), 7.16−7.23 (1H, m), 
7.29−7.38 (2H, m), 7.47−7.55 (2H, m), 7.57−7.62 (1H, m), 8.45 (2H, br. s); 13C 
NMR (CDCl3) δ 21.8 (CH3), 28.1 (CH2), 29.7 (CH2), 76.1 (CH), 126.3 (CH), 127.5 
(CH), 128.8 (CH), 134.4 (C), 135.0 (C), 136.2 (CH), 147.6 (CH), 149.8 (CH), 154.9 
(C), 156.0 (C); IR 3029, 2973, 2928, 1601, 1575, 960 cm
−1
. 
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Z isomer (colourless oil, selected peaks)
*
 
1
H NMR (CDCl3) 1.13−1.18 (6H, m), 4.12 
(1H, sept, J = 7.2 Hz). 
 
10.2.79 Synthesis of 1-(2,4-dichlorophenyl)-3-(3-pyridinyl)-1-propanone 
isopropyloxime (219) 
 
Hydrazine hydrate (135 µL, 0.159 g, 4.33 mmol) was added to a solution of N-
isopropoxyphthalimide 136 (0.103 g, 0.75 mmol) in ethanol (5 mL) and the reaction 
mixture was heated under reflux for 2 hours. The reaction mixture was cooled to 
room temperature before 1-(2,4-dichlorophenyl)-3-(3-pyridinyl)-1-propanone 209 
(0.204 g, 0.73 mmol) in ethanol (1 mL) and acetic acid (0.5 mL) were added. The 
reaction mixture was then heated under reflux for 3 days. The reaction mixture was 
poured into a solution of sodium hydrogen carbonate (1 M, 10 mL) and extracted 
with dichloromethane (5 × 10 mL). The combined extracts were dried over 
anhydrous magnesium sulfate and concentrated under reduced pressure. The 
resulting residue was subjected to flash chromatography. Elution with 50% ethyl 
acetate in petroleum spirits afforded the E isomer as a yellow oil (0.006 g, 3%):
 1
H 
NMR (CDCl3) δ 1.29 (6H, d, J = 6.2 Hz), 2.84−2.91 (2H, m), 3.02−3.10 (2H, m), 
4.42 (1H, sept, J = 5.9 Hz), 7.07 (1H, d, J = 8.2 Hz), 7.23 (1H, dd, J = 8.2, 2.1 Hz), 
7.42 (1H, d, J = 2.1 Hz), 7.70 (1H, d, J = 7.8 Hz), 8.32−8.68 (2H, m); 13C NMR 
(CDCl3) δ 21.9 (CH3), 28.9 (CH2), 29.9 (CH2), 76.4 (CH), 127.4 (CH), 130.0 (CH), 
130.0 (CH), 131.7 (CH), 134.4 (C), 135.5 (C), 138.8 (CH), 155.8 (C); IR 2926, 1719, 
1588, 961, 906, 727 cm
−1
. 
 
 
 
                                               
*
 The Z isomer was not isolated. Peaks were assigned based on the integration in the 
1
H NMR 
spectrum 
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10.2.80 Synthesis of 1-(2,4-dichlorophenyl)-3-(3-pyridinyl)-1-propanone O-
benzyloxime (220) 
 
1-(2,4-Dichlorophenyl)-3-(3-pyridinyl)-1-propanone 209 (0.261 g, 0.932 mmol), O-
benzylhydroxylamine hydrochloride 124 (0.150 g, 0.94 mmol) and sodium acetate 
(0.110 g, 1.34 mmol) were stirred in ethanol (5 mL) at room temperature for 4 days. 
The reaction mixture was concentrated under reduced pressure. The residue was 
washed with a solution of sodium hydrogen carbonate (1 M, 10 mL) and extracted 
with ethyl acetate (3 × 10 mL). The combined extracts were dried over anhydrous 
magnesium sulfate and concentrated under reduced pressure. The resulting oil was 
subjected to flash chromatography. Elution with 50% ethyl acetate in petroleum 
spirits with 1% triethylamine afforded one isomer as a colourless oil (0.087 g, 31%). 
HRMS m/z Calcd for C21H19Cl2N2O requires 385.0874, found 385.0874; 
1
H NMR 
(CDCl3) δ 2.74−2.81 (2H, m), 3.04−3.11 (2H, m), 5.22 (2H, s), 6.98 (1H, d, J = 8.2 
Hz), 7.13 (1H, dd, J = 7.8, 4.84 Hz), 7.19 (1H, dd, J = 8.2, 2.1 Hz), 7.32−7.42 (7H, 
m), 8.33 (1H, br. s), 8.42 (1H, d, J = 3.7 Hz); 
13
C NMR (CDCl3) δ 28.7 (CH2), 30.7 
(CH2), 76.6 (CH2), 123.5 (CH), 127.2 (CH), 128.1 (CH), 128.2 (CH), 128.5 (CH), 
129.8 (CH), 131.6 (CH), 133.6 (C), 134.0 (C), 135.5 (C), 136.5 (CH), 136.7(C), 
137.4 (C), 147.0 (CH), 149.0 (CH), 157.7 (C); IR 3030, 2928, 2864, 1587, 1551, 
1473, 1024, 696 cm
−1
. 
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10.2.81 Synthesis of 1,5-bis(4-chlorophenyl)-3-(3-pyridinyl)-1,5-pentanedione 
(226) 
 
A solution of sodium hydroxide (0.198 g, 4.95 mmol) in water (7.5 mL) and ethanol 
(7.5 mL) was added to 3-pyridinecarboxaldehyde 106 (0.465 g, 4.34 mmol) and 4ʹ-
chloroacetophenone 225 in ethanol (15 mL). The reaction mixture was left to stand 
for 10 minutes before water (400 mL) was added until the precipitate had formed. 
The solid was collected via vacuum filtration. The solid was subjected to flash 
chromatography. Elution with 50% ethyl acetate in petroleum spirits afforded the 1,
5-bis(4-chlorophenyl)-3-(3-pyridinyl)-1,5-pentanedione 226 as a pale yellow solid 
(0.712 g, 29%): HRMS m/z Calcd for C22H18Cl2NO2 requires 398.0715, found 
398.0702; 
1
H NMR (CDCl3) δ 3.35 (2H, dd, J = 10.0, 6.9 Hz), 3.51 (2H, dd, J = 
10.0, 6.9 Hz), 4.06 (1H, quin, J = 6.9 Hz), 7.22 (1H, dd, J = 7.1, 4.9 Hz), 7.42 (4H, d, 
J = 8.5 Hz), 7.65 (1H, d, J = 7.9 Hz), 7.87 (4H, d, J = 8.5 Hz), 8.45 (1H, br. s), 8.55 
(1H, br. s); 
13
C NMR (CDCl3) 34.6 (CH), 44.3 (CH2), 129.1 (CH), 129.2 (CH), 129.6 
(CH), 135.0 (C), 136.1 (CH), 140.0 (C), 147.8 (CH), 148.7 (CH), 171.2 (C), 196.7 
(C); IR 3035, 1879, 1679, 1588, 1266, 1090 cm
−1
. 
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10.2.82 Synthesis of 1,5-bis(4-fluorophenyl)-3-(3-pyridinyl)-1,5-pentanedione 
(228) 
 
A solution of sodium hydroxide (0.200 g, 5.00 mmol) in water (7.5 mL) and ethanol 
(7.5 mL) was added 3-pyridinecarboxaldehyde 106 (0.449 g, 4.19 mmol) and 4ʹ-
fluoroacetophenone 227 (1.158 g, 8.38 mmol) in ethanol (15 mL). The mixture was 
stirred for 30 minutes before water (200 mL) was added until the solution was 
opaque. The mixture was left to stand at room temperature overnight. The solid was 
collected via vacuum filtration. The solid was subjected to flash chromatography. 
Elution with 50% ethyl acetate in petroleum spirits afforded 1,5-bis(4-fluorophenyl)-
3-(3-pyridinyl)-1,5-pentanedione 228 as a pale yellow solid (0.072 g, 4.7%): HRMS 
m/z Calcd for C22H18F2NO2 requires 366.1306, found 366.1292; 
1
H NMR (CDCl3) δ 
3.37 (2H, dd, J = 10.0, 6.9 Hz), 3.54 (2H, dd, J = 10.0, 6.9 Hz), 4.10 (1H, quin, J = 
6.9 Hz), 7.09−7.17 (4H, m), 7.26 (1H, dd, J = 7.6, 4.8 Hz), 7.70−7.72 (1H, m), 
7.93−8.01 (4H, m), 8.46 (1H, br. s), 8.60 (1H, br. s); 13C NMR (CDCl3) δ 34.5 (CH), 
44.2 (CH2), 115.8 (CH, d, J = 21.5 Hz), 123.6 (CH), 130.8 (CH, d, J = 9.4 Hz), 133.0 
(C, d, J = 3.0 Hz), 135.8 (CH), 139.3 (C), 147.8 (CH), 148.8 (CH), 165.88 (C, d, J = 
255.5 Hz), 196.2 (C); IR 2923, 1685, 1608, 1514, 1278, 1107, 766, 714 cm
−1
. 
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10.2.83 Synthesis of 1,5-bis(3,4-difluorophenyl)-3-(3-pyridinyl)-1,5-
pentanedione (230) 
 
A solution of sodium hydroxide (0.200 g, 5.00 mmol) in water (3 mL) and ethanol (3 
mL) was added to 3-pyridinecarboxaldeyde 106 (0.23 mL, 0.260 g, 2.43 mmol) and 
3ʹ,4ʹ-difluoroacetophenone (0.772 g, 4.94 mmol) in ethanol (8 mL). The reaction 
mixture was stirred for 5 minutes before water (150 mL) was added until a solid 
precipitated out. The mixture was left to stand at room temperature for 30 minutes. 
The solid was collected via vacuum filtration. The solid was subjected to flash 
chromatography. Elution with 50% ethyl acetate in petroleum spirits afforded 1,5-
bis(3,4-difluoroophenyl)-3-(3-pyridinyl)- 1,5-pentanedione 230 (0.073 g 7.5%) and 
1-(3,4-fluorophenyl)-3-(3-pyridinyl)-2-propen-1-one (0.061 g, 10%). 
1-(3,4-fluorophenyl)-3-(3-pyridinyl)-2-propen-1-one (pale yellow solid) HRMS m/z 
Calcd for C14H10F2NO requires 246.0730, found 246.0721;
 1
H NMR (CDCl3) δ 
7.28−7.31 (1H, m), 7.37 (1H, dd, J = 8.0, 4.7 Hz), 7.52 (1H, d, J = 15.7 Hz), 
7.76−7.90 (3H, m), 7.93−7.96 (1H, m), 8.64 (1H, d, J = 4.1 Hz), 8.85 (1H, s); 13C 
NMR (CDCl3) δ 117.7 (CH, d, J = 17.8 Hz), 117.9 (CH, dd, J = 17.8, 1.7 Hz), 122.7 
(CH), 123.8 (CH), 125.5 (CH, dd, J = 7.4, 3.7), 130.4 (C), 134.7 (CH), 134.8 (C), 
141.9 (CH), 150.0 (CH), 150.5 (C, dd, J = 238.3, 13.1 Hz), 151.4 (CH), 153.7 (C, dd, 
J = 245.7, 11.8 Hz), 187.0 (C); IR 3047, 2924, 1661, 1539, 799 cm
−1
. 
1,5-bis(3,4-difluorophenyl)-3-(3-pyridinyl)-1,5-pentanedione 230 (pale yellow solid) 
1
H NMR (CDCl3) δ 3.26−3.37 (2H, m), 3.44−3.53 (2H, m), 4.04 (1H, quin, J = 6.9 
Hz), 7.19−7.28 (3H, m), 7.62−7.65 (1H, m), 7.69−7.79 (4H, m), 8.44 (1H, dd, J = 
4.8, 1.5 Hz), 8.54 (1H, d, J = 2.0 Hz);
 13
C NMR (CDCl3) δ 34.4 (CH), 44.0 (CH2), 
117.4 (CH, dd, J = 17.8, 1.7 Hz), 117.6 (CH, d, J = 17.8 Hz), 123.6 (CH), 125.1 (CH, 
dd, J = 7.6, 3.5 Hz), 133.6 (C, dd, J = 3.9, 3.9 Hz), 135.3 (CH), 138.7 (C), 148.4 
(CH), 149.1 (CH), 150.5 (C, dd, J = 238.6, 12.8 Hz), 153.8 (C, dd, J = 245.0, 12.5 
Hz), 195.2 (C); IR 2924, 1691, 1677, 1513, 1274, 1123 cm
−1
. 
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10.2.84 Synthesis of 1,5-bis(2,4-dichlorophenyl)-3-(3-pyridinyl)-1,5-
pentanedione (195) 
 
3-Pyridinecarboxaldehyde 106 (0.18 mL, 0.205 g, 1.92 mmol), 2ʹ,4ʹ-
dichloroacetophenone 193 (0.67 mL, 0.884 g, 4.68 mmol) and sodium hydroxide 
(0.233 g, 3.82 mmol) in methanol (1 mL) were ground together for 10 minutes at 
room temperature. The mixture was dissolved in dichloromethane (20 mL) and was 
washed with water (2 × 20 mL) and brine (20 mL). The organic layer was dried over 
anhydrous magnesium sulfate and concentrated under reduced pressure. The residue 
was subjected to flash chromatography. Elution with 50% ethyl acetate in petroleum 
spirits afforded the 1,5-bis(2,4-dichlorophenyl)-3-(3-pyridinyl)-1,5-pentanedione 195 
as a brown oil (0.240 g, 27%): HRMS m/z Calcd for C22H16Cl4NO2 requires 
465.9935, found 465.9915; 
1
H NMR (CDCl3) δ 3.34 (2H, dd, J = 9.0, 7.8 Hz), 3.44 
(2H, dd, J = 9.0, 7.8 Hz), 3.96 (1H, quin, J = 7.8 Hz), 7.17 (1H, dd, J = 7.8, 4.7 Hz), 
7.20−7.28 (4H, m), 7.37 (2H, d, J = 1.7 Hz), 7.55−7.58 (1H, m), 8.42 (1H, d, J = 3.8 
Hz), 8.47 (1H, br. s); 
13
C NMR (CDCl3) δ 38.4 (CH), 48.3 (CH2), 123.5 (CH), 127.5 
(CH), 130.2 (CH), 130.6 (CH), 132.1 (C), 135.4 (CH), 137.1 (C), 137.8 (C), 138.2 
(C), 148.5 (CH), 149.4 (CH), 199.53 (C); IR 3086, 1693, 1580, 1371, 817 cm
−1
. 
 
 
 
 
 
212 
 
10.3 Biology 
The inhibition of T. cruzi in an in vitro whole cell parasite assay was carried out by 
the School of Veterinary and Biomedical Science, Murdoch University in accordance 
to the procedure described by Buckner et al.
159
 and in the literature.
54,56
 
 
10.3.1 In vitro T. cruzi assay for the determination of IC50 
L6 cells were plated into 96-well, flat bottom tissue culture plates and incubated at 
37 °C in 5% CO2 for 24 hours to allow cells to adhere. T. cruzi trypomastigotes 
(Tulahuèn strain expressing the β-galactosidase gene) were then added at a 
multiplicity of infection of 3 and plates were incubated for a further 48 hours. 
Extracellular trypomastigotes were then removed and compounds were added in 7 
point serial dilutions performed in triplicate. Benznidazole (Epichem Pty Ltd) was 
included as a control. After 96 hours of incubation with the compounds, the 
colorimetric agent CPRG was added. Absorbance was read on a Dynex microplate 
reader at 530 nm. The % inhibition was calculated by the following equation: 
 
100
only) mediaonly (
only) compoundcompound with (
100n%Inhibitio 



T.cruzi
T.cruzi
 
 
For each compound, % inhibition values were used to generate a standard curve from 
which the IC50 was calculated. Each assay was performed twice and the average was 
used. 
 
10.3.2 In vitro assay for determination of cytotoxicity  
L6 cells were plated into 96-well flat bottom tissue culture plates and exposed to 
compounds for 72 hours in total. Compounds were initially screened at 100 μM, and 
those that showed toxicity were carried through to a dose response curve analysis to 
determine an IC50 value. Podophylotoxin was used as a control. Alamar Blue® (AbD 
Serotec) was added to the plates and absorbance was read on a Dynex microplate 
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reader at 570 nm and 630 nm. Each assay was performed twice and an average was 
used to determine the IC50. 
 
10.4 Crystallography  
The crystal data for compound 149 are summarized in Appendix with the structure 
depicted in Figure 42 where ellipsoids have been drawn at the 50% probability level.  
The crystallography was carried out by Professor Brian Skelton at the University of 
Western Australia. Crystallographic data for the structure were collected at 100(2) K 
on an Oxford Diffraction Xcalibur diffractometer fitted with Mo Kα radiation.  
Following multi-scan absorption corrections and solution by direct methods, the 
structure was refined against F
2
 with full-matrix least-squares using the program 
SHELXL-97.
160
 All hydrogen atoms were added at calculated positions and refined 
by use of a riding model with isotropic displacement parameters based on those of 
the parent atoms. Anisotropic displacement parameters were employed throughout 
for the non-hydrogen atoms.  
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Appendix A – Biological Results 
All compounds tested against T. cruzi in order of biological activity 
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Appendix B – Crystal data and structure refinement 
information 
Table 22. Crystal data and structure refinement for compound 149 
Empirical formula  C28H22N2O2 
Formula weight  418.48 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 11.6361(5) Å  
 b = 5.9352(3) Å  
 c = 15.2509(8) Å 
 β = 102.444(5)°  
Volume 1028.52(9) Å
3 
Z 2 
Density (calculated) 1.351 Mg/m
3
 
µ 0.086 mm
−1
 
Crystal size 0.50 × 0.19 × 0.16 mm
3
 
θ range for data collection 2.74 to 32.03° 
Index ranges −17<=h<=16, −8<=k<=8, −22<=l<=18 
Reflections collected 6464 
Independent reflections 3321 [R(int) = 0.0205] 
Completeness to θ = 30.50° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max./ min. transmission 0.9864/0.9585 
Refinement method Full-matrix least-squares on F
2 
Data / restraints / parameters 3321 / 0 / 145 
Goodness-of-fit on F
2
 1.029 
Final R indices [I>2σ(I)] R1 = 0.0446, wR2 = 0.1125 
R indices (all data) R1 = 0.0526, wR2 = 0.1186 
Largest diff. peak and hole 0.416 and −0.215 e.Å−3 
 
